<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:HCWB="http://hcwbiologics.com/20260930"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="hcwb-20260930.xsd" xlink:type="simple"/>
    <context id="From2026-01-01to2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-11-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2026-11-11</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-04-012026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-03-312025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-06-152026-06-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-06-15</startDate>
            <endDate>2026-06-15</endDate>
        </period>
    </context>
    <context id="From2026-03-162026-03-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-03-16</startDate>
            <endDate>2026-03-16</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_ContingentLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">HCWB:ContingentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_ContingentLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">HCWB:ContingentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_ContingentLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">HCWB:ContingentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ContingentLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">HCWB:ContingentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_InvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel1Member_custom_ContingentLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">HCWB:ContingentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel2Member_custom_ContingentLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">HCWB:ContingentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel3Member_custom_ContingentLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">HCWB:ContingentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_ContingentLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">HCWB:ContingentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-15_custom_TwoThousandTwentyTwoLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:TwoThousandTwentyTwoLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_TwoThousandTwentyTwoLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:TwoThousandTwentyTwoLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeniorNotesMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeniorNotesMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeniorNotesMember_srt_ExecutiveVicePresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveVicePresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeniorNotesMember_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeniorNotesMember_custom_GaryMWinerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HCWB:GaryMWinerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeniorNotesMember_custom_RickSGreeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HCWB:RickSGreeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_SeniorNotesMember_us-gaap_CollateralPledgedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CollateralPledgedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-05-012025-05-01_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-01</endDate>
        </period>
    </context>
    <context id="From2025-05-072025-05-07_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:TroubledDebtRestructuringOfSeniorSecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:TroubledDebtRestructuringOfSeniorSecuredNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:TroubledDebtRestructuringOfSeniorSecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ConvertiblePromissoryNotesMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ConvertiblePromissoryNotesMember_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ConvertiblePromissoryNotesMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-05-152025-05-15_custom_ConvertiblePromissoryNotesMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <context id="From2025-05-152025-05-15_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WugenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HCWB:WugenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_WugenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HCWB:WugenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-05-08_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-08</instant>
        </period>
    </context>
    <context id="From2025-05-082025-05-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2025-05-08</startDate>
            <endDate>2025-05-08</endDate>
        </period>
    </context>
    <context id="From2026-02-072026-02-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-02-07</startDate>
            <endDate>2026-02-07</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-23_custom_HingCWongMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HCWB:HingCWongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-23</instant>
        </period>
    </context>
    <context id="From2026-09-232026-09-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-09-23</startDate>
            <endDate>2026-09-23</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2026-09-23</instant>
        </period>
    </context>
    <context id="From2026-03-162026-03-16_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-16</startDate>
            <endDate>2026-03-16</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_LicensedIPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:LicensedIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-21_custom_AlloTeraTherapeuticsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HCWB:AlloTeraTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-21</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_LicensedIPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:LicensedIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_PrepaidTechnologyTransferCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:PrepaidTechnologyTransferCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_PrepaidTechnologyTransferCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:PrepaidTechnologyTransferCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_MasterCellBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:MasterCellBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_MasterCellBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:MasterCellBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-05-132025-05-13_us-gaap_CommonStockMember_custom_MayTwoThousandTwentyFiveEquityFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandTwentyFiveEquityFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-13</startDate>
            <endDate>2025-05-13</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember_srt_MaximumMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandTwentyFiveEquityFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-13</instant>
        </period>
    </context>
    <context id="AsOf2025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandTwentyFiveEquityFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-13</instant>
        </period>
    </context>
    <context id="From2025-05-132025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandTwentyFiveEquityFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-13</startDate>
            <endDate>2025-05-13</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandTwentyFiveEquityFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-13</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_MayTwoThousandTwentyFiveEquityFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandTwentyFiveEquityFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockWarrantsMember_custom_MayTwoThousandTwentyFiveEquityFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandTwentyFiveEquityFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockWarrantsMember_custom_NovemberTwoThousandAndTwentyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:NovemberTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-05-15_custom_InducementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:InducementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-15</instant>
        </period>
    </context>
    <context id="From2025-05-152025-05-15_custom_InducementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:InducementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <context id="From2025-11-192025-11-19_custom_InducementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:InducementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-19</startDate>
            <endDate>2025-11-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-19_custom_InducementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:InducementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-19</instant>
        </period>
    </context>
    <context id="AsOf2025-11-19_custom_CommonStockWarrantsMember_custom_InducementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:InducementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-19</instant>
        </period>
    </context>
    <context id="AsOf2026-02-17_custom_FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="AsOf2026-02-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="AsOf2026-02-17_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="AsOf2026-02-17_custom_FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="AsOf2026-02-17_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="From2026-02-172026-02-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-02-17</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_ExistingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:ExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2026-03-16</instant>
        </period>
    </context>
    <context id="AsOf2026-02-17_custom_ExistingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:ExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="From2026-05-212026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-21</startDate>
            <endDate>2026-05-21</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-21</instant>
        </period>
    </context>
    <context id="AsOf2026-05-21_custom_PreFundedWarrantsMember_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-21</instant>
        </period>
    </context>
    <context id="AsOf2026-05-21_custom_CommonStockWarrantsMember_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-21</instant>
        </period>
    </context>
    <context id="AsOf2026-05-21_custom_PreFundedWarrantsAndCommonStockWarrantsMember_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsAndCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-21</instant>
        </period>
    </context>
    <context id="From2026-05-212026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-21</startDate>
            <endDate>2026-05-21</endDate>
        </period>
    </context>
    <context id="From2026-05-212026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-21</startDate>
            <endDate>2026-05-21</endDate>
        </period>
    </context>
    <context id="From2026-05-212026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-21</startDate>
            <endDate>2026-05-21</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_HingCWongMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HCWB:HingCWongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-21</instant>
        </period>
    </context>
    <context id="AsOf2026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-21</instant>
        </period>
    </context>
    <context id="AsOf2026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-21</instant>
        </period>
    </context>
    <context id="From2026-06-222026-06-22_custom_MayTwoThousandAndTwentySixOfferingMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentySixOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-22</startDate>
            <endDate>2026-06-22</endDate>
        </period>
    </context>
    <context id="From2026-07-292026-07-29_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-29</startDate>
            <endDate>2026-07-29</endDate>
        </period>
    </context>
    <context id="AsOf2026-07-29_us-gaap_CommonStockMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-07-29_custom_PreFundedWarrantsMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="From2026-07-292026-07-29_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-29</startDate>
            <endDate>2026-07-29</endDate>
        </period>
    </context>
    <context id="From2026-07-292026-07-29_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-29</startDate>
            <endDate>2026-07-29</endDate>
        </period>
    </context>
    <context id="From2026-07-292026-07-29_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-29</startDate>
            <endDate>2026-07-29</endDate>
        </period>
    </context>
    <context id="AsOf2026-07-29_custom_CommonStockWarrantsMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-07-29_srt_BoardOfDirectorsChairmanMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_srt_BoardOfDirectorsChairmanMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-09-232026-09-23_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-23</startDate>
            <endDate>2026-09-23</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-23_custom_PreFundedWarrantsMember_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-23</instant>
        </period>
    </context>
    <context id="AsOf2026-09-23_us-gaap_CommonStockMember_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-23</instant>
        </period>
    </context>
    <context id="From2026-09-232026-09-23_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-23</startDate>
            <endDate>2026-09-23</endDate>
        </period>
    </context>
    <context id="From2026-09-232026-09-23_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-23</startDate>
            <endDate>2026-09-23</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-23_custom_CommonStockWarrantsMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-23</instant>
        </period>
    </context>
    <context id="AsOf2026-10-13_custom_SeptemberTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SeptemberTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-10-13</instant>
        </period>
    </context>
    <context id="AsOf2026-10-23_custom_SeptemberTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SeptemberTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-10-23</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_NovemberTwoThousandAndTwentyFourCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:NovemberTwoThousandAndTwentyFourCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_MayTwoThousandAndTwentyFiveCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:MayTwoThousandAndTwentyFiveCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ConversionCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:ConversionCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NovemberTwoThousandAndTwentyFiveCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:NovemberTwoThousandAndTwentyFiveCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_ConversionCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:ConversionCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-02-202025-02-20_custom_EquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">HCWB:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-20_custom_EquityPurchaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">HCWB:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-20</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_EquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">HCWB:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-03-122025-03-12_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">HCWB:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-12</startDate>
            <endDate>2025-03-12</endDate>
        </period>
    </context>
    <context id="From2025-04-162025-04-16_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">HCWB:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-16</startDate>
            <endDate>2025-04-16</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">HCWB:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">HCWB:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_EquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">HCWB:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:NovemberTwoThousandAndTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:NovemberTwoThousandAndTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:NovemberTwoThousandAndTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:NovemberTwoThousandAndTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_WarrantMember_custom_MayTwoThousandAndTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:MayTwoThousandAndTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_MayTwoThousandAndTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:MayTwoThousandAndTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_WarrantMember_custom_MayTwoThousandAndTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:MayTwoThousandAndTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_WarrantMember_custom_MayTwoThousandAndTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:MayTwoThousandAndTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_WarrantMember_custom_WarrantsFromDebtConversionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:WarrantsFromDebtConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_WarrantsFromDebtConversionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:WarrantsFromDebtConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_WarrantMember_custom_WarrantsFromDebtConversionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:WarrantsFromDebtConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_WarrantMember_custom_WarrantsFromDebtConversionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:WarrantsFromDebtConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:NovemberTwoThousandAndTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:NovemberTwoThousandAndTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:NovemberTwoThousandAndTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">HCWB:NovemberTwoThousandAndTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_WarrantMember32129062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HCWB:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HCWB:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HCWB:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HCWB:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HCWB:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SingleReportableSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">HCWB:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:SalariesBenefitsAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:SalariesBenefitsAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:SalariesBenefitsAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:SalariesBenefitsAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ManufacturingAndMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ManufacturingAndMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ManufacturingAndMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ManufacturingAndMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ManufacturingAndMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ManufacturingAndMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ManufacturingAndMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ManufacturingAndMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_PreclinicalExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:PreclinicalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_PreclinicalExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:PreclinicalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_PreclinicalExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:PreclinicalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_PreclinicalExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:PreclinicalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ClinicalTrialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ClinicalTrialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ClinicalTrialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ClinicalTrialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_OverheadAllocationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:OverheadAllocationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_OverheadAllocationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:OverheadAllocationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_OverheadAllocationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:OverheadAllocationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_OverheadAllocationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:OverheadAllocationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProfessionalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProfessionalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProfessionalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProfessionalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_FacilitiesAndOfficeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:FacilitiesAndOfficeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_FacilitiesAndOfficeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:FacilitiesAndOfficeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_FacilitiesAndOfficeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:FacilitiesAndOfficeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_FacilitiesAndOfficeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:FacilitiesAndOfficeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_DepreciationExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:DepreciationExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_DepreciationExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:DepreciationExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_DepreciationExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:DepreciationExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_DepreciationExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:DepreciationExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_RentAndOccupancyExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:RentAndOccupancyExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_RentAndOccupancyExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:RentAndOccupancyExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_RentAndOccupancyExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:RentAndOccupancyExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_RentAndOccupancyExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:RentAndOccupancyExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_InsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:InsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_InsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:InsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_InsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:InsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_InsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:InsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_TaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:TaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_TaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:TaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_TaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:TaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_TaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:TaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_OtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:OtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_OtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:OtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_OtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:OtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_OtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:OtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <instant>2025-03-01</instant>
        </period>
    </context>
    <context id="From2025-03-012025-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-01</endDate>
        </period>
    </context>
    <context id="From2026-03-012026-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-01</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HCWB:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-12-302025-12-30_custom_CooleyLLPSettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:CooleyLLPSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CooleyLLPSettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:CooleyLLPSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_CooleyLLPSettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:CooleyLLPSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_BEAndKComplaintMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:BEAndKComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-06-262026-06-26_custom_BAndIContractorsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:BAndIContractorsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-26</startDate>
            <endDate>2026-06-26</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-07-08_custom_SettlementAndReleaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SettlementAndReleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-08</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_SettlementAndReleaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SettlementAndReleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SettlementAndReleaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:SettlementAndReleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-05-262026-05-26_custom_EirGenixIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:EirGenixIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-26</startDate>
            <endDate>2026-05-26</endDate>
        </period>
    </context>
    <context id="From2025-12-092025-12-09_custom_EirGenixIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HCWB:EirGenixIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-09</startDate>
            <endDate>2025-12-09</endDate>
        </period>
    </context>
    <context id="From2026-07-292026-07-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-07-29</startDate>
            <endDate>2026-07-29</endDate>
        </period>
    </context>
    <context id="From2026-11-042026-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
        </entity>
        <period>
            <startDate>2026-11-04</startDate>
            <endDate>2026-11-04</endDate>
        </period>
    </context>
    <context id="From2026-10-272026-10-27_custom_CooleyLLPMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HCWB:CooleyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-10-27</startDate>
            <endDate>2026-10-27</endDate>
        </period>
    </context>
    <context id="From2027-01-292027-01-29_custom_CooleyLLPMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HCWB:CooleyLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-29</startDate>
            <endDate>2027-01-29</endDate>
        </period>
    </context>
    <context id="AsOf2026-10-27_us-gaap_SubsequentEventMember_custom_CooleyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HCWB:CooleyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-10-27</instant>
        </period>
    </context>
    <context id="AsOf2026-11-03_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-11-03</instant>
        </period>
    </context>
    <context id="AsOf2026-11-03_custom_ConvertiblePromissoryNotesOneMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:ConvertiblePromissoryNotesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-11-03</instant>
        </period>
    </context>
    <context id="AsOf2026-11-03_custom_ConvertiblePromissoryNotesTwoMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HCWB:ConvertiblePromissoryNotesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-11-03</instant>
        </period>
    </context>
    <context id="From2026-11-032026-11-03_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-03</startDate>
            <endDate>2026-11-03</endDate>
        </period>
    </context>
    <context id="From2026-11-032026-11-03_srt_MinimumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828673</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-03</startDate>
            <endDate>2026-11-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="RMB">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="Segment">
        <measure>HCWB:Segment</measure>
    </unit>
    <unit id="Area">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2026-01-01to2026-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2026-01-01to2026-09-30" id="Fact000004">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2026-01-01to2026-09-30" id="Fact000005">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2026-01-01to2026-09-30" id="Fact000006">0001828673</dei:EntityCentralIndexKey>
    <us-gaap:ReceivablesNetCurrent
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0055"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IndirectTaxExpense
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IndirectTaxExpense
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0184"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IndirectTaxExpense
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0185"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ChangeInFairValueOfContingentLiabilityNet
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0204"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ChangeInFairValueOfContingentLiabilityNet
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockUponSquareGate
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueDebtExtinguishment
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueOfWarrantsToExtinguishRestructuredDebt
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueOfWarrantsToExtinguishRestructuredDebt
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:GainOnConversionOfDebtWithRelatedPartiesNet
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:GainOnConversionOfDebtWithRelatedPartiesNet
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderStandbyEquityPurchaseAgreement
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueIssuedInConnectionWithAbeyance
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueIssuedInConnectionWithAbeyance
      contextRef="From2026-01-012026-03-31"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-04-012026-06-30"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0619"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0621"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:NoncashRevenueFromLicensingAgreement
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IncreaseDecreaseInFairValueOfWarrantLiability
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0704"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0708"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ChangeInFairValueOfContingentLiabilityNet
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:CommitmentFee
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0714"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0720"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:LossOnConversionOfDebtWithRelatedParties
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0723"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ProceedsFromIssuanceOfCommonStockUnderSepaNet
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0750"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0758"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:PutSharesIssuedButNotPricedUnderSepa
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0795"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:ExtinguishmentOfRestructuredDebtWithRelatedParties
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0798"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IssuanceOfCommonStockWarrantsAndOtherRightsUponExtinguishmentOfRestructuredDebtWithRelatedParties
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0801"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:GainOnExtinguishmentOfDebtWithRelatedParties
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0804"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0855"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0856"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentsMember"
      id="xdx2ixbrl0859"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentsMember"
      id="xdx2ixbrl0860"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_ContingentLiabilityMember"
      id="xdx2ixbrl0864"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_ContingentLiabilityMember"
      id="xdx2ixbrl0865"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0870"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0875"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0876"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentsMember"
      id="xdx2ixbrl0879"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentsMember"
      id="xdx2ixbrl0880"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel1Member_custom_ContingentLiabilityMember"
      id="xdx2ixbrl0884"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel2Member_custom_ContingentLiabilityMember"
      id="xdx2ixbrl0885"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0890"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2026-09-30_custom_LicensedIPMember"
      id="xdx2ixbrl1090"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl1331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFourWarrantsMember"
      id="xdx2ixbrl1379"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFourWarrantsMember"
      id="xdx2ixbrl1381"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_us-gaap_WarrantMember_custom_MayTwoThousandAndTwentyFiveWarrantsMember"
      id="xdx2ixbrl1387"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-09-30_us-gaap_WarrantMember_custom_MayTwoThousandAndTwentyFiveWarrantsMember"
      id="xdx2ixbrl1389"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFiveWarrantsMember"
      id="xdx2ixbrl1399"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFiveWarrantsMember"
      id="xdx2ixbrl1401"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl1434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl1443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl1444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl1446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl1447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl1449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl1452"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IndirectTaxExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1600"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IndirectTaxExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1601"
      unitRef="USD"
      xsi:nil="true"/>
    <HCWB:IndirectTaxExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1608"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1628"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2026-01-01to2026-09-30" id="Fact000016">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2026-01-01to2026-09-30" id="Fact000017">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2026-01-01to2026-09-30" id="Fact000018">2026-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2026-01-01to2026-09-30" id="Fact000019">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2026-01-01to2026-09-30" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2026-01-01to2026-09-30" id="Fact000021">001-40591</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2026-01-01to2026-09-30" id="Fact000022">HCW Biologics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-01-01to2026-09-30" id="Fact000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2026-01-01to2026-09-30" id="Fact000024">82-5024477</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2026-01-01to2026-09-30" id="Fact000025">2929     N</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2026-01-01to2026-09-30" id="Fact000026">Commerce Parkway</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2026-01-01to2026-09-30" id="Fact000027">Miramar</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2026-01-01to2026-09-30" id="Fact000028">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2026-01-01to2026-09-30" id="Fact000029">33025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2026-01-01to2026-09-30" id="Fact000030">(954)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2026-01-01to2026-09-30" id="Fact000031">842&#x2013;2024</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2026-01-01to2026-09-30" id="Fact000032">Common Stock, par value     $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2026-01-01to2026-09-30" id="Fact000033">HCWB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2026-01-01to2026-09-30" id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2026-01-01to2026-09-30" id="Fact000035">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2026-01-01to2026-09-30" id="Fact000036">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2026-01-01to2026-09-30" id="Fact000037">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2026-01-01to2026-09-30" id="Fact000038">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2026-01-01to2026-09-30" id="Fact000039">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2026-01-01to2026-09-30" id="Fact000040">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2026-01-01to2026-09-30" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-11-11"
      decimals="INF"
      id="Fact000042"
      unitRef="Shares">3139938</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000043"
      unitRef="USDPShares">0.0001</dei:EntityListingParValuePerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">1952464</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000052"
      unitRef="USD">955458</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">32175</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">222156</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000058"
      unitRef="USD">239998</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">77564</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000061"
      unitRef="USD">85202</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">2284359</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000064"
      unitRef="USD">1280658</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">1326329</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000067"
      unitRef="USD">4854028</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">20880849</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">18963834</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">28476</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">28476</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">24520013</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">25126996</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">13143394</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000088"
      unitRef="USD">9435785</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">1110104</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000091"
      unitRef="USD">1046440</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">6809215</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000094"
      unitRef="USD">6831899</us-gaap:ShortTermBorrowings>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000097"
      unitRef="USD">297101</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">21062713</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000100"
      unitRef="USD">17611225</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">692531</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000103"
      unitRef="USD">692531</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">21755244</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000106"
      unitRef="USD">18303756</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000117"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000119"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000121"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000125"
      unitRef="Shares">546635</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">2236324</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">55</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000115"
      unitRef="USD">223</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">111280560</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000132"
      unitRef="USD">120308443</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">-108515846</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000135"
      unitRef="USD">-113485426</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">2764769</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000138"
      unitRef="USD">6823240</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000140"
      unitRef="USD">24520013</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000141"
      unitRef="USD">25126996</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000148"
      unitRef="USD">15606</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000149"
      unitRef="USD">55463</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000150"
      unitRef="USD">27222</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000151"
      unitRef="USD">6734032</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000153"
      unitRef="USD">12485</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000154"
      unitRef="USD">27345</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000155"
      unitRef="USD">21777</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000156"
      unitRef="USD">267871</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000158"
      unitRef="USD">3121</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000159"
      unitRef="USD">28118</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000160"
      unitRef="USD">5445</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000161"
      unitRef="USD">6466161</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">1404247</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">1242577</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000170"
      unitRef="USD">4109782</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000171"
      unitRef="USD">3703877</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000173"
      unitRef="USD">1884994</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">1366386</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">6187296</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000176"
      unitRef="USD">5070038</us-gaap:GeneralAndAdministrativeExpense>
    <HCWB:LegalExpensesNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">6006</HCWB:LegalExpensesNet>
    <HCWB:LegalExpensesNet
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">9058</HCWB:LegalExpensesNet>
    <HCWB:LegalExpensesNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">-1590945</HCWB:LegalExpensesNet>
    <HCWB:LegalExpensesNet
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">14583</HCWB:LegalExpensesNet>
    <HCWB:IndirectTaxExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">198146</HCWB:IndirectTaxExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000188"
      unitRef="USD">3295247</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">2618021</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000190"
      unitRef="USD">8706133</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000191"
      unitRef="USD">8986644</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000193"
      unitRef="USD">-3292126</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000194"
      unitRef="USD">-2589903</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">-8700688</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000196"
      unitRef="USD">-2520483</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000198"
      unitRef="USD">127070</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000199"
      unitRef="USD">141797</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000200"
      unitRef="USD">632923</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">351612</us-gaap:InterestExpense>
    <HCWB:ChangeInFairValueOfContingentLiabilityNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000203"
      unitRef="USD">1055825</HCWB:ChangeInFairValueOfContingentLiabilityNet>
    <HCWB:ChangeInFairValueOfContingentLiabilityNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000205"
      unitRef="USD">-692531</HCWB:ChangeInFairValueOfContingentLiabilityNet>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-2022109</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000210"
      unitRef="USD">1474935</us-gaap:GainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000216"
      unitRef="USD">-1775992</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000218"
      unitRef="USD">182146</us-gaap:LossOnSaleOfInvestments>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000220"
      unitRef="USD">182146</us-gaap:LossOnSaleOfInvestments>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000224"
      unitRef="USD">-494683</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-494683</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000231"
      unitRef="USD">483383</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000233"
      unitRef="USD">13290</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000234"
      unitRef="USD">3554</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000235"
      unitRef="USD">54412</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000236"
      unitRef="USD">19992</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000238"
      unitRef="USD">-4554336</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-3222829</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000240"
      unitRef="USD">-8678941</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-4639395</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000246"
      unitRef="USD">330186</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000248"
      unitRef="USD">-4554336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-3222829</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000250"
      unitRef="USD">-8678941</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000251"
      unitRef="USD">-4969581</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000254"
      unitRef="USD">2718837</us-gaap:DividendsCommonStockStock>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000255"
      unitRef="USD">10153799</us-gaap:DividendsCommonStockStock>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000256"
      unitRef="USD">14361951</us-gaap:DividendsCommonStockStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-4554336</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-5941666</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000260"
      unitRef="USD">-18832740</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000261"
      unitRef="USD">-19331532</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000263"
      unitRef="USDPShares">-12.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000265"
      unitRef="USDPShares">-12.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000267"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000269"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000271"
      unitRef="USDPShares">-68.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000273"
      unitRef="USDPShares">-68.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000275"
      unitRef="USDPShares">-13.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000277"
      unitRef="USDPShares">-13.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000279"
      unitRef="Shares">376678</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">376678</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">2101872</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000285"
      unitRef="Shares">2101872</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000287"
      unitRef="Shares">276889</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">276889</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">1448485</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000293"
      unitRef="Shares">1448485</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000300"
      unitRef="Shares">185589</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000295"
      unitRef="USD">19</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">93785946</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">-100556137</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">-6770172</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000307"
      unitRef="Shares">34</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">1654</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000305"
      unitRef="USD">1654</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <HCWB:IssuanceOfCommonStockUponSquareGateShares
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000314"
      unitRef="Shares">1603</HCWB:IssuanceOfCommonStockUponSquareGateShares>
    <HCWB:IssuanceOfCommonStockUponSquareGate
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">1</HCWB:IssuanceOfCommonStockUponSquareGate>
    <HCWB:IssuanceOfCommonStockUponSquareGate
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000310"
      unitRef="USD">149999</HCWB:IssuanceOfCommonStockUponSquareGate>
    <HCWB:IssuanceOfCommonStockUponSquareGate
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000312"
      unitRef="USD">150000</HCWB:IssuanceOfCommonStockUponSquareGate>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">-22297</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-22297</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000322"
      unitRef="USD">275642</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000324"
      unitRef="USD">275642</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">-2196875</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-2196875</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000336"
      unitRef="Shares">187226</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">20</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000332"
      unitRef="USD">94190944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000333"
      unitRef="USD">-102753012</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000334"
      unitRef="USD">-8562048</us-gaap:StockholdersEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000343"
      unitRef="Shares">32374</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">3</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">1592782</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000341"
      unitRef="USD">1592785</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">4207718</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000348"
      unitRef="USD">4207718</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">9650404</HCWB:IssuanceOfCommonStockWarrants>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000353"
      unitRef="USD">9650404</HCWB:IssuanceOfCommonStockWarrants>
    <HCWB:ExerciseOfPreFundedWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">85523</HCWB:ExerciseOfPreFundedWarrants>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">9</HCWB:ExerciseOfPreFundedWarrantsValue>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">42</HCWB:ExerciseOfPreFundedWarrantsValue>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000358"
      unitRef="USD">51</HCWB:ExerciseOfPreFundedWarrantsValue>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">-70094</HCWB:IssuanceCostsOfCommonStock>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000365"
      unitRef="USD">-70094</HCWB:IssuanceCostsOfCommonStock>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000368"
      unitRef="USD">-504861</HCWB:IssuanceCostOfPrefundedWarrants>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000370"
      unitRef="USD">-504861</HCWB:IssuanceCostOfPrefundedWarrants>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">-227646</HCWB:IssuanceCostsOfCommonStockWarrants>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-227646</HCWB:IssuanceCostsOfCommonStockWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">10153780</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000380"
      unitRef="USD">10153780</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <HCWB:StockIssuedDuringPeriodSharesDebtExtinguishment
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000387"
      unitRef="Shares">42181</HCWB:StockIssuedDuringPeriodSharesDebtExtinguishment>
    <HCWB:StockIssuedDuringPeriodValueDebtExtinguishment
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000382"
      unitRef="USD">4</HCWB:StockIssuedDuringPeriodValueDebtExtinguishment>
    <HCWB:StockIssuedDuringPeriodValueDebtExtinguishment
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000383"
      unitRef="USD">1774108</HCWB:StockIssuedDuringPeriodValueDebtExtinguishment>
    <HCWB:StockIssuedDuringPeriodValueDebtExtinguishment
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000385"
      unitRef="USD">1774112</HCWB:StockIssuedDuringPeriodValueDebtExtinguishment>
    <HCWB:StockIssuedDuringPeriodValueOfWarrantsToExtinguishRestructuredDebt
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000390"
      unitRef="USD">544249</HCWB:StockIssuedDuringPeriodValueOfWarrantsToExtinguishRestructuredDebt>
    <HCWB:StockIssuedDuringPeriodValueOfWarrantsToExtinguishRestructuredDebt
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000392"
      unitRef="USD">544249</HCWB:StockIssuedDuringPeriodValueOfWarrantsToExtinguishRestructuredDebt>
    <HCWB:GainOnConversionOfDebtWithRelatedPartiesNet
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">3346562</HCWB:GainOnConversionOfDebtWithRelatedPartiesNet>
    <HCWB:GainOnConversionOfDebtWithRelatedPartiesNet
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000397"
      unitRef="USD">3346562</HCWB:GainOnConversionOfDebtWithRelatedPartiesNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">278307</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000402"
      unitRef="USD">278307</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000409"
      unitRef="Shares">10464</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">1</HCWB:StockIssuedDuringPeriodValueReverseStockSplits>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000405"
      unitRef="USD">-1</HCWB:StockIssuedDuringPeriodValueReverseStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000413"
      unitRef="USD">-1927730</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000414"
      unitRef="USD">-1927730</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000421"
      unitRef="Shares">357768</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000416"
      unitRef="USD">37</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000417"
      unitRef="USD">104628734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000418"
      unitRef="USD">-104680742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000419"
      unitRef="USD">-51971</us-gaap:StockholdersEquity>
    <HCWB:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUnderStandbyEquityPurchaseAgreement
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000428"
      unitRef="Shares">79167</HCWB:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUnderStandbyEquityPurchaseAgreement>
    <HCWB:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderStandbyEquityPurchaseAgreement
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">8</HCWB:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderStandbyEquityPurchaseAgreement>
    <HCWB:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderStandbyEquityPurchaseAgreement
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">2357112</HCWB:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderStandbyEquityPurchaseAgreement>
    <HCWB:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderStandbyEquityPurchaseAgreement
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000426"
      unitRef="USD">2357120</HCWB:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderStandbyEquityPurchaseAgreement>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-63501</HCWB:IssuanceCostsOfCommonStockWarrants>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000433"
      unitRef="USD">-63501</HCWB:IssuanceCostsOfCommonStockWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000436"
      unitRef="USD">205492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000438"
      unitRef="USD">205492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000445"
      unitRef="Shares">1</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000449"
      unitRef="USD">-4554336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000450"
      unitRef="USD">-4554336</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000457"
      unitRef="Shares">436936</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000452"
      unitRef="USD">45</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000453"
      unitRef="USD">107127837</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000454"
      unitRef="USD">-109235078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000455"
      unitRef="USD">-2107196</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000464"
      unitRef="Shares">546635</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">55</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">111280560</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">-108515846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">2764769</us-gaap:StockholdersEquity>
    <HCWB:StockIssuedDuringPeriodSharesIssuedInConnectionWithAbeyance
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000471"
      unitRef="Shares">162834</HCWB:StockIssuedDuringPeriodSharesIssuedInConnectionWithAbeyance>
    <HCWB:StockIssuedDuringPeriodValueIssuedInConnectionWithAbeyance
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">16</HCWB:StockIssuedDuringPeriodValueIssuedInConnectionWithAbeyance>
    <HCWB:StockIssuedDuringPeriodValueIssuedInConnectionWithAbeyance
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">-16</HCWB:StockIssuedDuringPeriodValueIssuedInConnectionWithAbeyance>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">1499753</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000476"
      unitRef="USD">1499753</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <HCWB:ExerciseOfPreFundedWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000483"
      unitRef="Shares">412882</HCWB:ExerciseOfPreFundedWarrants>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000478"
      unitRef="USD">41</HCWB:ExerciseOfPreFundedWarrantsValue>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000479"
      unitRef="USD">206</HCWB:ExerciseOfPreFundedWarrantsValue>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">247</HCWB:ExerciseOfPreFundedWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">-1595778</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">-1595778</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000491"
      unitRef="USD">1488472</HCWB:IssuanceOfCommonStockWarrants>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000493"
      unitRef="USD">1488472</HCWB:IssuanceOfCommonStockWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000496"
      unitRef="USD">1488472</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">1488472</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000501"
      unitRef="USD">-181198</HCWB:IssuanceCostsOfCommonStockWarrants>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000503"
      unitRef="USD">-181198</HCWB:IssuanceCostsOfCommonStockWarrants>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000506"
      unitRef="USD">-207858</HCWB:IssuanceCostOfPrefundedWarrants>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000508"
      unitRef="USD">-207858</HCWB:IssuanceCostOfPrefundedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000511"
      unitRef="USD">10019</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000513"
      unitRef="USD">10019</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">3472480</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000518"
      unitRef="USD">3472480</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000525"
      unitRef="Shares">1122351</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">112</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000521"
      unitRef="USD">110805688</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000522"
      unitRef="USD">-105043366</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000523"
      unitRef="USD">5762434</us-gaap:StockholdersEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000532"
      unitRef="Shares">71174</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">7</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000528"
      unitRef="USD">1101772</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000530"
      unitRef="USD">1101779</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000535"
      unitRef="USD">6243229</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000537"
      unitRef="USD">6243229</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000540"
      unitRef="USD">6809392</HCWB:IssuanceOfCommonStockWarrants>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000542"
      unitRef="USD">6809392</HCWB:IssuanceOfCommonStockWarrants>
    <HCWB:ExerciseOfPreFundedWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">403322</HCWB:ExerciseOfPreFundedWarrants>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">40</HCWB:ExerciseOfPreFundedWarrantsValue>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000545"
      unitRef="USD">202</HCWB:ExerciseOfPreFundedWarrantsValue>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000547"
      unitRef="USD">242</HCWB:ExerciseOfPreFundedWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000552"
      unitRef="USD">3371770</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000554"
      unitRef="USD">3371770</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000557"
      unitRef="USD">10154642</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000559"
      unitRef="USD">10154642</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000562"
      unitRef="USD">-38031</HCWB:IssuanceCostsOfCommonStock>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000564"
      unitRef="USD">-38031</HCWB:IssuanceCostsOfCommonStock>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000567"
      unitRef="USD">-215502</HCWB:IssuanceCostOfPrefundedWarrants>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000569"
      unitRef="USD">-215502</HCWB:IssuanceCostOfPrefundedWarrants>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000572"
      unitRef="USD">-235046</HCWB:IssuanceCostsOfCommonStockWarrants>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000574"
      unitRef="USD">-235046</HCWB:IssuanceCostsOfCommonStockWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000577"
      unitRef="USD">1220</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000579"
      unitRef="USD">1220</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000586"
      unitRef="Shares">20795</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-04-012026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000581"
      unitRef="USD">2</HCWB:StockIssuedDuringPeriodValueReverseStockSplits>
    <HCWB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-04-012026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000582"
      unitRef="USD">-2</HCWB:StockIssuedDuringPeriodValueReverseStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000590"
      unitRef="USD">-5219231</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-04-012026-06-30"
      decimals="0"
      id="Fact000591"
      unitRef="USD">-5219231</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000598"
      unitRef="Shares">1617642</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000593"
      unitRef="USD">161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000594"
      unitRef="USD">117690050</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000595"
      unitRef="USD">-110262597</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000596"
      unitRef="USD">7427614</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000605"
      unitRef="Shares">1617642</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000600"
      unitRef="USD">161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000601"
      unitRef="USD">117690050</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000602"
      unitRef="USD">-110262597</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000603"
      unitRef="USD">7427614</us-gaap:StockholdersEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000612"
      unitRef="Shares">218682</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000607"
      unitRef="USD">22</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000608"
      unitRef="USD">564178</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000610"
      unitRef="USD">564200</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000615"
      unitRef="USD">2531915</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000617"
      unitRef="USD">2531915</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000620"
      unitRef="USD">2721891</HCWB:IssuanceOfCommonStockWarrants>
    <HCWB:IssuanceOfCommonStockWarrants
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000622"
      unitRef="USD">2721891</HCWB:IssuanceOfCommonStockWarrants>
    <HCWB:ExerciseOfPreFundedWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000629"
      unitRef="Shares">400000</HCWB:ExerciseOfPreFundedWarrants>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000624"
      unitRef="USD">40</HCWB:ExerciseOfPreFundedWarrantsValue>
    <HCWB:ExerciseOfPreFundedWarrantsValue
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000627"
      unitRef="USD">40</HCWB:ExerciseOfPreFundedWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000632"
      unitRef="USD">2718837</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000634"
      unitRef="USD">2718837</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000637"
      unitRef="USD">-46656</HCWB:IssuanceCostsOfCommonStock>
    <HCWB:IssuanceCostsOfCommonStock
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000639"
      unitRef="USD">-46656</HCWB:IssuanceCostsOfCommonStock>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">-209376</HCWB:IssuanceCostOfPrefundedWarrants>
    <HCWB:IssuanceCostOfPrefundedWarrants
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000644"
      unitRef="USD">-209376</HCWB:IssuanceCostOfPrefundedWarrants>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000647"
      unitRef="USD">-225086</HCWB:IssuanceCostsOfCommonStockWarrants>
    <HCWB:IssuanceCostsOfCommonStockWarrants
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000649"
      unitRef="USD">-225086</HCWB:IssuanceCostsOfCommonStockWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000652"
      unitRef="USD">364</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000654"
      unitRef="USD">364</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000658"
      unitRef="USD">-3222829</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000659"
      unitRef="USD">-3222829</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">-3222829</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000664"
      unitRef="USD">-3222829</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000671"
      unitRef="Shares">2236324</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000666"
      unitRef="USD">223</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000667"
      unitRef="USD">120308443</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000668"
      unitRef="USD">-113485426</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000669"
      unitRef="USD">6823240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000678"
      unitRef="Shares">2236324</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000673"
      unitRef="USD">223</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000674"
      unitRef="USD">120308443</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000675"
      unitRef="USD">-113485426</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000676"
      unitRef="USD">6823240</us-gaap:StockholdersEquity>
    <HCWB:StockIssuedDuringPeriodSharesIssuedInConnectionWithAbeyance
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">162834</HCWB:StockIssuedDuringPeriodSharesIssuedInConnectionWithAbeyance>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000686"
      unitRef="USD">-8678941</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000687"
      unitRef="USD">-4969581</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000692"
      unitRef="USD">884831</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000693"
      unitRef="USD">389216</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000695"
      unitRef="USD">759441</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000696"
      unitRef="USD">11603</us-gaap:ShareBasedCompensation>
    <HCWB:NoncashRevenueFromLicensingAgreement
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000699"
      unitRef="USD">3500000</HCWB:NoncashRevenueFromLicensingAgreement>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000702"
      unitRef="USD">483383</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <HCWB:IncreaseDecreaseInFairValueOfWarrantLiability
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000705"
      unitRef="USD">-1775992</HCWB:IncreaseDecreaseInFairValueOfWarrantLiability>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000707"
      unitRef="USD">1474935</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <HCWB:ChangeInFairValueOfContingentLiabilityNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000710"
      unitRef="USD">-692531</HCWB:ChangeInFairValueOfContingentLiabilityNet>
    <HCWB:CommitmentFee
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000713"
      unitRef="USD">150000</HCWB:CommitmentFee>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000717"
      unitRef="USD">-494683</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000719"
      unitRef="USD">182146</us-gaap:LossOnSaleOfInvestments>
    <HCWB:LossOnConversionOfDebtWithRelatedParties
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000722"
      unitRef="USD">131135</HCWB:LossOnConversionOfDebtWithRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000728"
      unitRef="USD">-551534</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000729"
      unitRef="USD">-32175</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000731"
      unitRef="USD">-162903</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000732"
      unitRef="USD">53179</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000734"
      unitRef="USD">-3134475</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000735"
      unitRef="USD">-2156618</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000738"
      unitRef="USD">297101</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000740"
      unitRef="USD">-10036100</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000741"
      unitRef="USD">-8161991</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000746"
      unitRef="USD">1475939</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000747"
      unitRef="USD">612643</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <HCWB:ProceedsFromIssuanceOfCommonStockUnderSepaNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000749"
      unitRef="USD">1992779</HCWB:ProceedsFromIssuanceOfCommonStockUnderSepaNet>
    <HCWB:ProceedsFromIssuanceOfCommonStockWarrantsAndPrefundedWarrantsNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000752"
      unitRef="USD">3822894</HCWB:ProceedsFromIssuanceOfCommonStockWarrantsAndPrefundedWarrantsNet>
    <HCWB:ProceedsFromIssuanceOfCommonStockWarrantsAndPrefundedWarrantsNet
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000753"
      unitRef="USD">7986565</HCWB:ProceedsFromIssuanceOfCommonStockWarrantsAndPrefundedWarrantsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000755"
      unitRef="USD">150000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000756"
      unitRef="USD">250000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000759"
      unitRef="USD">84687</us-gaap:PaymentsOfStockIssuanceCosts>
    <HCWB:PaymentsOfStockIssuanceCostsAndPrefundedWarrants
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000761"
      unitRef="USD">888399</HCWB:PaymentsOfStockIssuanceCostsAndPrefundedWarrants>
    <HCWB:PaymentsOfStockIssuanceCostsAndPrefundedWarrants
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000762"
      unitRef="USD">1274065</HCWB:PaymentsOfStockIssuanceCostsAndPrefundedWarrants>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000764"
      unitRef="USD">-94776</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000765"
      unitRef="USD">-325471</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000767"
      unitRef="USD">6458437</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000768"
      unitRef="USD">7164985</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000770"
      unitRef="USD">-3577663</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000771"
      unitRef="USD">-997006</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000773"
      unitRef="USD">4674572</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000774"
      unitRef="USD">1952464</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000776"
      unitRef="USD">1096909</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000777"
      unitRef="USD">955458</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000782"
      unitRef="USD">496268</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000783"
      unitRef="USD">359519</us-gaap:InterestPaidNet>
    <HCWB:PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndOther
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000788"
      unitRef="USD">23000</HCWB:PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndOther>
    <HCWB:PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndOther
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000789"
      unitRef="USD">89812</HCWB:PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndOther>
    <HCWB:PutSharesIssuedButNotPricedUnderSepa
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000794"
      unitRef="USD">182195</HCWB:PutSharesIssuedButNotPricedUnderSepa>
    <HCWB:ExtinguishmentOfRestructuredDebtWithRelatedParties
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000797"
      unitRef="USD">7440462</HCWB:ExtinguishmentOfRestructuredDebtWithRelatedParties>
    <HCWB:IssuanceOfCommonStockWarrantsAndOtherRightsUponExtinguishmentOfRestructuredDebtWithRelatedParties
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000800"
      unitRef="USD">3962766</HCWB:IssuanceOfCommonStockWarrantsAndOtherRightsUponExtinguishmentOfRestructuredDebtWithRelatedParties>
    <HCWB:GainOnExtinguishmentOfDebtWithRelatedParties
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000803"
      unitRef="USD">3477696</HCWB:GainOnExtinguishmentOfDebtWithRelatedParties>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000806"
      unitRef="USD">10153799</us-gaap:DividendsCommonStockStock>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000807"
      unitRef="USD">14361951</us-gaap:DividendsCommonStockStock>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000809">&lt;p id="xdx_802_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_z3L9wdyczuW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_827_zECv5z1pPhSf"&gt;Organization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Organization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;HCW
Biologics Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics
to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The Company
also has commercial-ready reagents that are based on its proprietary immunotherapeutic compounds that are designed to support the production
of immunotherapeutics for cancer and infectious diseases. The Company is located in Miramar, Florida and was incorporated in the state
of Delaware in April 2018.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reverse
Stock Splits&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 31, 2025, &lt;span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20250331__20250331_zjMMTeoC9ARi" title="Stockholders' equity, reverse stock split"&gt;at a Special Meeting of the Stockholders, the stockholders of the Company approved a reverse stock split of all outstanding
shares of the Company&#x2019;s common stock (&#x201c;Common Stock&#x201d;), and the Board approved a reverse stock split of the Common Stock
at a final ratio of one-for-forty (1::40). This reverse stock split was effective on April 11, 2025, and the Common Stock commenced trading
on a reverse split-adjusted basis when the markets opened on April 11, 2025, under the existing trading symbol &#x201c;HCWB.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 15, 2026, &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20260615__20260615_z1pTdlbJmE72" title="Stockholders' equity, reverse stock split"&gt;at the Company&#x2019;s Annual Meeting of Stockholders, the stockholders of the Company approved one or more reverse
stock splits of all outstanding shares of Common Stock up to an aggregate of one-for-twenty (1::20) for a period of one year. On
June 24, 2026, the Board approved a reverse
stock split at a final ratio of one-for-six (1::6), or the Reverse Stock Split, which was effective at 12:01 a.m. Eastern
Time on Tuesday, June 30, 2026 (the &#x201c;Effective Date&#x201d;). The Common Stock commenced trading on a Reverse Stock
Split-adjusted basis under the Company&#x2019;s existing trading symbol, &#x201c;HCWB,&#x201d; at market open on Tuesday, June 30,
2026.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
issued and outstanding shares of Common Stock, stock option awards, and per share data included in this Quarterly Report on Form 10-Q
have been recast to give retrospective effect to the reverse stock splits for all periods presented. The reverse stock splits did not
have any effect on the stated par value of the Company&#x2019;s Common Stock or the rights and privileges of the holders of shares of
Common Stock. Options, warrants and convertible securities outstanding immediately prior to the reverse stock splits were appropriately
adjusted to reflect the reverse stock splits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity
and Going Concern&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 205-40,
Presentation of Financial Statements &#x2013; Going Concern (&#x201c;Topic 205-40&#x201d;), management is required to evaluate whether there
are conditions and events, considered in the aggregate that raise substantial doubt about the Company&#x2019;s ability to continue as
a going concern for at least 12 months from the issuance date of the Company&#x2019;s condensed financial statements. This evaluation
does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented or
are not within control of the Company as of the date the condensed financial statements are issued. When substantial doubt exists under
this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the
Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered
if both (1) it is probable that the plans will be effectively implemented within one year after the date that the condensed financial
statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that
raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the condensed
financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026, the Company had not generated any revenue from commercial product sales of its internally developed immunotherapeutic
products. During its development activities, the Company has sustained operating losses, experienced negative operating cash flows and
negative working capital position and expects to continue to incur operating losses for the foreseeable future. Since inception to September
30, 2026, the Company incurred cumulative net losses of $&lt;span id="xdx_90B_ecustom--CumulativeLossesToConductProductResearchAndDevelopmentInFuture_pn5n6_c20260101__20260930_zGWjhmnomY2l" title="Cumulative net losses"&gt;110.8&lt;/span&gt; million. These factors raise substantial doubt regarding the Company&#x2019;s
ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed financial statements have been prepared on a going-concern basis, which contemplates the realization of assets
and satisfaction of liabilities in the ordinary course of business. The continuation of the Company as a going concern is dependent upon
the ability of the Company to obtain debt or equity financings to continue operations. The financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might
result from the outcome of the uncertainties described above. The Company believes that substantial doubt exists regarding its ability
to continue as a going concern for at least 12 months from the date of issuance of the Company&#x2019;s condensed financial statements
and that the substantial doubt that existed in its going concern analysis was not alleviated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
of Significant Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhAPZdkIDcW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zABGFYudzx"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Consolidated
Financial Results&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On September 29, 2026, the Company formed
HCWB Holdings, LLC (the &#x201c;Subsidiary&#x201d;), a Utah limited liability company of which the Company is the sole member. The Subsidiary
has no employees or physical location. As of September 30, 2026, the Subsidiary had no assets, liabilities and had not commenced operations.
Accordingly, the formation of the Subsidiary had no impact on the Company&#x2019;s financial position or results of operations as of and
for the three months ended September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Beginning with the Company&#x2019;s
Annual Report for the year ended December 31, 2026, the Company will present consolidated financial statements that include the accounts
of HCW Biologics Inc. and its wholly owned Subsidiary. All intercompany balances and transactions, if any, will be eliminated in consolidation.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unaudited
Interim Financial Information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed financial statements as of September 30, 2026 and for the three and nine months ended September 30,
2025 and 2026 have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Article 10 of Regulation
S-X of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Accordingly, they do not include all of the information
and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal
and recurring adjustments that the Company believes are necessary to fairly state the Company&#x2019;s financial position and the results
of its operations and cash flows. The results for the three and nine months ended September 30, 2026 are not necessarily indicative of
the results expected for the full fiscal year or any subsequent interim period. The condensed balance sheet at December 31, 2025 has
been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete
financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein,
these unaudited condensed financial statements and the notes accompanying them should be read in conjunction with the Company&#x2019;s
audited financial statements for the year ended December 31, 2025 which appear in our Annual Report on Form 10-K for the year ended December
31, 2025 filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 31, 2026 (the &#x201c;Annual Report&#x201d;)
and in other filings with the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zcndEJfmWGu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zvYQFBhSurgi"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing
transformative fusion immunotherapeutics for diseases promoted by chronic inflammation, including autoimmune disorders and other inflammatory
diseases, cancer and senescence-associated dysplasia. The Company&#x2019;s chief executive officer, who is the chief operating decision
maker (&#x201c;CODM&#x201d;), reviews financial information on an aggregate basis for allocating and evaluating financial performance.
In addition, the Company&#x2019;s CODM is regularly provided with detailed results of preclinical and clinical data which is considered
in his decision for the allocation of resources. See Note 11. Segment Reporting for further details. The single operating segment constitutes
all of the Company activity, and the CODM regularly reviews the entity-wide operating results and performance. All long-lived assets
are maintained in the United States of America.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zRk9rtwCnhC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zGNhqI4h1wb3"&gt;Reclassification
of Prior Period Amounts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Certain prior-period amounts have
been reclassified to conform to the current-period presentation. Specifically, the change in fair value of the contingent liability created
by transferring rights to a portion of the proceeds from the sale or liquidation of the Company&#x2019;s investment in AlloTera Therapeutics
in connection with restructuring the Secured Notes in May 2025 and the change in fair value of the investment in AlloTera Therapeutics
shares, which were previously presented together as a single line item as of and for the three and nine months ended September 30, 2025,
are now presented separately in the accompanying financial statements for enhanced clarity. The reclassification had no effect on previously
reported net loss, total assets, total liabilities, stockholders&#x2019; equity, or cash flows.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zY5R47baYuek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z7kFLGLkeiXh"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts in the financial statements and accompanying notes. Management uses estimates in financial statements to approximate
monetary amounts for items that cannot be measured precisely, such as asset valuations, liabilities, and revenue recognition. These estimates
are based on subjective judgments, experience, and future assumptions. The Company evaluates its estimates and assumptions on an ongoing
basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.
Actual results could differ from estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_znDOVkGUke2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zfYBQQ9yBwq"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. FASB ASC 820, Fair Value Measurement (&#x201c;Topic 820&#x201d;) establishes a fair value
hierarchy for those instruments measured at fair value that distinguishes between fair value measurements based on market data (observable
inputs) and those based on the Company&#x2019;s own assumptions (unobservable inputs). This hierarchy maximizes the use of observable
inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Unobservable inputs in which there is little or no market data, which require a reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment
of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets
and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values takes into account the
market for the Company&#x2019;s financial assets and liabilities, the associated credit risk, and other factors as required. The Company
considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide
pricing information on an ongoing basis. See Note 2. Fair Value of Financial Instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_z4y69t7TKHVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zZTfwRABSSp2"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for revenues in accordance with FASB ASC 606, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). To determine
revenue recognition for arrangements that fall within the scope of Topic 606, the Company performs the following five steps: (i) identify
the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv)
allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies
a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration
it is entitled to in exchange for the goods or services transferred to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, the Company&#x2019;s
revenues have been generated exclusively from license agreements, which consist of licenses of intellectual property, research and development
cost reimbursements and service fees, upfront signing fees, milestone payments and royalties on future licensee&#x2019;s product sales.
From time to time, the Company may retain manufacturing rights when it enters license agreements, and in this case, the Company and its
licensee will enter a separate supply agreement, under which the Company will agree to sell clinical materials needed for research and
clinical trials to the licensee, for which the Company will recognize revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
Grants:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
out-licensing arrangements that include a grant of a license to the Company&#x2019;s intellectual property, the Company considers whether
the license grant is distinct from the other performance obligations included in the arrangement. For licenses that are distinct, the
Company recognizes revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term
has begun and the Company has provided all necessary information regarding the underlying intellectual property to the customer, which
generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
related Services:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
license agreements that include service-based performance obligations, the Company evaluates whether these separately identifiable services
are distinct performance obligations. The Company considers whether the customer could benefit from the licensed intellectual property
with other readily available resources, whether the performance of the service would significantly modify or customize the licensed intellectual
property or whether the service is highly interrelated or interdependent with the licensed intellectual property. Revenue attributable
to services that are deemed distinct performance obligations are recognized over time as the customer simultaneously receives and consumes
the benefits of the Company&#x2019;s performance. The Company measures progress toward completion using an input method, typically cost-to-cost,
which reflects the pattern in which services are delivered. Amounts received in advance for optional future services are recorded as
deferred revenue and recognized as revenue when the related services are performed or when the option expires. The transaction price
is allocated to the service performance obligations based on their relative standalone selling prices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Milestone
and Contingent Payments:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the inception of the arrangement and at each reporting date thereafter, the Company assesses whether it should include any milestone
and contingent payments or other forms of variable consideration in the transaction price using the most likely amount method. If it
is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty, the associated milestone
value is included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability
of achievement of each such milestone and any related constraint and, if necessary, adjusts its estimate of the overall transaction price.
Since milestone and contingent payments may become payable to the Company upon the initiation of a clinical study or filing for or receipt
of regulatory approval, the Company reviews the relevant facts and circumstances to determine when the Company should update the transaction
price, which may occur before the triggering event. When the Company updates the transaction price for milestone and contingent payments,
the Company allocates the changes in the total transaction price to each performance obligation in the agreement on the same basis as
the initial allocation. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment, which may result
in recognizing revenue for previously satisfied performance obligations in such period. The Company&#x2019;s licensees will generally
pay milestone payments subsequent to achievement of the triggering event.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Materials
Supply:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides clinical and research grade materials so that licensees may develop products based on the licensed molecules, or alternatively,
so that distributors may supply their network of research and commercial customers with the Company&#x2019;s proprietary molecules. Under
a license agreement, the amounts billed are recognized as revenue as the performance obligations are satisfied by the Company, once the
Company determines that a contract exists. Revenue from sales to distributors is recognized once control of the goods transfers to the distributor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--InvestmentPolicyTextBlock_zkBypyrkP5Qh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zqzdCe29jVNf"&gt;Investments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of its financing strategy, the Company may enter into licensing or collaboration agreements under which it receives consideration
in the form of a minority equity interest in a counterparty, in lieu of or in addition to cash payments. These financial instruments
are presented within Investments in the accompanying condensed balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
consideration is an equity interest in a private entity whose equity has limited marketability with no readily determinable fair value
and for which the Company does not have significant influence over the investee, the Company measures the equity interest using the measurement
alternative, at cost less impairment, adjusted for observable price changes in orderly transactions for the identical or similar investment
of the same issuer (ASC Topic 321, Investments - Equity Securities or Topic 321), unless the fair value method is otherwise elected.
If the Company elects to measure an equity security at fair value, the entity shall measure all identical or similar investments of the
same issuer, including future purchases of identical or similar investments of the same issuer, at fair value. The election to measure
those securities at fair value shall be irrevocable. Any resulting gains or losses on the securities for which that election is made
shall be recorded in earnings at the time of the election and each reporting period thereafter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the second quarter of 2025, the Company elected to account for its shares of AlloTera Therapeutics, Inc. (&#x201c;AlloTera Therapeutics&#x201d;)
formerly Wugen, Inc. (&#x201c;Wugen&#x201d;), previously accounted for under the measurement alternative, at fair value determined by using
financial valuation techniques and market information available. The Company remeasures the change in fair value of the AlloTera Therapeutics
shares in reporting periods subsequent to the second quarter of 2025 and recognizes the change in fair value in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has transferred the rights to a portion of the proceeds that may be received upon the sale or liquidation of its shares of AlloTera
Therapeutics, if such event occurs, which gave rise to a contingent liability. These rights were transferred as part of the consideration
given in exchange for restructuring, converting or settling debt, including restructure of some of the Secured Notes in May 2025, conversion
of the Convertible Bridge Notes in May 2025, and settlement of the remaining outstanding Secured Notes on October 1, 2026. See
Note 13. Subsequent Events. The contingent liability is measured based on the fair value of the relevant number of shares of AlloTera
Therapeutics common stock underlying the rights that were transferred, with the change in fair value recognized in earnings beginning
in the second quarter of 2025 and each reporting period thereafter. See Note 2. Fair Value of Financial Instruments and Note 4. Debt,
Net.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 16, 2026, the Company received full payment of the nonrefundable upfront license fee from Beijing Trimmune Biotech Co. Ltd. (&#x201c;Trimmune&#x201d;),
a private company based in China, which included an in-kind payment of a transferable equity interest in Trimmune. The Company has elected
to use the measurement alternative under ASC 321-10-35-2 to account for this investment. The initial fair value was derived by reference
to the implied post-financing valuation of Trimmune of RMB &lt;span id="xdx_907_eus-gaap--PaymentsForProceedsFromInvestments_uRMB_c20260316__20260316_zUSlqwCn4vvh" title="Related party amount"&gt;175,000,000&lt;/span&gt; of a contemporaneous Licensee Funding Transaction (&#x201c;LFT&#x201d;)
with unrelated third party investors (a Level 2 fair value indicator under Topic 820), using the exchange rate on the closing date of
the LFT. In subsequent reporting periods, the Company will measure the value of this investment at cost less impairment, adjusted for
observable price changes in orderly transactions for the identical or similar investment of the same issuer. See Note 5. License Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company invests excess cash in U.S. Treasury bills and notes, which are classified as trading securities. As of December
31, 2025 and September 30, 2026, the Company had &lt;span id="xdx_903_eus-gaap--ShortTermInvestments_iI_do_c20251231_zAWpWnqHcuw7" title="Short term investments"&gt;&lt;span id="xdx_900_eus-gaap--ShortTermInvestments_iI_do_c20260930_z8WMbYkvIJjl" title="Short term investments"&gt;no&lt;/span&gt;&lt;/span&gt; short-term investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUBt22WNuTc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_z2B1wypyySj7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying
value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future
undiscounted cash flows attributable to these assets. An impairment is recognized to the extent that an asset group is not
recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. Impairments, if
any, are recognized in earnings. It is the Company&#x2019;s policy to obtain an appraisal of long-lived assets at least once a year
in preparation for the Annual Report, and more often if the market appears to be weakening or other triggers for an indication of
impairment have occurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--StandbyEquityPurchaseAgreementPolicyPolicyTextBlock_z0TyfFp11Mg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zCb1eawwYVJ2"&gt;Standby
Equity Purchase Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and Square Gate Capital Master Fund, LLC - Series 4 (&#x201c;Square Gate&#x201d;) entered a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;)
providing for an equity line of credit with Square Gate on February 20, 2025. This agreement provides a mechanism for submission by the
Company and acceptance by Square Gate of Put Notices under the SEPA pursuant to which Square Gate and the Company may agree to and execute
one purchase and sale of Put Shares (&#x201c;Standard Put Shares&#x201d;). The Standard Put Notice has a pricing mechanism based on a volume-adjusted
weighted average trading price over three days following the acceptance of the Standard Put.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 14, 2025, the parties entered into a First Amendment to the SEPA (the &#x201c;First Amendment&#x201d;) to provide a mechanism for
submission by the Company and acceptance by Square Gate of Put Notices under the SEPA pursuant to which Square Gate and the Company may
agree to and execute multiple purchases and sales of Put Shares on the same trading day (&#x201c;Intraday Put Shares&#x201d;). Under the
First Amendment, among other things, the purchase price of the Intraday Put Shares will be the lowest traded price during a specified
valuation time period which begins with the acceptance of the Intraday Put and ends when trading volume reaches 1000% of the amount of
shares included in the Intraday Put.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
SEPA is an equity-linked instrument for which an investor has the right, but not the obligation, to purchase shares of the entity&#x2019;s
common stock over a specified period of time. The SEPA creates a purchase put option for the overarching arrangement which was determined
to be a derivative. Economically, before the entity has elected to sell shares, a SEPA represents a purchased put option on the entity&#x2019;s
own equity. However, once the entity &#x201c;draws&#x201d; on the SEPA, the related number of shares issued constitutes a financial instrument.
Thus, a SEPA contains both a purchased put option element and a forward share issuance element. This means that a SEPA generally does
not qualify for equity classification. Accordingly, entities must recognize an asset or liability for its SEPA. Such asset or liability
must be measured at fair value, with changes in fair value recognized in net (loss) income. Further, individual draws must also be evaluated
to determine if they meet criteria for equity classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
regards to the individual draws for a Standard Put under the SEPA, an individual draw would create a separate financial instrument with
settlement criteria that does not meet indexation guidance. While the number of shares is known at inception and therefore not subject
to the overarching share cap, there are two inputs into the settlement amount paid by the Investor which are not inputs into a fixed-for-fixed
option: (1) the maximum amount to be funded under the SEPA of $&lt;span id="xdx_903_eus-gaap--GuaranteeObligationsMaximumExposure_iI_pn5n6_c20260930__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zJgf7vBG4m43"&gt;20.0&lt;/span&gt; million, which inherently limits the settlement amount regardless
of the Company&#x2019;s stock price and (2) the discount which reduces the amount to be paid upon settlement. See Note 7. Standby Equity
Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zxCeKqJDtkB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z5LRP4wiC2Xj"&gt;Net
Income (Loss) Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net income (loss) per share is calculated by dividing the net income (loss) attributable to Common Stockholders by the daily weighted-average
number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net income (loss)
per share is computed by dividing the net income (loss) attributable to Common Stockholders by the sum of the daily weighted average
number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential
dilutive securities are excluded from diluted income or loss per share if the effect of such inclusion is anti-dilutive. The Company&#x2019;s
potentially dilutive securities, which include options granted under the 2019 Equity Incentive Plan (&#x201c;2019 Plan&#x201d;) and the
2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;) as well as the Company&#x2019;s Common Stock Warrants, have been excluded from the
computation of diluted net income (loss) per share as their exercise prices exceeded the average market price of the Company&#x2019;s
Common Stock during the period. Options and warrants are considered dilutive to the income per share calculation when their exercise
price is below the average market price of the stock (&#x201c;in-the-money&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has issued certain Common Stock Warrants that have a provision for participation in earnings. Under ASC 260, Earnings per Share,
undistributed earnings shall be allocated to Common Stock and participating securities utilizing the two-class method. The Company reports
distributed and undistributed allocations of earnings on a cumulative period basis in accordance with contractual participation rights
using the two-class method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfAUKlEWSHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zLD1dT89yGrb"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense
Disaggregation Disclosures (ASU 2024-03) which requires public business entities to provide enhanced disaggregation of expenses in financial
statements, including detailed disclosures on inventory purchases, employee compensation, depreciation, and amortization. The new guidance
is effective for the Company for fiscal periods beginning after December 15, 2026 and interim periods within fiscal years beginning after
December 15, 2027. The Company early adopted ASU 2024-03 on September 30, 2026 on a retrospective basis. See Note 11. Segment Reporting
for the disaggregation of relevant expense captions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU 2025-07&#x2014;Derivatives and Hedging (&#x201c;Topic 815&#x201d;) and Revenue from Contracts with Customers
(Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-based Noncash Consideration from a Customer in a Revenue
Contract, to expand the scope of contracts that are excluded from derivative accounting (i.e., measured at fair value through earnings).
ASU 2025-07 addresses stakeholders&#x2019; concerns about (1) the application of derivative accounting to contracts with features based
on the operations or activities of one of the parties to the contract and (2) the diversity in accounting for share-based noncash consideration
from a customer that is consideration for the transfer of goods or services. The guidance is effective for annual reporting periods beginning
after December 15, 2026, and interim periods within those annual periods. Entities may apply the guidance either on a modified retrospective
or prospective basis. Early adoption is permitted. The Company early adopted ASU 2025-07 prospectively, effective September 30, 2026.
The adoption did not have an impact on our financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zzOeMg257Df3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zecMe1LIjOZd"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU 2025-06, Intangibles &#x2014; Goodwill and Other &#x2014; Internal-Use Software (Subtopic 350-40):
Accounting for and Disclosure of Software Costs to update the accounting for internal use software costs. The guidance requires entities
to start capitalizing eligible costs when (1) management has authorized and committed to funding the software project, and (2) it is
probable that the project will be completed and the software will be used to perform the function intended. The guidance, which applies
to all entities, is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. Entities
may apply the guidance using a prospective, retrospective or modified transition approach. Early adoption is permitted. The Company is
evaluating the impact of the standard on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2025, the FASB issued ASU 2025-11, &#x201c;Interim Reporting (Topic 270): Narrow-Scope Improvements.&#x201d; This ASU clarifies
that the interim reporting requirements in Topic 270 apply to all entities that issue interim financial statements prepared in accordance
with U.S. GAAP and consolidates such requirements within Topic 270. The amendments provide a comprehensive list within Topic 270 of required
interim disclosures, establish a principle requiring disclosure of events or changes occurring after the end of the most recent annual
reporting period that have a material impact on interim results and clarifies the form and content requirements applicable to interim
financial statements. The amendments in ASU 2025-11 are effective for the interim reporting periods within annual reporting periods beginning
after December 15, 2027, with early adoption permitted. This ASU can be applied either prospectively or retrospectively to any or all
prior periods presented in the financial statements. The Company is currently evaluating ASU 2025-11 to determine the impact it may have
on our financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2026, the Company will cease to be an &#x2018;emerging growth company&#x2019; as defined in the Jumpstart Our Business
Startups Act of 2012. The Company expects to remain a non-accelerated filer and smaller reporting company. The Company is currently assessing
potential regulatory and operational changes that may be required as a result.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_857_zZnswrQTjong" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-03-312025-03-31" id="Fact000811">at a Special Meeting of the Stockholders, the stockholders of the Company approved a reverse stock split of all outstanding
shares of the Company&#x2019;s common stock (&#x201c;Common Stock&#x201d;), and the Board approved a reverse stock split of the Common Stock
at a final ratio of one-for-forty (1::40). This reverse stock split was effective on April 11, 2025, and the Common Stock commenced trading
on a reverse split-adjusted basis when the markets opened on April 11, 2025, under the existing trading symbol &#x201c;HCWB.&#x201d;</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-06-152026-06-15" id="Fact000813">at the Company&#x2019;s Annual Meeting of Stockholders, the stockholders of the Company approved one or more reverse
stock splits of all outstanding shares of Common Stock up to an aggregate of one-for-twenty (1::20) for a period of one year. On
June 24, 2026, the Board approved a reverse
stock split at a final ratio of one-for-six (1::6), or the Reverse Stock Split, which was effective at 12:01 a.m. Eastern
Time on Tuesday, June 30, 2026 (the &#x201c;Effective Date&#x201d;). The Common Stock commenced trading on a Reverse Stock
Split-adjusted basis under the Company&#x2019;s existing trading symbol, &#x201c;HCWB,&#x201d; at market open on Tuesday, June 30,
2026.</us-gaap:StockholdersEquityReverseStockSplit>
    <HCWB:CumulativeLossesToConductProductResearchAndDevelopmentInFuture
      contextRef="From2026-01-01to2026-09-30"
      decimals="-5"
      id="Fact000815"
      unitRef="USD">110800000</HCWB:CumulativeLossesToConductProductResearchAndDevelopmentInFuture>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000817">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhAPZdkIDcW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zABGFYudzx"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Consolidated
Financial Results&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On September 29, 2026, the Company formed
HCWB Holdings, LLC (the &#x201c;Subsidiary&#x201d;), a Utah limited liability company of which the Company is the sole member. The Subsidiary
has no employees or physical location. As of September 30, 2026, the Subsidiary had no assets, liabilities and had not commenced operations.
Accordingly, the formation of the Subsidiary had no impact on the Company&#x2019;s financial position or results of operations as of and
for the three months ended September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Beginning with the Company&#x2019;s
Annual Report for the year ended December 31, 2026, the Company will present consolidated financial statements that include the accounts
of HCW Biologics Inc. and its wholly owned Subsidiary. All intercompany balances and transactions, if any, will be eliminated in consolidation.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unaudited
Interim Financial Information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed financial statements as of September 30, 2026 and for the three and nine months ended September 30,
2025 and 2026 have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Article 10 of Regulation
S-X of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Accordingly, they do not include all of the information
and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal
and recurring adjustments that the Company believes are necessary to fairly state the Company&#x2019;s financial position and the results
of its operations and cash flows. The results for the three and nine months ended September 30, 2026 are not necessarily indicative of
the results expected for the full fiscal year or any subsequent interim period. The condensed balance sheet at December 31, 2025 has
been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete
financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein,
these unaudited condensed financial statements and the notes accompanying them should be read in conjunction with the Company&#x2019;s
audited financial statements for the year ended December 31, 2025 which appear in our Annual Report on Form 10-K for the year ended December
31, 2025 filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 31, 2026 (the &#x201c;Annual Report&#x201d;)
and in other filings with the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000819">&lt;p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zcndEJfmWGu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zvYQFBhSurgi"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing
transformative fusion immunotherapeutics for diseases promoted by chronic inflammation, including autoimmune disorders and other inflammatory
diseases, cancer and senescence-associated dysplasia. The Company&#x2019;s chief executive officer, who is the chief operating decision
maker (&#x201c;CODM&#x201d;), reviews financial information on an aggregate basis for allocating and evaluating financial performance.
In addition, the Company&#x2019;s CODM is regularly provided with detailed results of preclinical and clinical data which is considered
in his decision for the allocation of resources. See Note 11. Segment Reporting for further details. The single operating segment constitutes
all of the Company activity, and the CODM regularly reviews the entity-wide operating results and performance. All long-lived assets
are maintained in the United States of America.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2026-01-01to2026-09-30" id="Fact000821">&lt;p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zRk9rtwCnhC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zGNhqI4h1wb3"&gt;Reclassification
of Prior Period Amounts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Certain prior-period amounts have
been reclassified to conform to the current-period presentation. Specifically, the change in fair value of the contingent liability created
by transferring rights to a portion of the proceeds from the sale or liquidation of the Company&#x2019;s investment in AlloTera Therapeutics
in connection with restructuring the Secured Notes in May 2025 and the change in fair value of the investment in AlloTera Therapeutics
shares, which were previously presented together as a single line item as of and for the three and nine months ended September 30, 2025,
are now presented separately in the accompanying financial statements for enhanced clarity. The reclassification had no effect on previously
reported net loss, total assets, total liabilities, stockholders&#x2019; equity, or cash flows.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates contextRef="From2026-01-01to2026-09-30" id="Fact000823">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zY5R47baYuek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z7kFLGLkeiXh"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts in the financial statements and accompanying notes. Management uses estimates in financial statements to approximate
monetary amounts for items that cannot be measured precisely, such as asset valuations, liabilities, and revenue recognition. These estimates
are based on subjective judgments, experience, and future assumptions. The Company evaluates its estimates and assumptions on an ongoing
basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.
Actual results could differ from estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000825">&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_znDOVkGUke2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zfYBQQ9yBwq"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. FASB ASC 820, Fair Value Measurement (&#x201c;Topic 820&#x201d;) establishes a fair value
hierarchy for those instruments measured at fair value that distinguishes between fair value measurements based on market data (observable
inputs) and those based on the Company&#x2019;s own assumptions (unobservable inputs). This hierarchy maximizes the use of observable
inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Unobservable inputs in which there is little or no market data, which require a reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment
of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets
and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values takes into account the
market for the Company&#x2019;s financial assets and liabilities, the associated credit risk, and other factors as required. The Company
considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide
pricing information on an ongoing basis. See Note 2. Fair Value of Financial Instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000827">&lt;p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_z4y69t7TKHVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zZTfwRABSSp2"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for revenues in accordance with FASB ASC 606, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). To determine
revenue recognition for arrangements that fall within the scope of Topic 606, the Company performs the following five steps: (i) identify
the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv)
allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies
a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration
it is entitled to in exchange for the goods or services transferred to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction
price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, the Company&#x2019;s
revenues have been generated exclusively from license agreements, which consist of licenses of intellectual property, research and development
cost reimbursements and service fees, upfront signing fees, milestone payments and royalties on future licensee&#x2019;s product sales.
From time to time, the Company may retain manufacturing rights when it enters license agreements, and in this case, the Company and its
licensee will enter a separate supply agreement, under which the Company will agree to sell clinical materials needed for research and
clinical trials to the licensee, for which the Company will recognize revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
Grants:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
out-licensing arrangements that include a grant of a license to the Company&#x2019;s intellectual property, the Company considers whether
the license grant is distinct from the other performance obligations included in the arrangement. For licenses that are distinct, the
Company recognizes revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term
has begun and the Company has provided all necessary information regarding the underlying intellectual property to the customer, which
generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
related Services:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
license agreements that include service-based performance obligations, the Company evaluates whether these separately identifiable services
are distinct performance obligations. The Company considers whether the customer could benefit from the licensed intellectual property
with other readily available resources, whether the performance of the service would significantly modify or customize the licensed intellectual
property or whether the service is highly interrelated or interdependent with the licensed intellectual property. Revenue attributable
to services that are deemed distinct performance obligations are recognized over time as the customer simultaneously receives and consumes
the benefits of the Company&#x2019;s performance. The Company measures progress toward completion using an input method, typically cost-to-cost,
which reflects the pattern in which services are delivered. Amounts received in advance for optional future services are recorded as
deferred revenue and recognized as revenue when the related services are performed or when the option expires. The transaction price
is allocated to the service performance obligations based on their relative standalone selling prices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Milestone
and Contingent Payments:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the inception of the arrangement and at each reporting date thereafter, the Company assesses whether it should include any milestone
and contingent payments or other forms of variable consideration in the transaction price using the most likely amount method. If it
is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty, the associated milestone
value is included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability
of achievement of each such milestone and any related constraint and, if necessary, adjusts its estimate of the overall transaction price.
Since milestone and contingent payments may become payable to the Company upon the initiation of a clinical study or filing for or receipt
of regulatory approval, the Company reviews the relevant facts and circumstances to determine when the Company should update the transaction
price, which may occur before the triggering event. When the Company updates the transaction price for milestone and contingent payments,
the Company allocates the changes in the total transaction price to each performance obligation in the agreement on the same basis as
the initial allocation. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment, which may result
in recognizing revenue for previously satisfied performance obligations in such period. The Company&#x2019;s licensees will generally
pay milestone payments subsequent to achievement of the triggering event.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Materials
Supply:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides clinical and research grade materials so that licensees may develop products based on the licensed molecules, or alternatively,
so that distributors may supply their network of research and commercial customers with the Company&#x2019;s proprietary molecules. Under
a license agreement, the amounts billed are recognized as revenue as the performance obligations are satisfied by the Company, once the
Company determines that a contract exists. Revenue from sales to distributors is recognized once control of the goods transfers to the distributor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000829">&lt;p id="xdx_844_eus-gaap--InvestmentPolicyTextBlock_zkBypyrkP5Qh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zqzdCe29jVNf"&gt;Investments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of its financing strategy, the Company may enter into licensing or collaboration agreements under which it receives consideration
in the form of a minority equity interest in a counterparty, in lieu of or in addition to cash payments. These financial instruments
are presented within Investments in the accompanying condensed balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
consideration is an equity interest in a private entity whose equity has limited marketability with no readily determinable fair value
and for which the Company does not have significant influence over the investee, the Company measures the equity interest using the measurement
alternative, at cost less impairment, adjusted for observable price changes in orderly transactions for the identical or similar investment
of the same issuer (ASC Topic 321, Investments - Equity Securities or Topic 321), unless the fair value method is otherwise elected.
If the Company elects to measure an equity security at fair value, the entity shall measure all identical or similar investments of the
same issuer, including future purchases of identical or similar investments of the same issuer, at fair value. The election to measure
those securities at fair value shall be irrevocable. Any resulting gains or losses on the securities for which that election is made
shall be recorded in earnings at the time of the election and each reporting period thereafter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the second quarter of 2025, the Company elected to account for its shares of AlloTera Therapeutics, Inc. (&#x201c;AlloTera Therapeutics&#x201d;)
formerly Wugen, Inc. (&#x201c;Wugen&#x201d;), previously accounted for under the measurement alternative, at fair value determined by using
financial valuation techniques and market information available. The Company remeasures the change in fair value of the AlloTera Therapeutics
shares in reporting periods subsequent to the second quarter of 2025 and recognizes the change in fair value in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has transferred the rights to a portion of the proceeds that may be received upon the sale or liquidation of its shares of AlloTera
Therapeutics, if such event occurs, which gave rise to a contingent liability. These rights were transferred as part of the consideration
given in exchange for restructuring, converting or settling debt, including restructure of some of the Secured Notes in May 2025, conversion
of the Convertible Bridge Notes in May 2025, and settlement of the remaining outstanding Secured Notes on October 1, 2026. See
Note 13. Subsequent Events. The contingent liability is measured based on the fair value of the relevant number of shares of AlloTera
Therapeutics common stock underlying the rights that were transferred, with the change in fair value recognized in earnings beginning
in the second quarter of 2025 and each reporting period thereafter. See Note 2. Fair Value of Financial Instruments and Note 4. Debt,
Net.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 16, 2026, the Company received full payment of the nonrefundable upfront license fee from Beijing Trimmune Biotech Co. Ltd. (&#x201c;Trimmune&#x201d;),
a private company based in China, which included an in-kind payment of a transferable equity interest in Trimmune. The Company has elected
to use the measurement alternative under ASC 321-10-35-2 to account for this investment. The initial fair value was derived by reference
to the implied post-financing valuation of Trimmune of RMB &lt;span id="xdx_907_eus-gaap--PaymentsForProceedsFromInvestments_uRMB_c20260316__20260316_zUSlqwCn4vvh" title="Related party amount"&gt;175,000,000&lt;/span&gt; of a contemporaneous Licensee Funding Transaction (&#x201c;LFT&#x201d;)
with unrelated third party investors (a Level 2 fair value indicator under Topic 820), using the exchange rate on the closing date of
the LFT. In subsequent reporting periods, the Company will measure the value of this investment at cost less impairment, adjusted for
observable price changes in orderly transactions for the identical or similar investment of the same issuer. See Note 5. License Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company invests excess cash in U.S. Treasury bills and notes, which are classified as trading securities. As of December
31, 2025 and September 30, 2026, the Company had &lt;span id="xdx_903_eus-gaap--ShortTermInvestments_iI_do_c20251231_zAWpWnqHcuw7" title="Short term investments"&gt;&lt;span id="xdx_900_eus-gaap--ShortTermInvestments_iI_do_c20260930_z8WMbYkvIJjl" title="Short term investments"&gt;no&lt;/span&gt;&lt;/span&gt; short-term investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2026-03-162026-03-16"
      decimals="0"
      id="Fact000831"
      unitRef="RMB">175000000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000833"
      unitRef="USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000835"
      unitRef="USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000837">&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUBt22WNuTc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_z2B1wypyySj7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying
value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future
undiscounted cash flows attributable to these assets. An impairment is recognized to the extent that an asset group is not
recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. Impairments, if
any, are recognized in earnings. It is the Company&#x2019;s policy to obtain an appraisal of long-lived assets at least once a year
in preparation for the Annual Report, and more often if the market appears to be weakening or other triggers for an indication of
impairment have occurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <HCWB:StandbyEquityPurchaseAgreementPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000839">&lt;p id="xdx_841_ecustom--StandbyEquityPurchaseAgreementPolicyPolicyTextBlock_z0TyfFp11Mg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zCb1eawwYVJ2"&gt;Standby
Equity Purchase Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and Square Gate Capital Master Fund, LLC - Series 4 (&#x201c;Square Gate&#x201d;) entered a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;)
providing for an equity line of credit with Square Gate on February 20, 2025. This agreement provides a mechanism for submission by the
Company and acceptance by Square Gate of Put Notices under the SEPA pursuant to which Square Gate and the Company may agree to and execute
one purchase and sale of Put Shares (&#x201c;Standard Put Shares&#x201d;). The Standard Put Notice has a pricing mechanism based on a volume-adjusted
weighted average trading price over three days following the acceptance of the Standard Put.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 14, 2025, the parties entered into a First Amendment to the SEPA (the &#x201c;First Amendment&#x201d;) to provide a mechanism for
submission by the Company and acceptance by Square Gate of Put Notices under the SEPA pursuant to which Square Gate and the Company may
agree to and execute multiple purchases and sales of Put Shares on the same trading day (&#x201c;Intraday Put Shares&#x201d;). Under the
First Amendment, among other things, the purchase price of the Intraday Put Shares will be the lowest traded price during a specified
valuation time period which begins with the acceptance of the Intraday Put and ends when trading volume reaches 1000% of the amount of
shares included in the Intraday Put.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
SEPA is an equity-linked instrument for which an investor has the right, but not the obligation, to purchase shares of the entity&#x2019;s
common stock over a specified period of time. The SEPA creates a purchase put option for the overarching arrangement which was determined
to be a derivative. Economically, before the entity has elected to sell shares, a SEPA represents a purchased put option on the entity&#x2019;s
own equity. However, once the entity &#x201c;draws&#x201d; on the SEPA, the related number of shares issued constitutes a financial instrument.
Thus, a SEPA contains both a purchased put option element and a forward share issuance element. This means that a SEPA generally does
not qualify for equity classification. Accordingly, entities must recognize an asset or liability for its SEPA. Such asset or liability
must be measured at fair value, with changes in fair value recognized in net (loss) income. Further, individual draws must also be evaluated
to determine if they meet criteria for equity classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
regards to the individual draws for a Standard Put under the SEPA, an individual draw would create a separate financial instrument with
settlement criteria that does not meet indexation guidance. While the number of shares is known at inception and therefore not subject
to the overarching share cap, there are two inputs into the settlement amount paid by the Investor which are not inputs into a fixed-for-fixed
option: (1) the maximum amount to be funded under the SEPA of $&lt;span id="xdx_903_eus-gaap--GuaranteeObligationsMaximumExposure_iI_pn5n6_c20260930__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zJgf7vBG4m43"&gt;20.0&lt;/span&gt; million, which inherently limits the settlement amount regardless
of the Company&#x2019;s stock price and (2) the discount which reduces the amount to be paid upon settlement. See Note 7. Standby Equity
Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HCWB:StandbyEquityPurchaseAgreementPolicyPolicyTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="AsOf2026-09-30_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-5"
      id="Fact000840"
      unitRef="USD">20000000.0</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000842">&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zxCeKqJDtkB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z5LRP4wiC2Xj"&gt;Net
Income (Loss) Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net income (loss) per share is calculated by dividing the net income (loss) attributable to Common Stockholders by the daily weighted-average
number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net income (loss)
per share is computed by dividing the net income (loss) attributable to Common Stockholders by the sum of the daily weighted average
number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential
dilutive securities are excluded from diluted income or loss per share if the effect of such inclusion is anti-dilutive. The Company&#x2019;s
potentially dilutive securities, which include options granted under the 2019 Equity Incentive Plan (&#x201c;2019 Plan&#x201d;) and the
2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;) as well as the Company&#x2019;s Common Stock Warrants, have been excluded from the
computation of diluted net income (loss) per share as their exercise prices exceeded the average market price of the Company&#x2019;s
Common Stock during the period. Options and warrants are considered dilutive to the income per share calculation when their exercise
price is below the average market price of the stock (&#x201c;in-the-money&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has issued certain Common Stock Warrants that have a provision for participation in earnings. Under ASC 260, Earnings per Share,
undistributed earnings shall be allocated to Common Stock and participating securities utilizing the two-class method. The Company reports
distributed and undistributed allocations of earnings on a cumulative period basis in accordance with contractual participation rights
using the two-class method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000844">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfAUKlEWSHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zLD1dT89yGrb"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense
Disaggregation Disclosures (ASU 2024-03) which requires public business entities to provide enhanced disaggregation of expenses in financial
statements, including detailed disclosures on inventory purchases, employee compensation, depreciation, and amortization. The new guidance
is effective for the Company for fiscal periods beginning after December 15, 2026 and interim periods within fiscal years beginning after
December 15, 2027. The Company early adopted ASU 2024-03 on September 30, 2026 on a retrospective basis. See Note 11. Segment Reporting
for the disaggregation of relevant expense captions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU 2025-07&#x2014;Derivatives and Hedging (&#x201c;Topic 815&#x201d;) and Revenue from Contracts with Customers
(Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-based Noncash Consideration from a Customer in a Revenue
Contract, to expand the scope of contracts that are excluded from derivative accounting (i.e., measured at fair value through earnings).
ASU 2025-07 addresses stakeholders&#x2019; concerns about (1) the application of derivative accounting to contracts with features based
on the operations or activities of one of the parties to the contract and (2) the diversity in accounting for share-based noncash consideration
from a customer that is consideration for the transfer of goods or services. The guidance is effective for annual reporting periods beginning
after December 15, 2026, and interim periods within those annual periods. Entities may apply the guidance either on a modified retrospective
or prospective basis. Early adoption is permitted. The Company early adopted ASU 2025-07 prospectively, effective September 30, 2026.
The adoption did not have an impact on our financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <HCWB:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000846">&lt;p id="xdx_84A_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zzOeMg257Df3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zecMe1LIjOZd"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU 2025-06, Intangibles &#x2014; Goodwill and Other &#x2014; Internal-Use Software (Subtopic 350-40):
Accounting for and Disclosure of Software Costs to update the accounting for internal use software costs. The guidance requires entities
to start capitalizing eligible costs when (1) management has authorized and committed to funding the software project, and (2) it is
probable that the project will be completed and the software will be used to perform the function intended. The guidance, which applies
to all entities, is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. Entities
may apply the guidance using a prospective, retrospective or modified transition approach. Early adoption is permitted. The Company is
evaluating the impact of the standard on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2025, the FASB issued ASU 2025-11, &#x201c;Interim Reporting (Topic 270): Narrow-Scope Improvements.&#x201d; This ASU clarifies
that the interim reporting requirements in Topic 270 apply to all entities that issue interim financial statements prepared in accordance
with U.S. GAAP and consolidates such requirements within Topic 270. The amendments provide a comprehensive list within Topic 270 of required
interim disclosures, establish a principle requiring disclosure of events or changes occurring after the end of the most recent annual
reporting period that have a material impact on interim results and clarifies the form and content requirements applicable to interim
financial statements. The amendments in ASU 2025-11 are effective for the interim reporting periods within annual reporting periods beginning
after December 15, 2027, with early adoption permitted. This ASU can be applied either prospectively or retrospectively to any or all
prior periods presented in the financial statements. The Company is currently evaluating ASU 2025-11 to determine the impact it may have
on our financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2026, the Company will cease to be an &#x2018;emerging growth company&#x2019; as defined in the Jumpstart Our Business
Startups Act of 2012. The Company expects to remain a non-accelerated filer and smaller reporting company. The Company is currently assessing
potential regulatory and operational changes that may be required as a result.&lt;/span&gt;&lt;/p&gt;

</HCWB:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000848">&lt;p id="xdx_80A_eus-gaap--FairValueDisclosuresTextBlock_z1IvXSIifZrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_824_zrqoTgON1pT4"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses,
other current assets, U.S. government-backed securities with maturity dates up to one year, accounts payable and accrued liabilities,
approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money
market funds included in cash and cash equivalents and U.S. government-backed securities are measured at fair value based on quoted prices
in active markets, which are considered Level 1 inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2026, the Company agreed to modify certain outstanding warrants, subject to stockholder approval. Since
there was a contingency in the terms of settlement, the Company recognized a warrant liability as of March 31, 2026. The warrant liability
was measured at fair value using the Black-Scholes option pricing model. The fair value was classified as Level 3 within the fair value
hierarchy due to the use of significant unobservable inputs. The change in fair value was recognized in earnings. On June 15, 2026, at
the Company&#x2019;s Annual Meeting of Stockholders, the stockholders approved the repricing of the warrants underlying this warrant liability,
after which the warrants met all requirements for classification as equity. On that date, the Company remeasured the warrant liability
at fair value and recognized the change in fair value in earnings. In the nine months ended September 30, 2026, the Company recognized
the change in fair value of the warrant liability of $&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20260101__20260930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeH9ZHzaIXTg" title="Change in fair value of warrant liability"&gt;1.8&lt;/span&gt; million. There was no warrant liability outstanding as of September 30, 2026.
See Note 6. Sale of Common Stock and Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s investment in shares of AlloTera Therapeutics common stock is classified as Level 3 within the fair value hierarchy due
to the use of significant unobservable inputs. The fair value is estimated using a combination of valuation techniques, including an
adjusted enterprise valuation method and a backsolve method, which incorporates information from recent financing transactions and the
Company&#x2019;s assessment of the underlying enterprise value of AlloTera Therapeutics. Significant unobservable inputs used in these
valuations include assumptions related to the enterprise value of AlloTera Therapeutics, discounts for lack of marketability, the capital
structure of the investee, and the probability and timing of potential liquidity events. The fair value of the AlloTera Therapeutics
investment is reassessed each reporting period based on updated assumptions and available market information with the change in fair
value recognized in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reports a contingent liability for the fair value of the rights transferred to certain note holders with respect to a
portion of the proceeds the Company may receive upon the sale or liquidation of its shares in AlloTera Therapeutics, if such an
event occurs. The contingent liability arose in May 2025, when the Company transferred rights to certain holders of Secured Notes
and Convertible Bridge Notes as part of the terms to restructure and convert their debt to equity. The valuation of the contingent
liability is based on assumptions consistent with those used in valuing the related underlying AlloTera Therapeutics shares,
including the expected distribution of proceeds upon a liquidity event. The fair value of the contingent liability is reassessed
each reporting period with the change in fair value recognized in earnings. See Note 4. Debt, Net.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no material changes in the valuation techniques or significant unobservable inputs used to measure these Level 3 instruments during
the nine months ended September 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z1mmu993QVEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities which were measured at fair value at December 31, 2025 and September
30, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zXzuL3tlXrD2" style="display: none"&gt;Schedule
of Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeNVNuwLNn9l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMnBKZUGIPz4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqOtGxlIkMAi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zeebuawBCG9j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zIZlHw6YqT7d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; padding-left: 10pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,607,009&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0856"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,607,009&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--InvestmentsMember_zUDZnv31xpV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iNI_di_hus-gaap--FairValueByLiabilityClassAxis__custom--ContingentLiabilityMember_zvxssDmxRA3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Contingent liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(692,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(692,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_zjg70kbvjKfk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,607,009&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;633,798&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,240,807&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20260930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWB21OhyxeBe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4iDPNS0NCXj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUWkTIZ79H61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260930_zPIJgfTOPFI4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September&#160;30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ztqn28o7ZCy5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;631,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;631,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--InvestmentsMember_zadBhP2OA3r8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 10pt"&gt;Investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0879"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LiabilitiesFairValueDisclosure_iNI_di_hus-gaap--FairValueByLiabilityClassAxis__custom--ContingentLiabilityMember_zAIkNqObwF62" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 10pt"&gt;Contingent Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0885"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(692,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(692,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FairValueNetAssetLiability_iI_zHkCN8SL0pHa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;631,097&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;633,798&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,264,895&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zlYoIpREKMEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-01-012026-09-30_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact000850"
      unitRef="USD">1800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000852">&lt;p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z1mmu993QVEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities which were measured at fair value at December 31, 2025 and September
30, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zXzuL3tlXrD2" style="display: none"&gt;Schedule
of Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeNVNuwLNn9l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMnBKZUGIPz4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqOtGxlIkMAi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zeebuawBCG9j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zIZlHw6YqT7d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; padding-left: 10pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,607,009&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0856"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,607,009&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--InvestmentsMember_zUDZnv31xpV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iNI_di_hus-gaap--FairValueByLiabilityClassAxis__custom--ContingentLiabilityMember_zvxssDmxRA3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Contingent liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(692,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(692,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_zjg70kbvjKfk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,607,009&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;633,798&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,240,807&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20260930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWB21OhyxeBe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4iDPNS0NCXj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUWkTIZ79H61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260930_zPIJgfTOPFI4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September&#160;30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ztqn28o7ZCy5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;631,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;631,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--InvestmentsMember_zadBhP2OA3r8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 10pt"&gt;Investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0879"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LiabilitiesFairValueDisclosure_iNI_di_hus-gaap--FairValueByLiabilityClassAxis__custom--ContingentLiabilityMember_zAIkNqObwF62" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 10pt"&gt;Contingent Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0885"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(692,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(692,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FairValueNetAssetLiability_iI_zHkCN8SL0pHa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;631,097&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;633,798&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,264,895&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      id="Fact000854"
      unitRef="USD">1607009</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      id="Fact000857"
      unitRef="USD">1607009</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_InvestmentsMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">1326329</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_InvestmentsMember"
      decimals="0"
      id="Fact000862"
      unitRef="USD">1326329</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_ContingentLiabilityMember"
      decimals="0"
      id="Fact000866"
      unitRef="USD">692531</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_ContingentLiabilityMember"
      decimals="0"
      id="Fact000867"
      unitRef="USD">692531</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000869"
      unitRef="USD">1607009</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000871"
      unitRef="USD">633798</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000872"
      unitRef="USD">2240807</us-gaap:FairValueNetAssetLiability>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      id="Fact000874"
      unitRef="USD">631097</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      id="Fact000877"
      unitRef="USD">631097</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_InvestmentsMember"
      decimals="0"
      id="Fact000881"
      unitRef="USD">1326329</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_InvestmentsMember"
      decimals="0"
      id="Fact000882"
      unitRef="USD">1326329</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel3Member_custom_ContingentLiabilityMember"
      decimals="0"
      id="Fact000886"
      unitRef="USD">692531</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-09-30_custom_ContingentLiabilityMember"
      decimals="0"
      id="Fact000887"
      unitRef="USD">692531</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000889"
      unitRef="USD">631097</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2026-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000891"
      unitRef="USD">633798</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000892"
      unitRef="USD">1264895</us-gaap:FairValueNetAssetLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000894">&lt;p id="xdx_809_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z2tS6FbkP3re" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_82B_zx6ewWKwKTn5"&gt;Accrued Liabilities and Other Current Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company had a balance of $&lt;span id="xdx_907_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_pn5n6_c20251231_ztjbVlh0sZH1" title="Accounts payable and other accrued liabilities, current"&gt;1.1&lt;/span&gt; million included in Accrued liabilities and other current liabilities in the
accompanying condensed balance sheet, consisting of $&lt;span id="xdx_903_eus-gaap--ConstructionPayableCurrentAndNoncurrent_iI_c20251231_zYowXII71yp6" title="Construction payable"&gt;422,000&lt;/span&gt; for construction expenses, $&lt;span id="xdx_90D_eus-gaap--InterestPayableCurrent_iI_c20251231_zmKmrz9tegC3" title="Interest payable"&gt;87,000&lt;/span&gt; for accrued interest expense, $&lt;span id="xdx_900_eus-gaap--ManufacturingCosts_c20250101__20251231_zu6wc69oFSCd" title="Manufacturing expenses"&gt;49,000&lt;/span&gt;
for manufacturing expenses, $&lt;span id="xdx_90C_eus-gaap--LegalFees_c20250101__20251231_zW0kBx8LVAxe" title="Legal fees"&gt;159,000&lt;/span&gt; for legal fees, $&lt;span id="xdx_909_ecustom--ClinicalExpenses_iI_c20251231_zVVOnqfZYtmi" title="Clinical expenses"&gt;186,000&lt;/span&gt; for clinical expenses, $&lt;span id="xdx_90D_eus-gaap--AccruedSalariesCurrent_iI_c20251231_zj3iEC1BDEQ" title="Accrued salaries"&gt;79,000&lt;/span&gt; for salary expenses and $&lt;span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20251231_zOetsV3IhgR1" title="Accounts payable and accrued liabilities, current"&gt;118,000&lt;/span&gt; for other
accrued expenses or current liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026, the Company had a balance of $&lt;span id="xdx_90A_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_pn5n6_c20260930_zK7x92ONXAyi" title="Accounts payable and other accrued liabilities, current"&gt;1.0&lt;/span&gt; million included in Accrued liabilities and other current liabilities in the
accompanying condensed balance sheet, consisting of $&lt;span id="xdx_90A_eus-gaap--ConstructionPayableCurrentAndNoncurrent_iI_c20260930_zm5e2gbHaxM7" title="Construction payable"&gt;422,000&lt;/span&gt; for construction expenses, $&lt;span id="xdx_904_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_c20251231_zlJI3Adcrgb4" title="Property tax"&gt;115,000&lt;/span&gt; for property tax, $&lt;span id="xdx_90F_eus-gaap--LegalFees_c20260101__20260930_zuR8I1CILmVc" title="Legal fees"&gt;104,000&lt;/span&gt; for legal
fees, $&lt;span id="xdx_902_ecustom--ClinicalExpenses_iI_c20260930_zqmewYCn3fv8" title="Clinical expenses"&gt;207,000&lt;/span&gt; for clinical expenses, $&lt;span id="xdx_90C_eus-gaap--AccruedSalariesCurrent_iI_c20260930_zr4dt05afvFa" title="Accrued salaries"&gt;131,000&lt;/span&gt; for salary expenses and $&lt;span id="xdx_908_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20260930_zeCKizgiEe2l" title="Accounts payable and accrued liabilities, current"&gt;21,000&lt;/span&gt; for other accrued expenses or current liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000896"
      unitRef="USD">1100000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000898"
      unitRef="USD">422000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000900"
      unitRef="USD">87000</us-gaap:InterestPayableCurrent>
    <us-gaap:ManufacturingCosts
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact000902"
      unitRef="USD">49000</us-gaap:ManufacturingCosts>
    <us-gaap:LegalFees
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact000904"
      unitRef="USD">159000</us-gaap:LegalFees>
    <HCWB:ClinicalExpenses
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000906"
      unitRef="USD">186000</HCWB:ClinicalExpenses>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000908"
      unitRef="USD">79000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000910"
      unitRef="USD">118000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="-5"
      id="Fact000912"
      unitRef="USD">1000000.0</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000914"
      unitRef="USD">422000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000916"
      unitRef="USD">115000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LegalFees
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000918"
      unitRef="USD">104000</us-gaap:LegalFees>
    <HCWB:ClinicalExpenses
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000920"
      unitRef="USD">207000</HCWB:ClinicalExpenses>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000922"
      unitRef="USD">131000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000924"
      unitRef="USD">21000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000926">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zY0WGJurspQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_824_zXXeKviP9Lvg"&gt;Debt, Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cogent
Bank Loan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 15, 2022, the Company entered into the 2022 Loan Agreement with Cogent Bank (the &#x201c;2022 Loan Agreement&#x201d;), pursuant
to which it received $&lt;span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20220815__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoLoanAgreementMember_zDu57nRsmP9a" title="Line of credit"&gt;6.5&lt;/span&gt; million in proceeds to purchase a property where the Company planned to construct a manufacturing facility
for biologics and upgraded research laboratory facilities (the &#x201c;Property&#x201d;). The loan is secured by a first priority lien
on the Property.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026, the Company had $&lt;span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn5n6_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoLoanAgreementMember_zTa7nqzrBCsb" title="Line of credit outstanding"&gt;6.1&lt;/span&gt; million in principal outstanding under the 2022 Loan Agreement. &lt;span id="xdx_903_eus-gaap--LineOfCreditFacilityFrequencyOfPayments_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoLoanAgreementMember_zs53LXFumRpl" title="Line of credit description"&gt;The interest-only period
was one year followed by 48 months of equal payments of principal and interest&lt;/span&gt; beginning on September 15, 2023 based on a 25-year amortization
rate. The unamortized balance is due on &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoLoanAgreementMember_zs9njxxdoDQ1" title="Maturity date"&gt;August 15, 2027&lt;/span&gt; (the &#x201c;2022 Loan Agreement Maturity Date&#x201d;), and bears interest at
a fixed per annum rate equal to &lt;span id="xdx_900_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoLoanAgreementMember_zeJVk1bdxZaa" title="Interest rate"&gt;5.75&lt;/span&gt;%. The Company has the option to prepay the outstanding balance of the loan prior to the 2022 Loan
Agreement Maturity Date without penalty. The Company is in compliance with covenants related to current payment of principal, interest,
property taxes and insurance as of September 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and September 30, 2026, the Company has reported this loan as Short-term debt, net. The 2022 Loan Agreement contains
a provision for a discretionary default in the event that the Company fails to pay sums due in connection with construction of any improvements.
This provision was triggered because certain subcontractors filed mechanics liens related to unpaid invoices issued in connection with
the Company&#x2019;s construction of its planned manufacturing facilities and upgraded research laboratories at the Property. On October
24, 2025, the Company was notified by Cogent Bank that it exercised its discretion to make a demand that the Company cure the mechanics
liens no later than thirty (30) days after receipt of this letter in strict compliance with Section 7.2(3) of the Loan Agreement by:
(i) paying and discharging all of the Claims of Lien and causing satisfactions to be recorded in the Public Records of Broward County,
Florida for all of the Claims of Lien, and (ii) resolving all litigation against the Borrower and the mortgaged property described in
the Mortgage and causing such claims in the Foreclosure Actions to be dismissed and all related notices of lis pendens to be released.
See Note 13. Subsequent Events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Secured
Notes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company received $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zFWdHX9wUVk2" title="Face amount"&gt;6.9&lt;/span&gt; million in funding from the issuance of Secured Notes. Investors included
Dr. Hing C. Wong, Founder and Chief Executive Officer, who invested $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_pn5n6_c20241231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOuicDMAduii" title="Investment owned"&gt;2.4&lt;/span&gt; million; Rebecca Byam, Chief Financial Officer, who invested
$&lt;span id="xdx_905_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_c20241231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zOptkTthOL2e" title="Investment owned"&gt;220,000&lt;/span&gt;; Lee Flowers, Senior Vice President of Business Development, who invested $&lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_c20241231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__srt--TitleOfIndividualAxis__srt--ExecutiveVicePresidentMember_zM26Ev1zLEEa" title="Investment owned"&gt;25,000&lt;/span&gt;; Scott T. Garrett, the Chairman of the Company&#x2019;s
board of directors, who invested $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_c20241231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zq0stGijr4M3" title="Investment owned"&gt;140,000&lt;/span&gt;; Gary M. Winer, who was serving as a member of the Company&#x2019;s board of directors at the
time of his investment, who invested $&lt;span id="xdx_909_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_c20241231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__srt--TitleOfIndividualAxis__custom--GaryMWinerMember_zLXpftkdkWqc" title="Investment owned"&gt;60,000&lt;/span&gt;; Rick S. Greene, a member of the board of directors, who invested $&lt;span id="xdx_900_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_c20241231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__srt--TitleOfIndividualAxis__custom--RickSGreeneMember_znqy4c0GpWwd" title="Investment owned"&gt;25,000&lt;/span&gt;, and other significant
investors. In July and October 2024, the terms of the Secured Notes were amended, including but not limited to a fixed bonus payable
on Maturity, or August 30, 2026 (the &#x201c;Maturity Date&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a condition to entering into the Amended and Restated Note Purchase Agreement, the Company, Mercedes M. Sellek, P.A. (&#x201c;Escrow Agent&#x201d;),
and the Purchasers entered into that certain Escrow Agreement and Amended and Restated Pledge Agreement, dated July 2, 2024, pursuant
to which the Company agreed to pledge its equity ownership interest in AlloTera Therapeutics (the &#x201c;Pledged Collateral&#x201d;),
to be held and released by Escrow Agent according to the terms of the Escrow Agreement, as security for the Secured Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Secured Notes bear interest at a rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zahwnt7ik5Pc" title="Interest rate"&gt;9&lt;/span&gt;% per annum, payable quarterly in arrears, and mature on &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_za1XtKUrKXW1" title="Maturity date"&gt;August 30, 2026&lt;/span&gt; (the &#x201c;Maturity
Date&#x201d;), on which date the principal balance, accrued but unpaid interest, and other amounts that may be due under the terms of
the Amended and Restated Note Purchase Agreement shall be due and payable. The Amended and Restated Note Purchase Agreement provides
for a 30-day period in which to cure the default event for nonpayment. The Senior Notes have a provision for repayment upon a mandatory
redemption event during the term or on the Maturity Date. A mandatory redemption event requires the sale or liquidation of the Company&#x2019;s
shares of AlloTera Therapeutics. If the Secured Notes are repaid on the Maturity Date, holders will receive their pro rata share of
a fixed bonus payment of $&lt;span id="xdx_90C_ecustom--FixedBonusPayment_pn5n6_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zvKx1UfKCkW7" title="Fixed bonus payment"&gt;3.4&lt;/span&gt; million in addition to payment of outstanding principal and accrued interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
agreement contains default provisions, according to which, following an event of default, the Company may be required to distribute the
Pledged Collateral to the Purchasers on a pro rata basis based on a $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20260930__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__us-gaap--CollateralAxis__us-gaap--CollateralPledgedMember_z50ivR2i1ZM4" title="Face amount"&gt;10.0&lt;/span&gt; million issuance of Secured Notes, in full satisfaction of
the indebtedness evidenced by the Secured Notes. The Pledged Collateral will be held and released according to the terms of the Escrow
Agreement, as security for the Secured Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Secured Notes were deemed to be a hybrid instrument, consisting of a debt host with embedded derivatives requiring bifurcation and accounting
for separately. The embedded derivatives consist of the Mandatory Redemption, which depends on certain events occurring, and the fixed
bonus payable upon the Maturity Date. The fair value of the embedded derivative, which incorporated the likelihood of certain events
occurring, was immaterial. Thus, as of December 31, 2025 and September 30, 2026, the Company did not recognize the embedded derivative
in the accompanying condensed balance sheets. The Company accounts for the fixed bonus payment to be paid if the Secured Notes are repaid
on the Maturity Date by accreting the bonus payment to the full amount due on the Maturity Date, utilizing the effective interest rate
method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2025, noteholders holding $&lt;span id="xdx_90D_eus-gaap--ExtinguishmentOfDebtAmount_pn5n6_c20250501__20250501__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zcdwK2uyBFch" title="Extinguishment of debt amount"&gt;6.6&lt;/span&gt; million of the principal of the outstanding Secured Notes elected to convert their outstanding
indebtedness to equity and entered into the Second Amendment to the Amended and Restated Note Purchase Agreement (the &#x201c;Conversion
Agreement&#x201d;). On May 7, 2025, the conversion date, the Company extinguished $&lt;span id="xdx_904_eus-gaap--ExtinguishmentOfDebtAmount_pn5n6_c20250507__20250507__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zqzuF4kiR90a" title="Extinguishment of debt amount"&gt;6.6&lt;/span&gt; million of the outstanding principal amount of
Secured Notes and $&lt;span id="xdx_90A_ecustom--DerecognitionOfAccumulatedAccretionOfFixedBonusForSecuredNotes_c20250507__20250507__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zydte6xB0meb" title="Accumulated accretion"&gt;860,462&lt;/span&gt; of accumulated accretion of a fixed bonus to be paid on the Maturity Date. For those noteholders who converted
to equity, the right to a fixed bonus payable on the Maturity Date was terminated and the previously accumulated fixed bonus was waived.
See section &#x201c;Troubled Debt Restructuring of Secured Notes&#x201d; below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
those Secured Notes which remained outstanding as of December 31, 2025 and September 30, 2026, the Company reported $&lt;span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_c20251231__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_z66UdFcpEscl" title="Short term borrowings"&gt;397,065&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ShortTermBorrowings_iI_c20260930__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_z5NmSF5723Ae" title="Short term borrowings"&gt;442,823&lt;/span&gt;,
respectively, including outstanding principal, accrued interest and accumulated accretion of a fixed bonus payment due upon Maturity
Date as a current liability in Short-term debt, net in the accompanying condensed balance sheets. As of October 1, 2026, the Secured Notes were settled by allocating a portion of the proceeds upon the sale or liquidation of AlloTera Therapeutics
shares. See
Note 13. Subsequent Events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended September 30, 2025 and 2026, the Company recognized $&lt;span id="xdx_90A_eus-gaap--AccretionExpense_c20250701__20250930__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zVXmXNMfUte" title="Accretion expense"&gt;15,502&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--AccretionExpense_c20260701__20260930__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zyBD53NbuEfb" title="Accretion expense"&gt;9,609&lt;/span&gt;, respectively, as an expense for accretion
of the fixed bonus payment due in the event the Secured Notes are repaid on the Maturity Date, presented within General and administrative
expenses in the accompanying condensed statements of operations. For the nine months ended September 30, 2025 and 2026, the Company recognized
$&lt;span id="xdx_902_eus-gaap--AccretionExpense_c20250101__20250930__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zfebRfG7RBv1" title="Accretion expense"&gt;390,809&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AccretionExpense_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zGE8c9JGQnp2" title="Accretion expense"&gt;38,435&lt;/span&gt;, respectively, for this expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Troubled
Debt Restructuring of Secured Notes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into the Second Amendment to its Amended and Restated Note Purchase Agreement in which certain Secured Note noteholders
and the Company agreed to the terms to effectively extinguish $&lt;span id="xdx_906_eus-gaap--ExtinguishmentOfDebtAmount_pn5n6_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__custom--TroubledDebtRestructuringOfSeniorSecuredNotesMember_zHuyJDx3VUM6" title="Extinguishment of debt amount"&gt;7.4&lt;/span&gt; million of debt through the issuance of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__custom--TroubledDebtRestructuringOfSeniorSecuredNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuqr3FHvWf61" title="Issuance of shares"&gt;42,181&lt;/span&gt; shares of Common Stock,
warrants to purchase up to &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__custom--TroubledDebtRestructuringOfSeniorSecuredNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0hSDjPFq17" title="Conversion of stock"&gt;21,099&lt;/span&gt; shares of Common Stock, and rights to receive a pro rata share of the proceeds or shares from the Company&#x2019;s
shares in AlloTera Therapeutics common stock, which equals &lt;span id="xdx_909_ecustom--PercentageOfRightToProRataShares_pid_dp_uPure_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__custom--TroubledDebtRestructuringOfSeniorSecuredNotesMember_zmtwfRdVnM05" title="Pro rate share"&gt;49.11&lt;/span&gt;% of total proceeds. The transaction was accounted for under ASC Subtopic
470-50, Debt Modifications and Extinguishments, and ASC Subtopic 470-60, Troubled Debt Restructurings by Debtors as a troubled debt extinguishment,
as the Company was experiencing financial difficulty and it was granted a concession by Secured Note noteholders whereby the fair value
of consideration transferred was less than the carrying amount of the Secured Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net carrying amount of the restructured Secured Notes was $&lt;span id="xdx_902_ecustom--NetCarryingAmountOfTheRestructuredSecuredNotes_iI_pn5n6_c20260930__us-gaap--LongtermDebtTypeAxis__custom--TroubledDebtRestructuringOfSeniorSecuredNotesMember_zbfVUkJ8Lq6c" title="Net carrying amount of restructured secured notes"&gt;7.4&lt;/span&gt; million, including principal of $&lt;span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__custom--TroubledDebtRestructuringOfSeniorSecuredNotesMember_zQ3J3yLrCtvi" title="Debt conversion"&gt;6.6&lt;/span&gt; million and accumulated accretion
of a fixed bonus payable upon Maturity Date of $&lt;span id="xdx_90D_ecustom--AccumulatedAccretionOfFixedBonusPayable_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__custom--TroubledDebtRestructuringOfSeniorSecuredNotesMember_zR5Vah5OTzqj" title="Accumulated accretion of fixed bonus"&gt;860,462&lt;/span&gt;. The fair value of consideration transferred was $&lt;span id="xdx_90E_ecustom--FairValueOfConsiderationTransferredForDebtRestructuring_pn5n6_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__custom--TroubledDebtRestructuringOfSeniorSecuredNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn4MioEWvX9" title="Fair value of consideration transferred"&gt;4.0&lt;/span&gt; million, including Common
Stock, warrants to purchase Common Stock, and rights to a portion of the proceeds of the Company&#x2019;s shares of AlloTera Therapeutics
common stock, with the difference of $&lt;span id="xdx_902_eus-gaap--GainsLossesOnRestructuringOfDebt_pn5n6_c20260101__20260930__us-gaap--LongtermDebtTypeAxis__custom--TroubledDebtRestructuringOfSeniorSecuredNotesMember_zO5LKya0iO6" title="Gains losses on restructuring of debt"&gt;3.5&lt;/span&gt; million being recognized as a troubled debt restructuring gain. Due to the related party nature
of the converting noteholders, the gain was recorded to additional paid-in capital and is reflected in the beginning balance as of January
1, 2026 for the period ended September 30, 2026, in the accompanying condensed statements of stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Unsecured
Promissory Notes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2025, the Company issued a total of $&lt;span id="xdx_909_eus-gaap--UnsecuredDebt_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zh2XaNJvrkQ4" title="Unsecured debt"&gt;270,000&lt;/span&gt; principal amount of unsecured convertible promissory notes with
a maturity date of May 5, 2026 with paid-in-kind interest accruing thereon, payable quarterly in arrears at &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_ztBIPCwNCEZd" title="Interest rate"&gt;10&lt;/span&gt;% per annum (the &#x201c;Convertible
Bridge Notes&#x201d;). In accordance with the terms of the agreement, following the completion of a qualified offering, the Convertible
Bridge Notes had a mandatory conversion feature to convert into shares of our Common Stock at the final offering price in an offering
that closed on May 15, 2025. In addition, upon conversion, the holders of the Convertible Bridge Notes received rights to a portion of
the proceeds of the Company&#x2019;s shares of AlloTera Therapeutics common stock, if and when such shares are sold. The portion of proceeds
allocated to each noteholder was represented by the number of shares of AlloTera Therapeutics common stock, determined by multiplying
0.25 by the original principal amount invested, in dollars, of the Convertible Bridge Notes. Investors included: $&lt;span id="xdx_90A_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJ3O7YxVkvWb" title="Investment owned"&gt;60,000&lt;/span&gt; invested by
Hing C. Wong, the Company&#x2019;s Founder and CEO; $&lt;span id="xdx_906_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zF5nyjW8sg8a" title="Investment owned"&gt;100,000&lt;/span&gt; invested by Scott T. Garrett, the Chairman of the Company&#x2019;s board of
directors; and $&lt;span id="xdx_901_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zrDrAhuCbitg" title="Investment owned"&gt;10,000&lt;/span&gt; invested by Gary M. Winer, who was serving as a member of the Company&#x2019;s board of directors at the time of
his investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of May 15, 2025, the outstanding principal of the Convertible Bridge Notes were converted. The fair value of consideration transferred
including &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250515__20250515__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAU04tqTKhDl" title="Shares issued"&gt;6,041&lt;/span&gt; shares of Common Stock and rights to proceeds of a portion of the Company&#x2019;s shares of AlloTera Therapeutics common
stock was $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250515__20250515__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zRCTpdWsNhw6" title="Proceeds from issuance of common stock"&gt;401,134&lt;/span&gt;, with the difference of $&lt;span id="xdx_90C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20250515__20250515__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zZgvirXmdUDf" title="Extinguishment of debt"&gt;131,135&lt;/span&gt; being recognized as a loss on conversion. Due to the related party nature of the
converting noteholders, the loss was recorded to additional paid-in capital and is reflected in the beginning balance as of January 1,
2026 for the period ended September 30, 2026, in the accompanying condensed statements of stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contingent
Liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the second quarter of 2025, in connection with the Troubled Debt Restructuring and the conversion of the Convertible Bridge Notes discussed
above, the converting noteholders have a right to receive a portion of the proceeds of the sale or liquidation of the Company&#x2019;s
shares of AlloTera Therapeutics common stock, if such an event occurs. The Company reported this obligation in Contingent liability in
the accompanying condensed balance sheets. The Company reports the fair value of its &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250630_z9vtONZ3weX7" title="Fair value of shares"&gt;2.2&lt;/span&gt; million shares of AlloTera Therapeutics common
stock in Investments in the accompanying condensed balance sheets. As of December 31, 2025 and September 30, 2026, the fair value of
the Company&#x2019;s AlloTera Therapeutics shares was $&lt;span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20251231__dei--LegalEntityAxis__custom--WugenIncMember_zZiOFznMyWZ6" title="Carrying amount"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20260930__dei--LegalEntityAxis__custom--WugenIncMember_zV1S55czNm32" title="Carrying amount"&gt;1.3&lt;/span&gt;&lt;/span&gt; million and the fair value for the Contingent liability was $&lt;span id="xdx_90E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20251231_zi3kN5dP1nhj" title="Contingent liability"&gt;&lt;span id="xdx_909_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20260930_zQH2gAeQfJqe" title="Contingent liability"&gt;692,531&lt;/span&gt;&lt;/span&gt; in the
accompanying condensed balance sheets. See Note 2. Fair Value of Financial Instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Promissory
Note with Personal Guaranty&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 8, 2025, the Company issued a promissory note for $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20250508__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zF03mOFvhVX3" title="Face amount"&gt;150,000&lt;/span&gt;, secured by a personal guaranty and pledge given by the Company&#x2019;s
Founder and CEO, Dr. Hing C. Wong in accordance with the provisions of that certain Guaranty and Pledge Agreement of even date herewith
between the Company and the holder (the &#x201c;Guaranteed Promissory Note&#x201d;). The Guaranteed Promissory Note was issued with an
original issue discount of $&lt;span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_c20250508__20250508_zBW31AIugbxi" title="Original issue discount"&gt;75,000&lt;/span&gt;. On the Maturity Date of February 7, 2026, the Company was obligated to repay $&lt;span id="xdx_909_eus-gaap--RepaymentsOfSecuredDebt_c20260207__20260207_zPHDiPY1TwMk" title="Repayment of debt"&gt;225,000&lt;/span&gt;. The Company
repaid the Guaranteed Promissory Note in full on February 6, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended September 30, 2025 and 2026, the Company recognized accretion of original issue discount of $&lt;span id="xdx_906_ecustom--AccretionOfOriginalIssueDiscount_c20260701__20260930_zPmFpPP1hdAe" title="Accretion of original issue discount"&gt;25,000&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--AccretionOfOriginalIssueDiscount_c20250701__20250930_zHOR5ocsiJi4" title="Accretion of original issue discount"&gt;10,278&lt;/span&gt;,
respectively, and for the nine months ended September 30, 2025 and 2026, the Company recognized accretion of original issue discount
of $&lt;span id="xdx_90C_ecustom--AccretionOfOriginalIssueDiscount_c20260101__20260930_z4rZ6asEjLz7" title="Accretion of original issue discount"&gt;39,722&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--AccretionOfOriginalIssueDiscount_c20250101__20250930_zUEemypctvnj" title="Accretion of original issue discount"&gt;10,278&lt;/span&gt;, respectively, in Interest expense in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Secured
Promissory Note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2026, the Company issued a senior secured promissory note for $&lt;span id="xdx_907_eus-gaap--SecuredDebt_iI_c20260923__srt--TitleOfIndividualAxis__custom--HingCWongMember_zhwH4Uu97Rf3" title="Senior secured promissory note"&gt;250,000&lt;/span&gt; to Hing C. Wong, the Company&#x2019;s Founder and
Chief Executive Officer (the &#x201c;Secured Promissory Note&#x201d;). The Secured Promissory Note accrued $&lt;span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20260923__20260923_zeywy9dnUdJ4" title="Accrued interest"&gt;41,667&lt;/span&gt; in interest on the date
it was issued and will accrue an additional $&lt;span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20260923_z8AmAH7v4tu2" title="Additional amount"&gt;41,667&lt;/span&gt; each quarter it remains outstanding until the maturity date of &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20260923__20260923_zykqHPeqIoHi" title="Debt maturity date"&gt;June 23, 2027&lt;/span&gt; (the
&#x201c;Maturity Date&#x201d;). On the Maturity Date, the Company will repay $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfDebt_c20260923__20260923_zkYO6ssdYpL7" title="Repayment of debt"&gt;375,000&lt;/span&gt;. The Secured Promissory Note and accrued but unpaid
interest may be prepaid by the Company prior to the Maturity Date, in whole or in part, without penalty. The proceeds of the Secured
Promissory Note were used for general corporate purposes. As of September 30, 2026, the Company recognized a current liability of $&lt;span id="xdx_903_eus-gaap--ShortTermDebtRefinancedAmount_c20260101__20260930_zOHGuocEhhPg" title="Short term debt"&gt;291,667&lt;/span&gt;
in Short-term debt, net in the accompanying condensed balance sheet. In the three and nine months ended September 30, 2026, the Company
recognized $&lt;span id="xdx_907_eus-gaap--InterestExpenseDebt_c20260701__20260930_zg06X1mIeQNe" title="Interest expense"&gt;&lt;span id="xdx_900_eus-gaap--InterestExpenseDebt_c20260101__20260930_zfvBADhZNDH3" title="Interest expense"&gt;41,667&lt;/span&gt;&lt;/span&gt;, respectively, for interest within Interest expense in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2022-08-15_custom_TwoThousandTwentyTwoLoanAgreementMember"
      decimals="-5"
      id="Fact000928"
      unitRef="USD">6500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
      contextRef="From2026-01-012026-09-30_custom_TwoThousandTwentyTwoLoanAgreementMember"
      decimals="-5"
      id="Fact000930"
      unitRef="USD">6100000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
    <us-gaap:LineOfCreditFacilityFrequencyOfPayments
      contextRef="From2026-01-012026-09-30_custom_TwoThousandTwentyTwoLoanAgreementMember"
      id="Fact000932">The interest-only period
was one year followed by 48 months of equal payments of principal and interest</us-gaap:LineOfCreditFacilityFrequencyOfPayments>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2026-01-012026-09-30_custom_TwoThousandTwentyTwoLoanAgreementMember"
      id="Fact000934">2027-08-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2026-01-012026-09-30_custom_TwoThousandTwentyTwoLoanAgreementMember"
      decimals="INF"
      id="Fact000936"
      unitRef="Pure">0.0575</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_us-gaap_SeniorNotesMember"
      decimals="-5"
      id="Fact000938"
      unitRef="USD">6900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2024-12-31_us-gaap_SeniorNotesMember_srt_ChiefExecutiveOfficerMember"
      decimals="-5"
      id="Fact000940"
      unitRef="USD">2400000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2024-12-31_us-gaap_SeniorNotesMember_srt_ChiefFinancialOfficerMember"
      decimals="0"
      id="Fact000942"
      unitRef="USD">220000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2024-12-31_us-gaap_SeniorNotesMember_srt_ExecutiveVicePresidentMember"
      decimals="0"
      id="Fact000944"
      unitRef="USD">25000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2024-12-31_us-gaap_SeniorNotesMember_srt_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">140000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2024-12-31_us-gaap_SeniorNotesMember_custom_GaryMWinerMember"
      decimals="0"
      id="Fact000948"
      unitRef="USD">60000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2024-12-31_us-gaap_SeniorNotesMember_custom_RickSGreeneMember"
      decimals="0"
      id="Fact000950"
      unitRef="USD">25000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-31_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact000952"
      unitRef="Pure">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-012024-12-31_us-gaap_SeniorNotesMember"
      id="Fact000954">2026-08-30</us-gaap:DebtInstrumentMaturityDate>
    <HCWB:FixedBonusPayment
      contextRef="From2026-01-012026-09-30_us-gaap_SeniorNotesMember"
      decimals="-5"
      id="Fact000956"
      unitRef="USD">3400000</HCWB:FixedBonusPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_us-gaap_SeniorNotesMember_us-gaap_CollateralPledgedMember"
      decimals="-5"
      id="Fact000958"
      unitRef="USD">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="From2025-05-012025-05-01_us-gaap_SeniorNotesMember"
      decimals="-5"
      id="Fact000960"
      unitRef="USD">6600000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="From2025-05-072025-05-07_us-gaap_SeniorNotesMember"
      decimals="-5"
      id="Fact000962"
      unitRef="USD">6600000</us-gaap:ExtinguishmentOfDebtAmount>
    <HCWB:DerecognitionOfAccumulatedAccretionOfFixedBonusForSecuredNotes
      contextRef="From2025-05-072025-05-07_us-gaap_SeniorNotesMember"
      decimals="0"
      id="Fact000964"
      unitRef="USD">860462</HCWB:DerecognitionOfAccumulatedAccretionOfFixedBonusForSecuredNotes>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2025-12-31_us-gaap_SeniorNotesMember"
      decimals="0"
      id="Fact000966"
      unitRef="USD">397065</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2026-09-30_us-gaap_SeniorNotesMember"
      decimals="0"
      id="Fact000968"
      unitRef="USD">442823</us-gaap:ShortTermBorrowings>
    <us-gaap:AccretionExpense
      contextRef="From2025-07-012025-09-30_us-gaap_SeniorNotesMember"
      decimals="0"
      id="Fact000970"
      unitRef="USD">15502</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="From2026-07-012026-09-30_us-gaap_SeniorNotesMember"
      decimals="0"
      id="Fact000972"
      unitRef="USD">9609</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="From2025-01-012025-09-30_us-gaap_SeniorNotesMember"
      decimals="0"
      id="Fact000974"
      unitRef="USD">390809</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="From2026-01-012026-09-30_us-gaap_SeniorNotesMember"
      decimals="0"
      id="Fact000976"
      unitRef="USD">38435</us-gaap:AccretionExpense>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember"
      decimals="-5"
      id="Fact000978"
      unitRef="USD">7400000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000980"
      unitRef="Shares">42181</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Shares">21099</us-gaap:ConversionOfStockSharesIssued1>
    <HCWB:PercentageOfRightToProRataShares
      contextRef="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember"
      decimals="INF"
      id="Fact000984"
      unitRef="Pure">0.4911</HCWB:PercentageOfRightToProRataShares>
    <HCWB:NetCarryingAmountOfTheRestructuredSecuredNotes
      contextRef="AsOf2026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember"
      decimals="-5"
      id="Fact000986"
      unitRef="USD">7400000</HCWB:NetCarryingAmountOfTheRestructuredSecuredNotes>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember"
      decimals="-5"
      id="Fact000988"
      unitRef="USD">6600000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <HCWB:AccumulatedAccretionOfFixedBonusPayable
      contextRef="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember"
      decimals="0"
      id="Fact000990"
      unitRef="USD">860462</HCWB:AccumulatedAccretionOfFixedBonusPayable>
    <HCWB:FairValueOfConsiderationTransferredForDebtRestructuring
      contextRef="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000992"
      unitRef="USD">4000000.0</HCWB:FairValueOfConsiderationTransferredForDebtRestructuring>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="From2026-01-012026-09-30_custom_TroubledDebtRestructuringOfSeniorSecuredNotesMember"
      decimals="-5"
      id="Fact000994"
      unitRef="USD">3500000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:UnsecuredDebt
      contextRef="AsOf2025-12-31_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact000996"
      unitRef="USD">270000</us-gaap:UnsecuredDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-12-31_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2025-12-31_custom_ConvertiblePromissoryNotesMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001000"
      unitRef="USD">60000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2025-12-31_custom_ConvertiblePromissoryNotesMember_srt_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact001002"
      unitRef="USD">100000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2025-12-31_custom_ConvertiblePromissoryNotesMember_srt_DirectorMember"
      decimals="0"
      id="Fact001004"
      unitRef="USD">10000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-05-152025-05-15_custom_ConvertiblePromissoryNotesMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">6041</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-05-152025-05-15_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact001008"
      unitRef="USD">401134</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-05-152025-05-15_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact001010"
      unitRef="USD">131135</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact001012"
      unitRef="Shares">2.2</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2025-12-31_custom_WugenIncMember"
      decimals="-5"
      id="Fact001014"
      unitRef="USD">1300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2026-09-30_custom_WugenIncMember"
      decimals="-5"
      id="Fact001016"
      unitRef="USD">1300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001018"
      unitRef="USD">692531</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001020"
      unitRef="USD">692531</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-05-08_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001022"
      unitRef="USD">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2025-05-082025-05-08"
      decimals="0"
      id="Fact001024"
      unitRef="USD">75000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="From2026-02-072026-02-07"
      decimals="0"
      id="Fact001026"
      unitRef="USD">225000</us-gaap:RepaymentsOfSecuredDebt>
    <HCWB:AccretionOfOriginalIssueDiscount
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact001028"
      unitRef="USD">25000</HCWB:AccretionOfOriginalIssueDiscount>
    <HCWB:AccretionOfOriginalIssueDiscount
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001030"
      unitRef="USD">10278</HCWB:AccretionOfOriginalIssueDiscount>
    <HCWB:AccretionOfOriginalIssueDiscount
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001032"
      unitRef="USD">39722</HCWB:AccretionOfOriginalIssueDiscount>
    <HCWB:AccretionOfOriginalIssueDiscount
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact001034"
      unitRef="USD">10278</HCWB:AccretionOfOriginalIssueDiscount>
    <us-gaap:SecuredDebt
      contextRef="AsOf2026-09-23_custom_HingCWongMember"
      decimals="0"
      id="Fact001036"
      unitRef="USD">250000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2026-09-232026-09-23"
      decimals="0"
      id="Fact001038"
      unitRef="USD">41667</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2026-09-23"
      decimals="0"
      id="Fact001040"
      unitRef="USD">41667</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2026-09-232026-09-23" id="Fact001042">2027-06-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-09-232026-09-23"
      decimals="0"
      id="Fact001044"
      unitRef="USD">375000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ShortTermDebtRefinancedAmount
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001046"
      unitRef="USD">291667</us-gaap:ShortTermDebtRefinancedAmount>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact001048"
      unitRef="USD">41667</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001050"
      unitRef="USD">41667</us-gaap:InterestExpenseDebt>
    <HCWB:LicenseAgreementTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001052">&lt;p id="xdx_80B_ecustom--LicenseAgreementTextBlock_zrlno6lQmnSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_825_zy5mWvF373ik"&gt;License and Distribution Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Beijing
Trimmune Biotech Co. Ltd. License&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 17, 2025, the Company and Trimmune entered into an Amended and Restated License, Research and Co-Development Agreement (&#x201c;Trimmune
License&#x201d;) following the assignment of the original License, Research and Co-Development Agreement, which includes an exclusive
license to HCW11-006 for in vivo applications (&#x201c;WY Biotech License&#x201d;) from WY Biotech Co., Ltd. to Trimmune. The parties restructured
the terms of the original WY Biotech License to include the assignment of rights to Trimmune. In addition to the license for HCW11-006,
the parties agreed that for additional consideration, Trimmune has an option to license the exclusive China rights to clinical development
and commercialization for &lt;i&gt;in vivo&lt;/i&gt; applications of HCW9302, the Company&#x2019;s clinical-stage molecule currently being evaluated
for the treatment of an autoimmune disorder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 16, 2026, the Company received the full nonrefundable upfront license fee, consisting of $&lt;span id="xdx_909_ecustom--GrossProceedsFromUpfrontLicenseFee_pn5n6_c20260316__20260316_zLUvhmcgtU6k" title="Gross proceeds from upfront license fee"&gt;3.5&lt;/span&gt; million in gross cash proceeds, or
$&lt;span id="xdx_90D_ecustom--NetProceedsAfterTaxFormUpfrontLicenseFee_pn5n6_c20260316__20260316_zVZYIFndpH59" title="Net proceeds after tax from upfront license fee"&gt;2.9&lt;/span&gt; million net of foreign taxes, and a transferable minority equity ownership interest in Trimmune with a fair value of $&lt;span id="xdx_90C_eus-gaap--FairValueOfAssetsAcquired_pn5n6_c20260316__20260316_z79C4AdYikdi" title="Fair value"&gt;3.5&lt;/span&gt; million,
whereupon the transaction was deemed closed and the contract was binding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, the Company is eligible to receive up to $&lt;span id="xdx_90E_ecustom--ProceedsFromDevelopmentAndRegulatoryMilestonePayments_pn5n6_c20260316__20260316__srt--RangeAxis__srt--MaximumMember_zwK1SfhyHAMc" title="Proceeds from development and regulatory milestone payments"&gt;16.0&lt;/span&gt; million in development and regulatory milestone payments, royalties on future
product sales, and a share of proceeds from certain future transactions involving the licensed molecule. Trimmune is responsible for
all research, development, manufacturing, regulatory, and commercialization costs in its territory, including the Phase 1 clinical trial
in China. Following completion of that trial, the Company has a payment-free, milestone-free, and royalty-free option (the &#x201c;Opt-in
Right&#x201d;) to recapture development and commercialization rights to HCW11-006 in the United States, Canada, Central America, and South
America (the &#x201c;Opt-in Territory&#x201d;). If the Company exercises its Opt-in Right, it will be responsible for the costs of clinical
development in its territory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
the Trimmune License and the equity interest were negotiated as a package with a single commercial objective, the Company combined and
accounted for them as a single arrangement under ASC 606. The equity interest represents non-cash consideration, measured at its fair
value of $&lt;span id="xdx_909_eus-gaap--PaymentsToAcquireBusinessesGross_pn5n6_c20260101__20260930__srt--RangeAxis__srt--MaximumMember_zzLkpbFVr178" title="Equity interest non-cash consideration fair value amount"&gt;3.5&lt;/span&gt; million at contract inception. The corresponding equity investment is accounted for under the measurement alternative in
ASC 321. &lt;span id="xdx_902_eus-gaap--RevenuePerformanceObligationDescriptionOfTiming_c20260101__20260930_z8AquQFnWlZb" title="Performance obligation description"&gt;The Company identified two distinct performance obligations: (i) the delivery of licensed intellectual property&#x2014; comprising
the licensed patent rights, licensed know-how, a related license to HCW9109, and a technology transfer (collectively, the &#x201c;Licensed
IP&#x201d;); and (ii) post-transfer development services consisting of an improved cell line and a master cell bank (collectively, the
&#x201c;Services&#x201d;). The transaction price at inception was $6,650,000, reflecting the $7.0 million in upfront consideration, less
$350,000 that was carved out as a contract liability related to prepaid optional post-transfer services.&lt;/span&gt; Development and regulatory milestone
payments, royalties, and sales-based sublicensing consideration are fully constrained at inception and excluded from the transaction
price. Non-sales-based sublicensing consideration remains constrained until the related uncertainty is resolved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocated the transaction price to the two performance obligations using a relative standalone selling price basis. The standalone
selling price of the Services was estimated using contemporaneous third-party Contract Research Organization (&#x201c;CRO&#x201d;) and
Contract Manufacturing Organization (&#x201c;CMO&#x201d;) contracted pricing. The standalone selling price of the Licensed IP was estimated
using the residual approach. The Licensed IP has significant standalone functionality and the Company does not expect to undertake activities
that will change that functionality. Accordingly, the license is a right to use the Company&#x2019;s functional intellectual property,
and revenue allocated to the Licensed IP performance obligation was recognized at the point in time control of the Licensed IP transferred
to Trimmune. Trimmune simultaneously receives and consumes the benefits of the Services as they are performed; accordingly, revenue allocated
to the Services is recognized over time using a cost-to-cost measure of progress. Milestone payments will be recognized when the related
constraint is resolved, typically upon achievement of the underlying clinical or regulatory event. Royalties and sales-based sublicensing
consideration will be recognized when the underlying sales occur. The Opt-in Right is not a repurchase feature and does not require deferral
of revenue at inception. If exercised, the Opt-in Right will be accounted for as a contract modification at that time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and nine months ended September 30, 2026, the Company recognized $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260701__20260930_zh9z0IeudSRa" title="Revenues"&gt;51,169&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20260101__20260930_zgKEta1F1S0j" title="Revenues"&gt;6.7&lt;/span&gt; million of revenue, respectively, under the
Trimmune License. For the three months ended September 30, 2026, revenues were comprised of $&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260701__20260930__srt--ProductOrServiceAxis__us-gaap--ServiceMember_z27MI34T2mJc" title="Revenues"&gt;51,169&lt;/span&gt; of Services revenue. For the nine
months ended September 30, 2026, revenues were comprised of $&lt;span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20260101__20260930__srt--ProductOrServiceAxis__custom--LicensedIPMember_z7WRNlzIibNj" title="Revenues"&gt;6.3&lt;/span&gt; million allocated to the Licensed IP recognized at closing and $&lt;span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930__srt--ProductOrServiceAxis__us-gaap--ServiceMember_z7mcxa1pois5" title="Revenues"&gt;402,899&lt;/span&gt;
of Services revenue. As of September 30, 2026, a contract liability of $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20260930_zYGwtiXlx8Y9" title="Contract liability"&gt;297,101&lt;/span&gt; was reported in the accompanying condensed balance sheet.
This represents $&lt;span id="xdx_903_ecustom--RemainingServicesConsideration_iI_c20260930_zE8CtFhhgpPl" title="Remaining Services consideration"&gt;15,000&lt;/span&gt; of remaining Services consideration and a $&lt;span id="xdx_90E_ecustom--PrepaymentOfPostTransferServices_c20260101__20260930_zezScQr3BZxh" title="Prepayment of post transfer services"&gt;282,101&lt;/span&gt; prepayment associated with the optional post-transfer services.
There were no indications of impairment in the equity interest in Trimmune, thus as of September 30, 2026, the Company continued to report
an investment in Trimmune of $&lt;span id="xdx_90D_ecustom--CarryingValueOfEquityInterest_iI_pn5n6_c20260930_zJr3yHGkVe8b" title="Carrying value of equity interest"&gt;3.5&lt;/span&gt; million in Investments in the accompanying condensed balance sheet. See Note 1. Organization and Significant
Accounting Policies &#x2013; Investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Transaction
Price and Contract Liability as of September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zKEekCW3mDy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B9_z0XEnCVH3Gt5" style="display: none"&gt;Schedule
of Transaction
Price and Contract Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Revenue Recognized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Transaction Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Contract Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Licensed IP&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--TransactionPrice_c20260101__20260930__srt--ProductOrServiceAxis__custom--LicensedIPMember_zvvNLxNrxpKb" style="width: 16%; text-align: right" title="Transaction Price"&gt;6,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930__srt--ProductOrServiceAxis__custom--LicensedIPMember_z8jXvNHy75X2" style="width: 16%; text-align: right" title="Revenues Recognized"&gt;6,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20260930__srt--ProductOrServiceAxis__custom--LicensedIPMember_zKMF07R6I7Ae" style="width: 16%; text-align: right" title="Contract liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Prepaid technology transfer costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--TransactionPrice_c20260101__20260930__srt--ProductOrServiceAxis__custom--PrepaidTechnologyTransferCostsMember_zZJ3LfifXwYl" style="text-align: right" title="Transaction Price"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930__srt--ProductOrServiceAxis__custom--PrepaidTechnologyTransferCostsMember_ziBkPvBiDUP3" style="text-align: right" title="Revenues Recognized"&gt;217,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20260930__srt--ProductOrServiceAxis__custom--PrepaidTechnologyTransferCostsMember_zIcWkwMqrRz3" style="text-align: right" title="Contract liability"&gt;282,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;Master Cell Bank&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--TransactionPrice_c20260101__20260930__srt--ProductOrServiceAxis__custom--MasterCellBankMember_zS5QXquS2PWk" style="border-bottom: Black 1pt solid; text-align: right" title="Transaction Price"&gt;200,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930__srt--ProductOrServiceAxis__custom--MasterCellBankMember_zf3UtSvbXVkg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Recognized"&gt;185,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20260930__srt--ProductOrServiceAxis__custom--MasterCellBankMember_zWnfccBBsrUa" style="border-bottom: Black 1pt solid; text-align: right" title="Contract liability"&gt;15,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--TransactionPrice_c20260101__20260930_zyqc7njGFch3" style="border-bottom: Black 2.5pt double; text-align: right" title="Transaction Price"&gt;7,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930_zFWhQa9wfJtb" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Recognized"&gt;6,702,899&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20260930_zsydeIf2Lznc" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liability"&gt;297,101&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zj6MNrzRGDag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trimmune
is a variable interest entity. Through equity ownership in Trimmune, licensing fees, Opt-In Rights, milestone payments and other potential
payments, the Company has variable interests. As of the closing date of the Trimmune License, the Company concluded that it is not the
primary beneficiary and should not consolidate the entity. Subsequently, there have been no reconsideration events that could change
the conclusion. The Company has no control over the operating and business activities that most significantly impact Trimmune&#x2019;s
economic performance. The Company has contractually agreed to cede its voting rights as they relate to operations of the entity. This
was accomplished through a voting rights agreement in which all shares are voted by the Chief Executive Officer of Trimmune and an agreement
related to voting on the joint steering committee by which the Company agreed that Trimmune will have the tie-breaking vote. As a result,
the Company&#x2019;s role is to act as an advisor and expert for technical advice, but it does not have any power to control the activities
of the entity. The Company&#x2019;s exposure to loss is limited to its investment and rights under the contractual arrangement with Trimmune.
Risk of economic loss is borne by Trimmune&#x2019;s investors, who are not related parties with the Company. The Company is not obligated
to participate in future investment rounds in Trimmune, nor does the Company have contractual obligations or guarantees to Trimmune or
any of its employees or investors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recapture
of Rights &#x2013; Termination of AlloTera Therapeutics License&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 21, 2026, the Company elected to exercise its option to terminate the exclusive worldwide license agreement with AlloTera Therapeutics,
Inc. (the &#x201c;AlloTera Therapeutics License&#x201d;), whereupon the Company recaptured the worldwide exclusive &lt;i&gt;ex vivo&lt;/i&gt; rights
to the Company&#x2019;s molecules HCW9201 and HCW9206, for no cost. The termination was made pursuant to Section 1(b) of the 12-month
suspension letter agreement the parties entered into on May 29, 2025. The Company retained its &lt;span id="xdx_90B_ecustom--RetainedShares_iI_pid_c20260521__dei--LegalEntityAxis__custom--AlloTeraTherapeuticsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCUD5G5myqij" title="Retained shares"&gt;2.2&lt;/span&gt; million shares of AlloTera Therapeutics
common stock, which were transferred to the Company as an in-kind nonrefundable upfront license fee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Distribution
Agreement for Commercial-Ready Reagents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 4, 2026, the Company entered into an Exclusive Distribution Agreement (the &#x201c;Distribution Agreement&#x201d;) with Akron
Biotech (&#x201c;Akron&#x201d;), a leading manufacturer of ancillary materials and a contract development and manufacturing organization
for the distribution of the Company&#x2019;s commercial-ready molecule, HCW11-006, for use as a reagent in cell therapy manufacturing
and other ex vivo applications. The closing is subject to the satisfactory completion of due diligence and product testing but will occur
no later than November 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HCWB:LicenseAgreementTextBlock>
    <HCWB:GrossProceedsFromUpfrontLicenseFee
      contextRef="From2026-03-162026-03-16"
      decimals="-5"
      id="Fact001054"
      unitRef="USD">3500000</HCWB:GrossProceedsFromUpfrontLicenseFee>
    <HCWB:NetProceedsAfterTaxFormUpfrontLicenseFee
      contextRef="From2026-03-162026-03-16"
      decimals="-5"
      id="Fact001056"
      unitRef="USD">2900000</HCWB:NetProceedsAfterTaxFormUpfrontLicenseFee>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="From2026-03-162026-03-16"
      decimals="-5"
      id="Fact001058"
      unitRef="USD">3500000</us-gaap:FairValueOfAssetsAcquired>
    <HCWB:ProceedsFromDevelopmentAndRegulatoryMilestonePayments
      contextRef="From2026-03-162026-03-16_srt_MaximumMember"
      decimals="-5"
      id="Fact001060"
      unitRef="USD">16000000.0</HCWB:ProceedsFromDevelopmentAndRegulatoryMilestonePayments>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2026-01-012026-09-30_srt_MaximumMember"
      decimals="-5"
      id="Fact001062"
      unitRef="USD">3500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming contextRef="From2026-01-01to2026-09-30" id="Fact001064">The Company identified two distinct performance obligations: (i) the delivery of licensed intellectual property&#x2014; comprising
the licensed patent rights, licensed know-how, a related license to HCW9109, and a technology transfer (collectively, the &#x201c;Licensed
IP&#x201d;); and (ii) post-transfer development services consisting of an improved cell line and a master cell bank (collectively, the
&#x201c;Services&#x201d;). The transaction price at inception was $6,650,000, reflecting the $7.0 million in upfront consideration, less
$350,000 that was carved out as a contract liability related to prepaid optional post-transfer services.</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact001066"
      unitRef="USD">51169</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-01to2026-09-30"
      decimals="-5"
      id="Fact001068"
      unitRef="USD">6700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_us-gaap_ServiceMember"
      decimals="0"
      id="Fact001070"
      unitRef="USD">51169</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_LicensedIPMember"
      decimals="-5"
      id="Fact001072"
      unitRef="USD">6300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_us-gaap_ServiceMember"
      decimals="0"
      id="Fact001074"
      unitRef="USD">402899</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001076"
      unitRef="USD">297101</us-gaap:ContractWithCustomerLiabilityCurrent>
    <HCWB:RemainingServicesConsideration
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001078"
      unitRef="USD">15000</HCWB:RemainingServicesConsideration>
    <HCWB:PrepaymentOfPostTransferServices
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001080"
      unitRef="USD">282101</HCWB:PrepaymentOfPostTransferServices>
    <HCWB:CarryingValueOfEquityInterest
      contextRef="AsOf2026-09-30"
      decimals="-5"
      id="Fact001082"
      unitRef="USD">3500000</HCWB:CarryingValueOfEquityInterest>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001084">&lt;p id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zKEekCW3mDy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B9_z0XEnCVH3Gt5" style="display: none"&gt;Schedule
of Transaction
Price and Contract Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Revenue Recognized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Transaction Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Contract Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Licensed IP&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--TransactionPrice_c20260101__20260930__srt--ProductOrServiceAxis__custom--LicensedIPMember_zvvNLxNrxpKb" style="width: 16%; text-align: right" title="Transaction Price"&gt;6,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930__srt--ProductOrServiceAxis__custom--LicensedIPMember_z8jXvNHy75X2" style="width: 16%; text-align: right" title="Revenues Recognized"&gt;6,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20260930__srt--ProductOrServiceAxis__custom--LicensedIPMember_zKMF07R6I7Ae" style="width: 16%; text-align: right" title="Contract liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Prepaid technology transfer costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--TransactionPrice_c20260101__20260930__srt--ProductOrServiceAxis__custom--PrepaidTechnologyTransferCostsMember_zZJ3LfifXwYl" style="text-align: right" title="Transaction Price"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930__srt--ProductOrServiceAxis__custom--PrepaidTechnologyTransferCostsMember_ziBkPvBiDUP3" style="text-align: right" title="Revenues Recognized"&gt;217,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20260930__srt--ProductOrServiceAxis__custom--PrepaidTechnologyTransferCostsMember_zIcWkwMqrRz3" style="text-align: right" title="Contract liability"&gt;282,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;Master Cell Bank&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--TransactionPrice_c20260101__20260930__srt--ProductOrServiceAxis__custom--MasterCellBankMember_zS5QXquS2PWk" style="border-bottom: Black 1pt solid; text-align: right" title="Transaction Price"&gt;200,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930__srt--ProductOrServiceAxis__custom--MasterCellBankMember_zf3UtSvbXVkg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues Recognized"&gt;185,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20260930__srt--ProductOrServiceAxis__custom--MasterCellBankMember_zWnfccBBsrUa" style="border-bottom: Black 1pt solid; text-align: right" title="Contract liability"&gt;15,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--TransactionPrice_c20260101__20260930_zyqc7njGFch3" style="border-bottom: Black 2.5pt double; text-align: right" title="Transaction Price"&gt;7,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930_zFWhQa9wfJtb" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues Recognized"&gt;6,702,899&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20260930_zsydeIf2Lznc" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liability"&gt;297,101&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <HCWB:TransactionPrice
      contextRef="From2026-01-012026-09-30_custom_LicensedIPMember"
      decimals="0"
      id="Fact001086"
      unitRef="USD">6300000</HCWB:TransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_LicensedIPMember"
      decimals="0"
      id="Fact001088"
      unitRef="USD">6300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <HCWB:TransactionPrice
      contextRef="From2026-01-012026-09-30_custom_PrepaidTechnologyTransferCostsMember"
      decimals="0"
      id="Fact001092"
      unitRef="USD">500000</HCWB:TransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_PrepaidTechnologyTransferCostsMember"
      decimals="0"
      id="Fact001094"
      unitRef="USD">217899</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2026-09-30_custom_PrepaidTechnologyTransferCostsMember"
      decimals="0"
      id="Fact001096"
      unitRef="USD">282101</us-gaap:ContractWithCustomerLiabilityCurrent>
    <HCWB:TransactionPrice
      contextRef="From2026-01-012026-09-30_custom_MasterCellBankMember"
      decimals="0"
      id="Fact001098"
      unitRef="USD">200000</HCWB:TransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_MasterCellBankMember"
      decimals="0"
      id="Fact001100"
      unitRef="USD">185000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2026-09-30_custom_MasterCellBankMember"
      decimals="0"
      id="Fact001102"
      unitRef="USD">15000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <HCWB:TransactionPrice
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001104"
      unitRef="USD">7000000</HCWB:TransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001106"
      unitRef="USD">6702899</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001108"
      unitRef="USD">297101</us-gaap:ContractWithCustomerLiabilityCurrent>
    <HCWB:RetainedShares
      contextRef="AsOf2026-05-21_custom_AlloTeraTherapeuticsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001110"
      unitRef="Shares">2.2</HCWB:RetainedShares>
    <HCWB:StockholdersEquityNoteSaleOfCommonStockAndWarrantsTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001112">&lt;p id="xdx_808_ecustom--StockholdersEquityNoteSaleOfCommonStockAndWarrantsTextBlock_zW4YcaLtDLR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_82B_zWHzIeFe2FO6"&gt;Sale of Common Stock and Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;May
2025 Equity Financing&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 13, 2025, the Company entered into a securities purchase agreement with a single institutional investor (the &#x201c;Investor&#x201d;)
for the issuance and sale of (i) &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250513__20250513__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyFiveEquityFinancingMember_zT9ye0kIMjHk" title="Issuance of common stock, shares"&gt;26,334&lt;/span&gt; shares of the Company&#x2019;s Common Stock and (ii) pre-funded warrants to purchase up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250513__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyFiveEquityFinancingMember__srt--RangeAxis__srt--MaximumMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zTMS6H7Ez4c5" title="Warrants to purchase shares"&gt;85,524&lt;/span&gt;
shares of Common Stock (the &#x201c;Pre-Funded Warrants&#x201d;) in a follow-on public offering (the &#x201c;May 2025 Offering&#x201d;),
pursuant to a registration statement filed under Rule 424(b)(4) (File No. 333-287136), which was declared effective by the SEC on May
15, 2025. The Company also issued warrants to purchase up to an aggregate of &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250513__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyFiveEquityFinancingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zJ83KVJ4uRA7" title="Warrants to purchase shares"&gt;223,714&lt;/span&gt; shares of Common Stock (&#x201c;Common Stock Warrants&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
gross proceeds to the Company from the May 2025 Offering were approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250513__20250513__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyFiveEquityFinancingMember_zrg5cgrnBjvd" title="Proceeds from issuance of common stock"&gt;5.0&lt;/span&gt; million before deducting the placement agent&#x2019;s
fees and other offering expenses of $&lt;span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20250513__20250513__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyFiveEquityFinancingMember_zogsDEmlCxq3" title="Placement agent's fees and other offering expenses"&gt;802,602&lt;/span&gt; payable by the Company. The May 2025 Offering closed on May 15, 2025. In this financing,
the Company issued shares of Common Stock or Pre-Funded Warrants that may be exercised to purchase Common Stock in lieu thereof, and
warrants that may be exercised to purchase Common Stock. In a contemporaneous private agreement entered into with the Investor, the Company
agreed to reprice warrants to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250513__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyFiveEquityFinancingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWDAilFMfPs" title="Warrants to purchase shares"&gt;27,988&lt;/span&gt; shares of Common Stock that were issued to the Investor in a financing that closed
on November 20, 2024. The Company estimated the fair value of the securities issued, using the Black Scholes valuation model to estimate
the fair value of the warrants, and determined the fair value of securities issued was $&lt;span id="xdx_901_eus-gaap--StockIssued1_pn5n6_c20250513__20250513__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyFiveEquityFinancingMember_zuNJs6E3oIFc" title="Fair value of securities issued"&gt;15.2&lt;/span&gt; million. As this was a transaction with
an existing stockholder, the Company recognized a $&lt;span id="xdx_903_eus-gaap--DividendsCommonStockStock_pn5n6_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyFiveEquityFinancingMember_zUbXW96j7Jcg" title="Equity dividend to investor"&gt;10.2&lt;/span&gt; million deemed equity dividend to the Investor which was recorded in additional-paid-in
capital for the period ended December 31, 2025 in the accompanying condensed balance sheet and as an Equity dividend to investors for the nine months ended September
30, 2025 in the accompanying condensed statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Both
the Common Stock Warrants and Pre-Funded Warrants were classified as a component of permanent stockholders&#x2019; equity within additional
paid-in-capital and were recorded at the issuance date. The Common Stock Warrants and Pre-Funded Warrants are equity classified because
they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately
exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares
of Common Stock upon exercise, are indexed to the Company&#x2019;s Common Stock and meet the equity classification criteria. In addition,
the Common Stock Warrants and the Pre-Funded Warrants do not provide any guarantee of value or return.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the second quarter of 2025, all Pre-Funded Warrants issued in the May 2025 offering had been exercised. The May 2025 Common Warrants exercisable
for up to &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyFiveEquityFinancingMember_z6oKA6THh1fc" title="Warrants to purchase shares"&gt;223,714&lt;/span&gt; shares of Common Stock, together with the November 2024 Common Warrants (as repriced in connection with the May 2025
offering) exercisable for up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--NovemberTwoThousandAndTwentyFourMember_zKg1cyGFG72l" title="Warrants to purchase shares"&gt;27,988&lt;/span&gt; shares of Common Stock, were subsequently exercised in the November 2025 inducement transaction
discussed below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Inducement
Transaction and Shares held in Abeyance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 19, 2025, the Company entered into a warrant inducement agreement with the Investor (the &#x201c;Inducement Agreement&#x201d;),
pursuant to which the Investor agreed to immediately exercise in full all of its outstanding Common Stock Warrants originally issued
on November 20, 2024 (as amended on May 15, 2025) and on May 15, 2025 to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250515__us-gaap--TypeOfArrangementAxis__custom--InducementAgreementMember_zh5sRJDyLvFk" title="Purchase of shares"&gt;251,702&lt;/span&gt; shares of Common Stock, resulting in aggregate
gross proceeds to the Company of approximately $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250515__20250515__us-gaap--TypeOfArrangementAxis__custom--InducementAgreementMember_z6u6iG8gu36k" title="Aggregate gross proceeds"&gt;4.0&lt;/span&gt; million before fees and expenses. At closing, the Company issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251119__20251119__us-gaap--TypeOfArrangementAxis__custom--InducementAgreementMember_zO0012yh0uBk" title="Number of shares issued"&gt;49,834&lt;/span&gt; shares and
held &lt;span id="xdx_909_ecustom--StockHeldInAbeyanceDuringPeriodShares_iI_c20251119__us-gaap--TypeOfArrangementAxis__custom--InducementAgreementMember_zWYd67Z7edwl" title="Shares held in abeyance"&gt;201,868&lt;/span&gt; shares in abeyance, until such time as the Investor requested issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for the immediate exercise of the Common Stock Warrants, the Company issued to the Investor, in a private placement pursuant
to Section 4(a)(2) of the Securities Act, new Common Stock Warrants to purchase up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251119__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementAgreementMember_zEUHlHdUgpte" title="Warrants to purchase shares"&gt;503,402&lt;/span&gt; shares of Common Stock at an exercise price
of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251119__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementAgreementMember_zAHelHES3l2b" title="Exercise price"&gt;14.46&lt;/span&gt; per share. In a private transaction entered into contemporaneously with the February 2026 Sale of Common Stock and Warrants
discussed below, the Company agreed to an amendment to reduce the exercise price of these Common Stock Warrants to $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251119__us-gaap--TypeOfArrangementAxis__custom--InducementAgreementMember_zzBWJ3Gjn9e6" title="Exercise price"&gt;3.633&lt;/span&gt; per share,
which was approved by the Company&#x2019;s stockholders on June 15, 2026 at the Annual Meeting of Stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and September 30, 2026, there were &lt;span id="xdx_901_ecustom--StockHeldInAbeyanceDuringPeriodShares_iI_c20251231_z1bFOdZzNLQ9" title="Shares held in abeyance"&gt;162,834&lt;/span&gt; shares and &lt;span id="xdx_905_ecustom--StockHeldInAbeyanceDuringPeriodShares_iI_do_c20260930_zS51CKJI4tY8" title="Shares held in abeyance"&gt;no&lt;/span&gt; shares of Common Stock held in abeyance, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;February
2026 Sale of Common Stock and Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 17, 2026, the Company entered into a securities purchase agreement (&#x201c;February 2026 SPA&#x201d;) with the Investor, pursuant
to which the Company issued &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260217__us-gaap--TypeOfArrangementAxis__custom--FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z6YCl49i1dmi" title="Number of warrants issued"&gt;412,882&lt;/span&gt; units (the &#x201c;Units&#x201d;) consisting of (i) &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260217__us-gaap--TypeOfArrangementAxis__custom--FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z4WmL4xfKwU4" title="Number of warrants issued"&gt;412,882&lt;/span&gt; pre-funded warrants (the &#x201c;Pre-Funded
Warrants&#x201d;) to purchase up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260217__us-gaap--TypeOfArrangementAxis__custom--FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zfcf4xoWDXdh" title="Number of warrants issued"&gt;412,882&lt;/span&gt; shares of Common Stock, and (ii) up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260217__us-gaap--TypeOfArrangementAxis__custom--FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zhutNRsaOaAe" title="Number of warrants issued"&gt;412,882&lt;/span&gt; Common Stock purchase warrants (the &#x201c;Common
Warrants&#x201d;, and together with the Pre-Funded Warrants, the &#x201c;Warrants&#x201d;) to purchase up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260217__us-gaap--TypeOfArrangementAxis__custom--FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zvSIVaPJFvT6" title="Number of warrants issued"&gt;412,882&lt;/span&gt; shares of Common Stock.
The issuance of the Common Warrants was subject to stockholder approval, which was obtained at the Company&#x2019;s Annual Meeting of
Stockholders held on June 15, 2026. The securities were offered pursuant to a registration statement on Form S-1, as amended (File No.
333-293396), which was declared effective by the Securities and Exchange Commission on February 17, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
combined purchase price for each Unit consisting of one Pre-Funded Warrant that may be exercised for one share of Common Stock and
an accompanying Common Stock Warrant to purchase one share of Common Stock was $&lt;span id="xdx_903_ecustom--CombinedPurchasePricePerShare_iI_pid_c20260217_z29Y5NIQcftd" title="Combined purchase price per share"&gt;3.6329&lt;/span&gt;.
The Common Stock Warrants have an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260217__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zLrba9d1uNHi" title="Exercise price"&gt;3.633&lt;/span&gt;
per share and expire on the &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dtY_c20260217__us-gaap--TypeOfArrangementAxis__custom--FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zTE9Os9E0KEe" style="display: none" title="Warrants, expiration term"&gt;5&lt;/span&gt; five-year anniversary of receipt of stockholder approval. The Pre-Funded Warrants have an exercise
price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260217__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zAv0EIym7eO9" title="Exercise price"&gt;0.0001&lt;/span&gt;, are exercisable immediately and will not expire until exercised in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 17, 2026, the Company also entered into a privately negotiated agreement with the Investor, which holds certain existing outstanding
warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260217_zayzbgzScZE8" title="Warrants to purchase shares"&gt;503,402&lt;/span&gt; shares of Common Stock (the &#x201c;Existing Warrants&#x201d;), which were issued in the November 2025
Inducement Transaction, and agreed to reprice these warrants from $&lt;span id="xdx_90F_eus-gaap--WarrantExercisePriceIncrease_pid_c20260217__20260217_zoM1tp9dJTHb" title="Warrant exercise price increase"&gt;14.46&lt;/span&gt; to $&lt;span id="xdx_900_eus-gaap--WarrantExercisePriceDecrease_pid_c20260217__20260217_zCNnn9AxgAI6" title="Warrant exercise price decrease"&gt;3.633&lt;/span&gt;, which was approved by the Company&#x2019;s stockholders
on June 15, 2026 at the Annual Meeting of Stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stockholder
approval was required for the warrants issued or modified in the February 2026 transaction in order to comply with Nasdaq Stock Market
Rules. Nasdaq Stock Rule 5635(d) is referred to as the &#x201c;Nasdaq 20% Rule.&#x201d; In order to comply with the Nasdaq 20% Rule, the
Company must seek stockholder approval to permit the potential issuance of more than 19.99% of outstanding Common Stock upon exercise
of the Common Warrants in accordance with their terms. To meet the Nasdaq 20% Rule, the Company required stockholder approval under the
listing rules of Nasdaq to remove the Exchange Cap provisions in the February 2026 SPA to permit the potential issuance of more than
20% of its outstanding Common Stock in accordance with the terms of the SPA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
gross proceeds to the Company from the February 2026 Offering were approximately $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20260217__20260217_zn6MJZ2tcHP3" title="Gross cash proceeds"&gt;1.5&lt;/span&gt; million before deducting the placement agent&#x2019;s
fees and other offering expenses of $&lt;span id="xdx_90E_ecustom--FeesAndOtherOfferingExpenses_c20260217__20260217_zC0BjVQmYRb6" title="Fees and other offering expenses"&gt;389,056&lt;/span&gt; payable by the Company. The offering closed on February 19, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Investor may not exercise any portion of the Common Stock Warrants to the extent it would beneficially own more than the limits defined
in the respective Warrant Purchase Agreement. The exercise price and number of shares of Common Stock issuable upon the exercise of the
Common Stock Warrants are subject to adjustment in the event of any stock dividends and distributions, stock splits, stock combinations
or stock reclassifications, as described in the respective warrant agreements. Under certain circumstances, the warrants may be exercised
on a &#x201c;cashless&#x201d; basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Common Stock Warrants issued in this transaction was estimated at $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20260101__20260930_zc9bsCe1IVK4" title="Fair value of common stock warrants"&gt;1.3&lt;/span&gt; million using the Black-Scholes option pricing
model with assumptions including a term of &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20260101__20260930_z0WUv2U621Ce" title="Expected term (years)"&gt;5&lt;/span&gt; years, volatility of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260930_zzXkoHvtIYyk" title="Expected volatility"&gt;131.8&lt;/span&gt;% and a risk-free rate of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260930_zbNaLv0tBTu2" title="Risk-free interest rate"&gt;3.57&lt;/span&gt;%. The change in fair value of the
Existing Warrants which were amended to lower the exercise price from $&lt;span id="xdx_900_eus-gaap--WarrantExercisePriceIncrease_pid_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingWarrantsMember_zGlTJock7Cji" title="Warrant exercise price increase"&gt;14.46&lt;/span&gt; to $&lt;span id="xdx_90F_eus-gaap--WarrantExercisePriceDecrease_pid_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingWarrantsMember_zIt6yARpewjg" title="Warrant exercise price decrease"&gt;3.633&lt;/span&gt; per share was estimated at $&lt;span id="xdx_900_eus-gaap--StockIssued1_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingWarrantsMember_zf8iQDUKZRn4" title="Fair value of securities"&gt;193,910&lt;/span&gt; using the
Black Scholes pricing model with the assumptions including a term of &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingWarrantsMember_ztz4zBWWyoS7" title="Expected term (years)"&gt;5.26&lt;/span&gt; years, volatility of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingWarrantsMember_zw1Hl5zoOyv4" title="Expected volatility"&gt;131.8&lt;/span&gt;% and a risk-free rate of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingWarrantsMember_zJqWEIVdLWhb" title="Risk-free interest rate"&gt;3.57&lt;/span&gt;%.
As this was a transaction with an existing stockholder, the difference between the gross proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260101__20260930_ztPTJPJG4k9c" title="Gross proceeds warrants"&gt;1.5&lt;/span&gt; million and the fair value
of securities issued and the modification of the warrant, or $&lt;span id="xdx_90D_eus-gaap--DividendsCommonStockCash_pn5n6_c20260101__20260930_zkg0ZL9jYME5" title="Equity dividend to investor"&gt;3.0&lt;/span&gt; million, was deemed to be an equity dividend to the Investor, which
was recorded in additional-paid-in capital as of September 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 16, 2026, the Investor exercised all of its Pre-Funded Warrants issued from the February 2026 offering, and the Company issued
&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260316_z4sXCxyddWPk" title="Warrants to purchase shares"&gt;412,882&lt;/span&gt; shares of Common Stock. As of September 30, 2026, there were no Pre-Funded Warrants outstanding that were purchased in the February
2026 transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;February
2026 Offering and Warrant Classification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
February 2026 Common Stock Warrants that may be exercised to purchase up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260217_zg1iFnL5kVyi" title="Warrants exercised to purchase"&gt;412,882&lt;/span&gt; shares of Common Stock issued on February 17, 2026
were classified as a component of permanent stockholders&#x2019; equity within additional paid-in-capital and were recorded at the issuance
date. The Common Stock Warrants are equity classified because they are freestanding financial instruments that are legally detachable
and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase
its shares, permit the holders to receive a fixed number of shares of Common Stock upon exercise, are indexed to the Company&#x2019;s
Common Stock and meet the equity classification criteria. In addition, the Common Warrants and the Pre-Funded Warrants do not provide
any guarantee of value or return.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026, upon modification of the November 2025 Common Stock Warrants on February 17, 2026, these warrants were reclassified
from equity to a warrant liability due to a contingency in the settlement terms, and the Company recognized a warrant liability measured
at fair value. Upon stockholder approval of the new strike price of $&lt;span id="xdx_906_ecustom--StrikePricePerShare_iI_c20260217__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingWarrantsMember_zpRWRk3rQPdc" title="Strike price per share"&gt;3.633&lt;/span&gt; per share on June 15, 2026, the contingent strike price adjustment
was resolved and all requirements for equity classification were met. As of June 15, 2026, the Company remeasured the November 2025 Common
Stock Warrants at fair value and then reclassified them to permanent equity. See Note 2. Fair Value of Financial Instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;May
2026 Sale of Common Stock and Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 21, 2026, the Company completed a private placement with existing accredited investors, including the Investors in which it entered
into a Securities Purchase Agreement (the &#x201c;May 2026 SPA&#x201d;), pursuant to which the Company agreed to issue and sell an aggregate
of &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260521__20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRsd7Pjsvmud" title="Issuance of common stock, shares"&gt;474,496&lt;/span&gt; units, with each unit consisting of (i) one share of the Company&#x2019;s common stock, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_z3IoyYOVpWLa" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share (the &#x201c;Common
Stock&#x201d; or &#x201c;Shares&#x201d;), at a purchase price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_z5ZoCaXR4JOj" title="Purchase price per share"&gt;7.68&lt;/span&gt; per Share, or, in lieu thereof, one pre-funded warrant, and (ii)
one warrant to purchase one share of Common Stock (the &#x201c;Common Stock Warrants&#x201d;) at a purchase price of $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zkIh8Xb4tvD8" title="Purchase price per share"&gt;0.75&lt;/span&gt; per Common Warrant.
The units were sold at a purchase price of $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsAndCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zMI4MD7o7IQf" title="Purchase price per share"&gt;8.43&lt;/span&gt; per unit, and the Shares or Pre-Funded Warrants and Common Warrants comprising the units
are immediately separable and were issued separately. &lt;span id="xdx_900_ecustom--BeneficialOwnershipDescription_c20260521__20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zwTzN3O9yU3b" title="Beneficial ownership description"&gt;In lieu of Shares that would otherwise result in a purchaser&#x2019;s beneficial
ownership exceeding 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such
Shares, certain purchasers elected to receive pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) at a purchase price of $7.6799
per Pre-Funded Warrant (equal to the per Share purchase price less $0.0001).&lt;/span&gt; Each Pre-Funded Warrant is exercisable immediately upon
issuance for one share of Common Stock at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zvWLIUhDHFc" title="Exercise price"&gt;0.0001&lt;/span&gt; per share and will remain exercisable until exercised in full.
Each Common Stock Warrant is exercisable immediately upon issuance for one share of Common Stock at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_z6vujyoJZcf4" title="Exercise price"&gt;7.68&lt;/span&gt; per share
and will expire on the five and one-half year anniversary of the original issuance date. The shares of Common Stock issuable upon exercise
of the Pre-Funded Warrants and the Common Stock Warrants are referred to herein as the &#x201c;Warrant Shares.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the May 2026 SPA, the Company issued and sold an aggregate of &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260521__20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_z2Kid4OQY3ib" title="Issuance of common stock, shares"&gt;71,174&lt;/span&gt; Shares, &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260521__20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zU55tjgHPQYg" title="Issuance of common stock, shares"&gt;403,322&lt;/span&gt; Pre-Funded Warrants, and Common Warrants to purchase
an aggregate of up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_znRTOfq4ABk3" title="Warrants to purchase shares"&gt;474,496&lt;/span&gt; shares of Common Stock for aggregate gross proceeds of approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260521__20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zFuoi09CEG4a" title="Aggregate gross proceeds"&gt;4.0&lt;/span&gt; million at the closing, before
deducting fees payable to the placement agent and other offering expenses payable by the Company. The Investors included officers, directors
and significant stockholders. Scott Garrett, Chairman of our board of directors, purchased $&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--HingCWongMember_zJDvqOhr5jd9"&gt;250,000&lt;/span&gt; of securities, Hing C. Wong, our
Founder and Chief Executive Officer, purchased $&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOQWPDBMjMq9"&gt;160,000&lt;/span&gt; of securities, and Rebecca Byam, our Chief Financial Officer, purchased $&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260521__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zqXoebssVnX5"&gt;20,000&lt;/span&gt;
of securities. Such purchases were made on the same terms and conditions as those offered to other investors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the May 2026 SPA, the Company also entered into a Registration Rights Agreement with the Investors (the &#x201c;Registration
Rights Agreement&#x201d;), pursuant to which the Company agreed to provide certain registration rights with respect to the resale of the
Shares and the Warrant Shares. On June 18, 2026, the SEC declared effective a resale registration statement on Form S-1 (File No. 333-296577)
covering the resale of shares of Common Stock and warrants issued in this private placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Common Warrants may not be exercised to the extent that, after giving effect to such exercise, the holder would beneficially own more
than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 22, 2026, the holder exercised all Pre-Funded Warrants issued in the May 2026 offering, and the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260622__20260622__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentySixOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zWBjb2AHjLf1"&gt;403,322&lt;/span&gt; shares of
Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;July
2026 Sale of Common Stock and Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 29, 2026, the Company entered into a Securities Purchase Agreement (the &#x201c;July 2026 SPA&#x201d;) with certain accredited investors
(each, an investor, and collectively, the &#x201c;Investors&#x201d;), pursuant to which the Company agreed to issue and sell an aggregate
of &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260729__20260729__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zOlyYw3pyr1h" title="Issuance of common stock, shares"&gt;618,682&lt;/span&gt; units (the &#x201c;Units&#x201d;), with each Unit consisting of (i) one share of the Company&#x2019;s Common Stock, or, in lieu
thereof, one pre-funded warrant to purchase one share of Common Stock (the &#x201c;Pre-Funded Warrants&#x201d;), and (ii) the right to
receive one common stock purchase warrant (the &#x201c;Common Warrants&#x201d;) to purchase one share of Common Stock upon, and subject
to, stockholder approval of the issuance of the Common Warrants. The Units were sold at a purchase price of $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260729__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zpv8cIbUVBCi" title="Purchase price per share"&gt;2.585&lt;/span&gt; per Unit consisting
of one share of Common Stock and the right to receive one Common Warrant and $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260729__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zkXLExXeq363" title="Purchase price per share"&gt;2.5849&lt;/span&gt; per Unit consisting of one Pre-Funded Warrant and
the right to receive one Common Warrant. The Common Stock (or Pre-Funded Warrants) and Common Warrants comprising the Units are immediately
separable and will be issued separately, the Common Warrants to be issued only upon, and subject to, stockholder approval thereof, which
the Company is obligated to seek pursuant to the terms of the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the July 2026 SPA, the Company agreed to issue and sell Units that include an aggregate of &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260729__20260729__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhLQKAyZVmAk" title="Issuance of common stock, shares"&gt;218,682&lt;/span&gt; shares of Common Stock and
&lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260729__20260729__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zyvbRMfeLIpf" title="Issuance of common stock, shares"&gt;400,000&lt;/span&gt; Pre-Funded Warrants for aggregate gross proceeds of approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260729__20260729__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zVvFBb6mzOFa" title="Aggregate gross proceeds"&gt;1.6&lt;/span&gt; million before deducting offering expenses payable by
the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including
continuing clinical development activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Pre-Funded Warrants have an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260729__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_z5CdBTZvRb1j" title="Exercise price"&gt;0.0001&lt;/span&gt; per share, are exercisable immediately and will remain exercisable until exercised
in full. The Pre-Funded Warrants may not be exercised to the extent that, after giving effect to such exercise, the holder would beneficially
own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Investors are entitled to receive Common Warrants exercisable for an aggregate of up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260729__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zU1KyFAnU7Jg" title="Warrant outstanding"&gt;618,682&lt;/span&gt; shares of Common Stock. Under the terms
of the July 2026 SPA, issuance of the Common Warrants is subject to stockholder approval required under Nasdaq Listing Rule 5635(d).
Following receipt of such stockholder approval, the Company will issue the Common Warrants to the Investors. The Common Warrants will
have an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260729__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zOd0dIWJeVa2" title="Exercise price"&gt;2.585&lt;/span&gt; per share, be exercisable immediately upon issuance and expire on the date that is five and one-half
(&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260729__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zWnp9jrt7g85" title="Warrant term"&gt;5.5&lt;/span&gt;) years from the date of issuance. The Common Warrants will contain a beneficial ownership limitation of 4.99%, subject to adjustment
by the holder in accordance with their terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the July 2026 SPA, Hing C. Wong, Ph.D., the Company&#x2019;s Founder and Chief Executive Officer, Scott Garrett,
a member and the Chairman of the Company&#x2019;s Board of Directors, and Lee Flowers, the Company&#x2019;s Senior Vice President of Business
Development, participated in the private placement on the same terms and conditions as the other Investor and invested an aggregate of
$&lt;span id="xdx_90E_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_c20260729__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zwzYo5OYyDZe" title="Investment owned"&gt;100,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the July 2026 SPA, the Company also entered into a Registration Rights Agreement with the Investors (the &#x201c;Registration
Rights Agreement&#x201d;), pursuant to which the Company agreed to provide certain registration rights with respect to the resale of the
Shares and the Warrant Shares. On August 31, 2026, the SEC declared effective a resale registration statement on Form S-1 (File No. 333-298452)
covering the resale of shares of Common Stock and warrants issued in this private placement. On September 1, 2026, the holder exercised
all outstanding Pre-Funded Warrants issued in connection with this transaction, and the Company issued &lt;span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20260930__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zYuXyqznSEB8" title="Share issued"&gt;400,000&lt;/span&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;September
2026 Sale of Common Stock and Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2026, the Company entered into a Securities Purchase Agreement (the &#x201c;September 2026 SPA&#x201d;) with an
existing institutional investor (the &#x201c;Investor&#x201d;), pursuant to which the Company agreed to issue and sell an aggregate of &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260923__20260923__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zvvEgULs3z7k" title="Issuance of common stock, shares"&gt;903,614&lt;/span&gt;
units (the &#x201c;Units&#x201d;), with each Unit consisting of (i) one pre-funded warrant (the &#x201c;Pre-Funded Warrants&#x201d;) to
purchase one share of the Company&#x2019;s common stock, par value $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260923__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zvxbDLz7X5mc" title="Purchase price per share"&gt;0.0001&lt;/span&gt;
per share, (the &#x201c;Common Stock&#x201d;) and (ii) the right to receive one common stock purchase warrant (the &#x201c;Common
Warrants&#x201d;) to purchase one share of Common Stock upon, and subject to, stockholder approval of the issuance of the Common
Warrants. The Units were sold at a purchase price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260923__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zntOnEtQlFmk" title="Purchase price per share"&gt;1.6599&lt;/span&gt;
per Unit. The Pre-Funded Warrants and rights to receive Common Warrants comprising the Units are immediately separable and will be
issued separately, the Common Warrants to be issued only upon, and subject to, stockholder approval thereof, which the Company is
obligated to seek pursuant to the terms of the September 2026 SPA. Maxim Group LLC acted as the sole placement agent for this
offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the September 2026 SPA, the Company agreed to issue and sell Units that include an aggregate of &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260923__20260923__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zaAKIjbEQWY2" title="Issuance of common stock, shares"&gt;903,614&lt;/span&gt; Pre-Funded Warrants for aggregate
gross proceeds of approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260923__20260923__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zeV4dgixncah" title="Aggregate gross proceeds"&gt;1.5&lt;/span&gt; million before deducting offering expenses payable by the Company. The Company intends to use the
net proceeds from the offering for working capital and general corporate purposes, including continuing clinical development activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Pre-Funded Warrants have an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260923__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zkAPEW8sHoAd" title="Exercise price"&gt;0.0001&lt;/span&gt; per share, are exercisable immediately and will remain exercisable until exercised
in full. The Pre-Funded Warrants may not be exercised to the extent that, after giving effect to such exercise, the holder would beneficially
own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Investor is entitled to receive Common Warrants exercisable for an aggregate of up to &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260923__20260923__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember_zgAcWicsWxfe" title="Issuance of common stock, shares"&gt;903,614&lt;/span&gt; shares of Common Stock. Under the terms
of the September 2026 SPA, issuance of the Common Warrants is subject to stockholder approval required under Nasdaq Listing Rule 5635(d).
Following receipt of such stockholder approval, the Company will issue the Common Warrants to the Investor. The Common Warrants will
have an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260923__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_zFjSqsjj2au8" title="Exercise price"&gt;1.66&lt;/span&gt; per share, be exercisable immediately upon issuance and expire on the date that is five and one-half
(&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260923__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zrSLI5ff9Jhd" title="Warrant term"&gt;5.5&lt;/span&gt;) years from the date of issuance. The Common Warrants will contain a beneficial ownership limitation of 4.99%, subject to adjustment
by the holder in accordance with their terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the September 2026 SPA, the Company also entered into a Registration Rights Agreement with the Investors (the &#x201c;Registration
Rights Agreement&#x201d;), pursuant to which the Company agreed to provide certain registration rights with respect to the resale of the
Shares and the Warrant Shares. On October 9, 2026, the SEC declared effective a resale registration statement on Form S-1 (File No. 333-299271)
covering the resale of shares of Common Stock and warrants issued in this private placement. On October 13, 2026, the holder exercised
Pre-Funded Warrants issued in this transaction to purchase &lt;span title="Issuance of common stock, shares"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20261013__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zmRuCcfHAu4i" title="Number of warrants issued"&gt;755,614&lt;/span&gt;&lt;/span&gt; shares of Common Stock, and on October 23, 2026, the holder exercised
Pre-Funded Warrants issued in this transaction to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20261023__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zBUbkqsxhws8" title="Number of warrants issued"&gt;148,000&lt;/span&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Participating
Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
warrants issued by the Company are participating warrants. Under U.S. GAAP, participating warrants are instruments that grant the holder
the right to receive non-forfeitable dividends or dividend equivalents on an equal basis with common stockholders before exercise. Because
they are considered &#x201c;participating securities,&#x201d; the Company utilizes the two-class method to calculate and report basic and
diluted Earnings Per Share (EPS). See Note 9. Net Loss per Share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, outstanding participating warrants included: November 2024 Common Stock Warrants to purchase up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--NovemberTwoThousandAndTwentyFourCommonStockWarrantsMember_zEZqxqmg0R6" title="Warrants to purchase shares"&gt;27,988&lt;/span&gt; shares
of Common Stock, May 2025 Common Stock Warrants to purchase up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandAndTwentyFiveCommonStockWarrantsMember_zwpJArWZ87sj" title="Warrants to purchase shares"&gt;223,714&lt;/span&gt; shares of Common Stock, and Conversion Common Stock Warrants
issued to the Noteholders who converted Secured Notes to equity to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ConversionCommonStockWarrantsMember_zs3M0CXBPL1a" title="Warrants to purchase shares"&gt;21,099&lt;/span&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026, outstanding participating warrants included: November 2025 Common Stock Warrants to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--NovemberTwoThousandAndTwentyFiveCommonStockWarrantsMember_zuWHUpTbGVxh" title="Warrants to purchase shares"&gt;503,402&lt;/span&gt; shares
of Common Stock and Conversion Common Stock Warrants to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--ConversionCommonStockWarrantsMember_zo9vvpOCq3wd" title="Warrants to purchase shares"&gt;21,099&lt;/span&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HCWB:StockholdersEquityNoteSaleOfCommonStockAndWarrantsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-05-132025-05-13_us-gaap_CommonStockMember_custom_MayTwoThousandTwentyFiveEquityFinancingMember"
      decimals="INF"
      id="Fact001114"
      unitRef="Shares">26334</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember_srt_MaximumMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Shares">85524</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001118"
      unitRef="Shares">223714</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-05-132025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember"
      decimals="-5"
      id="Fact001120"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-05-132025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember"
      decimals="0"
      id="Fact001122"
      unitRef="USD">802602</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001124"
      unitRef="Shares">27988</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssued1
      contextRef="From2025-05-132025-05-13_custom_MayTwoThousandTwentyFiveEquityFinancingMember"
      decimals="-5"
      id="Fact001126"
      unitRef="USD">15200000</us-gaap:StockIssued1>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2025-01-012025-09-30_custom_MayTwoThousandTwentyFiveEquityFinancingMember"
      decimals="-5"
      id="Fact001128"
      unitRef="USD">10200000</us-gaap:DividendsCommonStockStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_custom_CommonStockWarrantsMember_custom_MayTwoThousandTwentyFiveEquityFinancingMember"
      decimals="INF"
      id="Fact001130"
      unitRef="Shares">223714</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_custom_CommonStockWarrantsMember_custom_NovemberTwoThousandAndTwentyFourMember"
      decimals="INF"
      id="Fact001132"
      unitRef="Shares">27988</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-15_custom_InducementAgreementMember"
      decimals="INF"
      id="Fact001134"
      unitRef="Shares">251702</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-05-152025-05-15_custom_InducementAgreementMember"
      decimals="-5"
      id="Fact001136"
      unitRef="USD">4000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-11-192025-11-19_custom_InducementAgreementMember"
      decimals="INF"
      id="Fact001138"
      unitRef="Shares">49834</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <HCWB:StockHeldInAbeyanceDuringPeriodShares
      contextRef="AsOf2025-11-19_custom_InducementAgreementMember"
      decimals="INF"
      id="Fact001140"
      unitRef="Shares">201868</HCWB:StockHeldInAbeyanceDuringPeriodShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-11-19_custom_CommonStockWarrantsMember_custom_InducementAgreementMember"
      decimals="INF"
      id="Fact001142"
      unitRef="Shares">503402</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-11-19_custom_CommonStockWarrantsMember_custom_InducementAgreementMember"
      decimals="INF"
      id="Fact001144"
      unitRef="USDPShares">14.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-11-19_custom_InducementAgreementMember"
      decimals="INF"
      id="Fact001146"
      unitRef="USDPShares">3.633</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <HCWB:StockHeldInAbeyanceDuringPeriodShares
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001148"
      unitRef="Shares">162834</HCWB:StockHeldInAbeyanceDuringPeriodShares>
    <HCWB:StockHeldInAbeyanceDuringPeriodShares
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact001150"
      unitRef="Shares">0</HCWB:StockHeldInAbeyanceDuringPeriodShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-02-17_custom_FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001152"
      unitRef="Shares">412882</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-02-17_custom_FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001154"
      unitRef="Shares">412882</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-02-17_custom_FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">412882</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-02-17_custom_FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001158"
      unitRef="Shares">412882</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-02-17_custom_FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001160"
      unitRef="Shares">412882</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <HCWB:CombinedPurchasePricePerShare
      contextRef="AsOf2026-02-17"
      decimals="INF"
      id="Fact001162"
      unitRef="USDPShares">3.6329</HCWB:CombinedPurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-02-17_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001164"
      unitRef="USDPShares">3.633</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2026-02-17_custom_FebruaryTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_CommonStockWarrantsMember"
      id="Fact001166">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-02-17_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001168"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-02-17"
      decimals="INF"
      id="Fact001170"
      unitRef="Shares">503402</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2026-02-172026-02-17"
      decimals="INF"
      id="Fact001172"
      unitRef="USDPShares">14.46</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2026-02-172026-02-17"
      decimals="INF"
      id="Fact001174"
      unitRef="USDPShares">3.633</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-02-172026-02-17"
      decimals="-5"
      id="Fact001176"
      unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <HCWB:FeesAndOtherOfferingExpenses
      contextRef="From2026-02-172026-02-17"
      decimals="0"
      id="Fact001178"
      unitRef="USD">389056</HCWB:FeesAndOtherOfferingExpenses>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2026-01-01to2026-09-30"
      decimals="-5"
      id="Fact001180"
      unitRef="USD">1300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2026-01-01to2026-09-30" id="Fact001182">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001184"
      unitRef="Pure">1.318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001186"
      unitRef="Pure">0.0357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2026-01-012026-09-30_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001188"
      unitRef="USDPShares">14.46</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2026-01-012026-09-30_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001190"
      unitRef="USDPShares">3.633</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:StockIssued1
      contextRef="From2026-01-012026-09-30_custom_ExistingWarrantsMember"
      decimals="0"
      id="Fact001192"
      unitRef="USD">193910</us-gaap:StockIssued1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-01-012026-09-30_custom_ExistingWarrantsMember"
      id="Fact001194">P5Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-01-012026-09-30_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001196"
      unitRef="Pure">1.318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-01-012026-09-30_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001198"
      unitRef="Pure">0.0357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2026-01-01to2026-09-30"
      decimals="-5"
      id="Fact001200"
      unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:DividendsCommonStockCash
      contextRef="From2026-01-01to2026-09-30"
      decimals="-5"
      id="Fact001202"
      unitRef="USD">3000000.0</us-gaap:DividendsCommonStockCash>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-03-16"
      decimals="INF"
      id="Fact001204"
      unitRef="Shares">412882</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-02-17"
      decimals="INF"
      id="Fact001206"
      unitRef="Shares">412882</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <HCWB:StrikePricePerShare
      contextRef="AsOf2026-02-17_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001208"
      unitRef="USDPShares">3.633</HCWB:StrikePricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-05-212026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001210"
      unitRef="Shares">474496</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001212"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-05-21_custom_PreFundedWarrantsMember_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001214"
      unitRef="USDPShares">7.68</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-05-21_custom_CommonStockWarrantsMember_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001216"
      unitRef="USDPShares">0.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-05-21_custom_PreFundedWarrantsAndCommonStockWarrantsMember_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001218"
      unitRef="USDPShares">8.43</us-gaap:SaleOfStockPricePerShare>
    <HCWB:BeneficialOwnershipDescription
      contextRef="From2026-05-212026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      id="Fact001220">In lieu of Shares that would otherwise result in a purchaser&#x2019;s beneficial
ownership exceeding 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such
Shares, certain purchasers elected to receive pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) at a purchase price of $7.6799
per Pre-Funded Warrant (equal to the per Share purchase price less $0.0001).</HCWB:BeneficialOwnershipDescription>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-05-21_custom_PreFundedWarrantsMember_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001222"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-05-21_custom_CommonStockWarrantsMember_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001224"
      unitRef="USDPShares">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-05-212026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001226"
      unitRef="Shares">71174</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-05-212026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001228"
      unitRef="Shares">403322</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-05-21_custom_CommonStockWarrantsMember_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001230"
      unitRef="Shares">474496</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2026-05-212026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="-5"
      id="Fact001232"
      unitRef="USD">4000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_HingCWongMember"
      decimals="0"
      id="Fact001233"
      unitRef="USD">250000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001234"
      unitRef="USD">160000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2026-05-21_custom_MayTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_srt_ChiefFinancialOfficerMember"
      decimals="0"
      id="Fact001235"
      unitRef="USD">20000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-06-222026-06-22_custom_MayTwoThousandAndTwentySixOfferingMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001236"
      unitRef="Shares">403322</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-07-292026-07-29_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001238"
      unitRef="Shares">618682</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-07-29_us-gaap_CommonStockMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001240"
      unitRef="USDPShares">2.585</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-07-29_custom_PreFundedWarrantsMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001242"
      unitRef="USDPShares">2.5849</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-07-292026-07-29_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001244"
      unitRef="Shares">218682</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-07-292026-07-29_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001246"
      unitRef="Shares">400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2026-07-292026-07-29_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="-5"
      id="Fact001248"
      unitRef="USD">1600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-07-29_custom_PreFundedWarrantsMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001250"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-07-29_custom_PreFundedWarrantsMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001252"
      unitRef="Shares">618682</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-07-29_custom_CommonStockWarrantsMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001254"
      unitRef="USDPShares">2.585</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2026-07-29_custom_PreFundedWarrantsMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      id="Fact001256">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="AsOf2026-07-29_srt_BoardOfDirectorsChairmanMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001258"
      unitRef="USD">100000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-30_srt_BoardOfDirectorsChairmanMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001260"
      unitRef="Shares">400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-09-232026-09-23_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001262"
      unitRef="Shares">903614</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-09-23_custom_PreFundedWarrantsMember_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001264"
      unitRef="USDPShares">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-09-23_us-gaap_CommonStockMember_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001266"
      unitRef="USDPShares">1.6599</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-09-232026-09-23_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001268"
      unitRef="Shares">903614</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2026-09-232026-09-23_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="-5"
      id="Fact001270"
      unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-09-23_custom_PreFundedWarrantsMember_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001272"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-09-232026-09-23_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001274"
      unitRef="Shares">903614</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-09-23_custom_CommonStockWarrantsMember_custom_JulyTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001276"
      unitRef="USDPShares">1.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2026-09-23_custom_PreFundedWarrantsMember_custom_SeptemberTwoThousandAndTwentySixSecuritiesPurchaseAgreementMember"
      id="Fact001278">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-10-13_custom_SeptemberTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001280"
      unitRef="Shares">755614</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-10-23_custom_SeptemberTwoThousandTwentySixSaleOfCommonStockAndWarrantsMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001282"
      unitRef="Shares">148000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-09-30_custom_NovemberTwoThousandAndTwentyFourCommonStockWarrantsMember"
      decimals="INF"
      id="Fact001284"
      unitRef="Shares">27988</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-09-30_custom_MayTwoThousandAndTwentyFiveCommonStockWarrantsMember"
      decimals="INF"
      id="Fact001286"
      unitRef="Shares">223714</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-09-30_custom_ConversionCommonStockWarrantsMember"
      decimals="INF"
      id="Fact001288"
      unitRef="Shares">21099</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-09-30_custom_NovemberTwoThousandAndTwentyFiveCommonStockWarrantsMember"
      decimals="INF"
      id="Fact001290"
      unitRef="Shares">503402</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2026-09-30_custom_ConversionCommonStockWarrantsMember"
      decimals="INF"
      id="Fact001292"
      unitRef="Shares">21099</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001294">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zpucOS7hohJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_824_zHCch3wuTFbb"&gt;Standby Equity Purchase Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
&lt;span id="xdx_906_ecustom--EquityPurchaseAgreementDate_iI_dd_c20250220__20250220__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember_zPqLNRbXb294" title="Equity purchase agreement date"&gt;February 20, 2025&lt;/span&gt;, the Company entered into an Equity Purchase Agreement (the &#x201c;Equity Purchase Agreement&#x201d;) with Square Gate
Capital Master Fund, LLC - Series 4 (&#x201c;Square Gate&#x201d;), which the Company deemed to be a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;).
Under the Equity Purchase Agreement, the Company will have the right, but not the obligation, to sell to Square Gate, and Square Gate
will have the obligation to purchase from the Company, up to $&lt;span id="xdx_907_eus-gaap--CommonStockValue_iI_c20250220__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zSeLAoVOmEfj" title="Common stock value"&gt;20,000,000&lt;/span&gt; (the &#x201c;Maximum Commitment Amount&#x201d;) worth of the Company&#x2019;s
shares of Common Stock, at the Company&#x2019;s sole discretion, over the next 36 months (the &#x201c;Put Shares&#x201d;), subject to certain
conditions precedent and other limitations. Square Gate has covenanted not to cause or engage in any short sales or hedging transactions
with respect to the shares of the Company&#x2019;s Common Stock. The Maxim Group LLC acted as the Company&#x2019;s exclusive Placement
Agent in connection with this transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 14, 2025, the Company and the Square Gate entered into a First Amendment to the Equity Purchase Agreement to provide a mechanism
for submission by the Company and acceptance by the Square Gate of Put Notices under the Equity Purchase Agreement pursuant to which
the Square Gate and the Company may agree to and execute multiple purchases and sales of Put Shares on the same trading day. Under the
First Amendment, among other things, the purchase price of the intraday Put Shares will be the lowest traded price during a specified
shortened valuation time period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--LongTermPurchaseCommitmentDescription_c20260101__20260930__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember_zJgXC0f6n13k" title="Purchase commitment, description"&gt;Unless
earlier terminated, the Equity Purchase Agreement will remain in effect until the earlier of February 18, 2028 (i.e., the expiry of the
36-month period commencing on the date of the Equity Purchase Agreement) or the date on which Square Gate has purchased the Maximum Commitment
Amount (the &#x201c;Commitment Period&#x201d;). The Company has the right to terminate the Equity Purchase Agreement at any time, subject
to certain provisions as set forth in the Equity Purchase Agreement. Square Gate has the right to terminate the Equity Purchase Agreement
under certain provisions as set forth in the Equity Purchase Agreement, including the continued listing of the Company&#x2019;s Common
Stock on an Eligible Market.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, the Company concluded that the Equity Purchase Agreement for Standard Put Shares does not qualify for equity classification.
On the effective date, the Company concluded that the fair value of the Equity Purchase Agreement at inception was zero and no asset
or liability was recorded. As a result, fees paid to Square Gate in excess of the fair value of the Equity Purchase Agreement were expensed
as incurred. Any issuance costs or other transaction costs attributable to a freestanding equity-linked financial instrument that is
classified as an asset or liability should be recognized in earnings in the period incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Commitment Fee was paid in-kind with an equivalent value of shares of the Company&#x2019;s Common Stock. On March 12, 2025, the Company
issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250312__20250312__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember_zD9npepFeGZk" title="Number of shares issued"&gt;1,603&lt;/span&gt; shares of the Company&#x2019;s Common Stock to Square Gate in payment of the Commitment Fee. At the Special Meeting of Stockholders
held on March 31, 2025, stockholders approved the Company&#x2019;s use of the Equity Purchase Agreement. Pursuant to the Registration
Agreement, the Company filed a registration statement to register the underlying shares. On April 16, 2025, the SEC declared a registration
statement effective to register the Commitment Shares and shares required to sell up to $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250416__20250416__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember_zqRoCmSo3d6" title="Number of shares issued, value"&gt;40.0&lt;/span&gt; million of the Company&#x2019;s shares to
Square Gate, according to provisions of the Equity Purchase Agreement. The Commitment Fee and issuance costs for the registration statement
to register the underlying shares of Common Stock issued under the Equity Purchase Agreement were expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the three and nine months ended September 30, 2025, the Company issued &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember_zgZ47AE5OU99" title="Number of shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember_zbwwF2rcRa59" title="Number of shares issued"&gt;475,000&lt;/span&gt;&lt;/span&gt; shares of Common Stock through the SEPA for proceeds of
$&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember_zrNqbItZYJ9j" title="Number of shares issued, value"&gt;2.2&lt;/span&gt; million, $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember_zGwNt9kJfavg" title="Number of shares issued, value"&gt;2.0&lt;/span&gt; million of which settled as of September 30, 2025. In the three months ended September 30, 2026, the Company did not
issue any shares through its SEPA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the nine months ended September 30, 2025, the Company expensed the $&lt;span id="xdx_900_ecustom--CommitmentFee_c20250101__20250930__us-gaap--TransactionTypeAxis__custom--EquityPurchaseAgreementMember_zL68zkNudgLb" title="Commitment fee"&gt;150,000&lt;/span&gt; Commitment Fee in the accompanying condensed statement of
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <HCWB:EquityPurchaseAgreementDate
      contextRef="From2025-02-202025-02-20_custom_EquityPurchaseAgreementMember"
      id="Fact001296">2025-02-20</HCWB:EquityPurchaseAgreementDate>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-02-20_custom_EquityPurchaseAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001298"
      unitRef="USD">20000000</us-gaap:CommonStockValue>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="From2026-01-012026-09-30_custom_EquityPurchaseAgreementMember"
      id="Fact001300">Unless
earlier terminated, the Equity Purchase Agreement will remain in effect until the earlier of February 18, 2028 (i.e., the expiry of the
36-month period commencing on the date of the Equity Purchase Agreement) or the date on which Square Gate has purchased the Maximum Commitment
Amount (the &#x201c;Commitment Period&#x201d;). The Company has the right to terminate the Equity Purchase Agreement at any time, subject
to certain provisions as set forth in the Equity Purchase Agreement. Square Gate has the right to terminate the Equity Purchase Agreement
under certain provisions as set forth in the Equity Purchase Agreement, including the continued listing of the Company&#x2019;s Common
Stock on an Eligible Market.</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-122025-03-12_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001302"
      unitRef="Shares">1603</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-162025-04-16_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember"
      decimals="-5"
      id="Fact001304"
      unitRef="USD">40000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001306"
      unitRef="Shares">475000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001308"
      unitRef="Shares">475000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember"
      decimals="-5"
      id="Fact001310"
      unitRef="USD">2200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember_custom_EquityPurchaseAgreementMember"
      decimals="-5"
      id="Fact001312"
      unitRef="USD">2000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <HCWB:CommitmentFee
      contextRef="From2025-01-012025-09-30_custom_EquityPurchaseAgreementMember"
      decimals="0"
      id="Fact001314"
      unitRef="USD">150000</HCWB:CommitmentFee>
    <us-gaap:PreferredStockTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001316">&lt;p id="xdx_807_eus-gaap--PreferredStockTextBlock_zxpCjMzfADoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_826_z6el4vabZDfh"&gt;Preferred Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and September 30, 2026, the Company had &lt;span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_zWOFBMUT5Lri" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260930_zGdRGzcQz4wi" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt;&lt;/span&gt; shares of preferred stock authorized and no shares of preferred
stock issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001318"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact001320"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001322">&lt;p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zous3FDXve2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_825_zG0w0z0HGSvh"&gt;Net Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdh8FuJbZlz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the computation of the basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zeUgpjYMm9Qa" style="display: none"&gt;Summary of Basic and Diluted Net Loss Per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250701__20250930_zfuEBz0zT50d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260701__20260930_zDUo7HzIjWCb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930_zz2XnRTnGF64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20260101__20260930_zKyMnycQ5hu" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--NetIncomeLoss_zoKqhY92BZf1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(4,554,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(3,222,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(8,678,941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(4,969,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DividendsCommonStockStock_iN_di_zluxi3t1zai1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;Equity dividend to investor&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1331"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,718,837&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,153,799&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,361,951&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z4dfNK5MAdAi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Net loss attributable to Common Stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,554,336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,941,666&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,832,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(19,331,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250701__20250930_zASntXOFweCi" title="Weighted-average common shares outstanding - basic"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250701__20250930_za1mSXdO9U34" title="Weighted-average common shares outstanding - diluted"&gt;376,678&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260701__20260930_z5cnNp8P3k31" title="Weighted-average common shares outstanding - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260701__20260930_zzAMns4Wtg47" title="Weighted-average common shares outstanding - diluted"&gt;2,101,872&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250930_zVh6ICKmuyPk" title="Weighted-average common shares outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250930_z6AeY3fbSoM4" title="Weighted-average common shares outstanding - diluted"&gt;276,889&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260930_z1mphOEutcFl" title="Weighted-average common shares outstanding - basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260930_zGjUCbB464ie" title="Weighted-average common shares outstanding - diluted"&gt;1,448,485&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Net loss per share, basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20250701__20250930_zjouQSkog9R6" title="Net loss per share - basic"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20250701__20250930_zKhbpD7JKhQh" title="Net loss per share - diluted"&gt;(12.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20260701__20260930_zIgqO9N2Djw8" title="Net loss per share - basic"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20260701__20260930_z9ie6QlvJFy8" title="Net loss per share - diluted"&gt;(2.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250930_zK4vHCyaLCOi" title="Net loss per share - basic"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250930_ziSHW91JcvMc" title="Net loss per share - diluted"&gt;(68.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20260101__20260930_zf8WSUgPtNt2" title="Net loss per share - basic"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20260101__20260930_zXLzchkYEs4" title="Net loss per share - diluted"&gt;(13.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zhVc9aK1kJmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfOutstandingWarrantsProvisionToParticipateInDistributionOfEarningsTextBlock_zC6feekp59fl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the outstanding warrants provision to participate in distribution of earnings. For the three and nine months
ended September 30, 2025 and 2026, these securities were excluded in the calculation for distribution of net loss:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zxwGny5ormJa" style="display: none"&gt;Summary of Outstanding Warrants Provision to Participate in Distribution of Earnings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;November 2024 warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFourWarrantsMember_zIAEUQhwctXl" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFourWarrantsMember_zBqNjRqeiXQ9" title="Potentially dilutive warrants"&gt;27,988&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFourWarrantsMember_zcdAS1cerAaa" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFourWarrantsMember_zvAH8JLgx72a" title="Potentially dilutive warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1379"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1381"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;May 2025 warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandAndTwentyFiveWarrantsMember_zqO1w4Aabl3b" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandAndTwentyFiveWarrantsMember_zF0oZeG3jxk1" title="Potentially dilutive warrants"&gt;223,714&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandAndTwentyFiveWarrantsMember_z0Jyi9Fxaiuc" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandAndTwentyFiveWarrantsMember_zSaaHvquxB92" title="Potentially dilutive warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1387"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants from Debt Conversion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromDebtConversionMember_zdgbfxihnb23" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromDebtConversionMember_z2rMT2qrQmRd" title="Potentially dilutive warrants"&gt;21,099&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromDebtConversionMember_zCA2X4ZZ9zRc" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromDebtConversionMember_zbP3Xv7rbLoc" title="Potentially dilutive warrants"&gt;21,099&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;November 2025 warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFiveWarrantsMember_zfAjmqOXZ5gf" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFiveWarrantsMember_zfOl9T9ip0l9" title="Potentially dilutive warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1399"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1401"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFiveWarrantsMember_zmz8MNhTH5o7" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFiveWarrantsMember_znd1BTxWUFV" title="Potentially dilutive warrants"&gt;503,402&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Potentially participating warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zekrQePeLGoh" title="Potentially participating warrants"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z6UKqoyxCS13" title="Potentially participating warrants"&gt;272,801&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zUuOvBlDib76" title="Potentially participating warrants"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIY96MjidSwc" title="Potentially participating warrants"&gt;524,501&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z6b8H8EatO4a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGmTbwcrkmRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the outstanding potentially dilutive securities. For the three and nine months ended September 30, 2025 and
2026, these securities were excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zBTTUZcroqNg" style="display: none"&gt;Summary of Outstanding Potentially Dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 0pt"&gt;Common stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zIAlbgcD8S8d"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_ze8ApymPXGP2"&gt;7,371&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zKjkGcL8ovP3"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zKdk63EG3dD6"&gt;7,367&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Common stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zO3URSjZ8lGh"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zEwE0myTJ2Il"&gt;272,801&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zjOJcLiUHOa5"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zsgrYdK4xyM2"&gt;1,411,780&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930_zJaDKIbGsj6i" title="Potentially dilutive securities"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zepTXB8LT421" title="Potentially dilutive securities"&gt;280,172&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930_zK9HHBwSQ93j" title="Potentially dilutive securities"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930_zByVhQQ3KMHh" title="Potentially dilutive securities"&gt;1,419,147&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AC_zWN90qsmLIFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001324">&lt;p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdh8FuJbZlz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the computation of the basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zeUgpjYMm9Qa" style="display: none"&gt;Summary of Basic and Diluted Net Loss Per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250701__20250930_zfuEBz0zT50d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260701__20260930_zDUo7HzIjWCb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930_zz2XnRTnGF64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20260101__20260930_zKyMnycQ5hu" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--NetIncomeLoss_zoKqhY92BZf1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(4,554,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(3,222,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(8,678,941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(4,969,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DividendsCommonStockStock_iN_di_zluxi3t1zai1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;Equity dividend to investor&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1331"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,718,837&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,153,799&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,361,951&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z4dfNK5MAdAi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Net loss attributable to Common Stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,554,336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,941,666&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,832,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(19,331,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250701__20250930_zASntXOFweCi" title="Weighted-average common shares outstanding - basic"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250701__20250930_za1mSXdO9U34" title="Weighted-average common shares outstanding - diluted"&gt;376,678&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260701__20260930_z5cnNp8P3k31" title="Weighted-average common shares outstanding - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260701__20260930_zzAMns4Wtg47" title="Weighted-average common shares outstanding - diluted"&gt;2,101,872&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250930_zVh6ICKmuyPk" title="Weighted-average common shares outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250930_z6AeY3fbSoM4" title="Weighted-average common shares outstanding - diluted"&gt;276,889&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260930_z1mphOEutcFl" title="Weighted-average common shares outstanding - basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260930_zGjUCbB464ie" title="Weighted-average common shares outstanding - diluted"&gt;1,448,485&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Net loss per share, basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20250701__20250930_zjouQSkog9R6" title="Net loss per share - basic"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20250701__20250930_zKhbpD7JKhQh" title="Net loss per share - diluted"&gt;(12.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20260701__20260930_zIgqO9N2Djw8" title="Net loss per share - basic"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20260701__20260930_z9ie6QlvJFy8" title="Net loss per share - diluted"&gt;(2.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250930_zK4vHCyaLCOi" title="Net loss per share - basic"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250930_ziSHW91JcvMc" title="Net loss per share - diluted"&gt;(68.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20260101__20260930_zf8WSUgPtNt2" title="Net loss per share - basic"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20260101__20260930_zXLzchkYEs4" title="Net loss per share - diluted"&gt;(13.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001326"
      unitRef="USD">-4554336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact001327"
      unitRef="USD">-3222829</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact001328"
      unitRef="USD">-8678941</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001329"
      unitRef="USD">-4969581</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact001332"
      unitRef="USD">2718837</us-gaap:DividendsCommonStockStock>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact001333"
      unitRef="USD">10153799</us-gaap:DividendsCommonStockStock>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001334"
      unitRef="USD">14361951</us-gaap:DividendsCommonStockStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001336"
      unitRef="USD">-4554336</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact001337"
      unitRef="USD">-5941666</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact001338"
      unitRef="USD">-18832740</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001339"
      unitRef="USD">-19331532</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact001341"
      unitRef="Shares">376678</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact001343"
      unitRef="Shares">376678</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact001345"
      unitRef="Shares">2101872</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact001347"
      unitRef="Shares">2101872</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">276889</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact001351"
      unitRef="Shares">276889</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001353"
      unitRef="Shares">1448485</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001355"
      unitRef="Shares">1448485</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact001357"
      unitRef="USDPShares">-12.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact001359"
      unitRef="USDPShares">-12.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact001361"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact001363"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact001365"
      unitRef="USDPShares">-68.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact001367"
      unitRef="USDPShares">-68.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001369"
      unitRef="USDPShares">-13.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001371"
      unitRef="USDPShares">-13.35</us-gaap:EarningsPerShareDiluted>
    <HCWB:ScheduleOfOutstandingWarrantsProvisionToParticipateInDistributionOfEarningsTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001373">&lt;p id="xdx_899_ecustom--ScheduleOfOutstandingWarrantsProvisionToParticipateInDistributionOfEarningsTextBlock_zC6feekp59fl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the outstanding warrants provision to participate in distribution of earnings. For the three and nine months
ended September 30, 2025 and 2026, these securities were excluded in the calculation for distribution of net loss:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zxwGny5ormJa" style="display: none"&gt;Summary of Outstanding Warrants Provision to Participate in Distribution of Earnings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;November 2024 warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFourWarrantsMember_zIAEUQhwctXl" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFourWarrantsMember_zBqNjRqeiXQ9" title="Potentially dilutive warrants"&gt;27,988&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFourWarrantsMember_zcdAS1cerAaa" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFourWarrantsMember_zvAH8JLgx72a" title="Potentially dilutive warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1379"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1381"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;May 2025 warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandAndTwentyFiveWarrantsMember_zqO1w4Aabl3b" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandAndTwentyFiveWarrantsMember_zF0oZeG3jxk1" title="Potentially dilutive warrants"&gt;223,714&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandAndTwentyFiveWarrantsMember_z0Jyi9Fxaiuc" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandAndTwentyFiveWarrantsMember_zSaaHvquxB92" title="Potentially dilutive warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1387"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants from Debt Conversion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromDebtConversionMember_zdgbfxihnb23" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromDebtConversionMember_z2rMT2qrQmRd" title="Potentially dilutive warrants"&gt;21,099&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromDebtConversionMember_zCA2X4ZZ9zRc" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromDebtConversionMember_zbP3Xv7rbLoc" title="Potentially dilutive warrants"&gt;21,099&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;November 2025 warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFiveWarrantsMember_zfAjmqOXZ5gf" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFiveWarrantsMember_zfOl9T9ip0l9" title="Potentially dilutive warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1399"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1401"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFiveWarrantsMember_zmz8MNhTH5o7" title="Potentially dilutive warrants"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandAndTwentyFiveWarrantsMember_znd1BTxWUFV" title="Potentially dilutive warrants"&gt;503,402&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Potentially participating warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zekrQePeLGoh" title="Potentially participating warrants"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z6UKqoyxCS13" title="Potentially participating warrants"&gt;272,801&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zUuOvBlDib76" title="Potentially participating warrants"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIY96MjidSwc" title="Potentially participating warrants"&gt;524,501&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</HCWB:ScheduleOfOutstandingWarrantsProvisionToParticipateInDistributionOfEarningsTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact001375"
      unitRef="Shares">27988</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact001377"
      unitRef="Shares">27988</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_WarrantMember_custom_MayTwoThousandAndTwentyFiveWarrantsMember"
      decimals="INF"
      id="Fact001383"
      unitRef="Shares">223714</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_MayTwoThousandAndTwentyFiveWarrantsMember"
      decimals="INF"
      id="Fact001385"
      unitRef="Shares">223714</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_WarrantMember_custom_WarrantsFromDebtConversionMember"
      decimals="INF"
      id="Fact001391"
      unitRef="Shares">21099</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_WarrantsFromDebtConversionMember"
      decimals="INF"
      id="Fact001393"
      unitRef="Shares">21099</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_us-gaap_WarrantMember_custom_WarrantsFromDebtConversionMember"
      decimals="INF"
      id="Fact001395"
      unitRef="Shares">21099</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-09-30_us-gaap_WarrantMember_custom_WarrantsFromDebtConversionMember"
      decimals="INF"
      id="Fact001397"
      unitRef="Shares">21099</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFiveWarrantsMember"
      decimals="INF"
      id="Fact001403"
      unitRef="Shares">503402</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-09-30_us-gaap_WarrantMember_custom_NovemberTwoThousandAndTwentyFiveWarrantsMember"
      decimals="INF"
      id="Fact001405"
      unitRef="Shares">503402</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001407"
      unitRef="Shares">272801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001409"
      unitRef="Shares">272801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001411"
      unitRef="Shares">524501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-09-30_us-gaap_WarrantMember32129062"
      decimals="INF"
      id="Fact001413"
      unitRef="Shares">524501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001415">&lt;p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGmTbwcrkmRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the outstanding potentially dilutive securities. For the three and nine months ended September 30, 2025 and
2026, these securities were excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zBTTUZcroqNg" style="display: none"&gt;Summary of Outstanding Potentially Dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 0pt"&gt;Common stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zIAlbgcD8S8d"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_ze8ApymPXGP2"&gt;7,371&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zKjkGcL8ovP3"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zKdk63EG3dD6"&gt;7,367&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Common stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zO3URSjZ8lGh"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zEwE0myTJ2Il"&gt;272,801&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zjOJcLiUHOa5"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zsgrYdK4xyM2"&gt;1,411,780&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930_zJaDKIbGsj6i" title="Potentially dilutive securities"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zepTXB8LT421" title="Potentially dilutive securities"&gt;280,172&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930_zK9HHBwSQ93j" title="Potentially dilutive securities"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930_zByVhQQ3KMHh" title="Potentially dilutive securities"&gt;1,419,147&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_custom_CommonStockOptionsMember"
      decimals="INF"
      id="Fact001416"
      unitRef="Shares">7371</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_custom_CommonStockOptionsMember"
      decimals="INF"
      id="Fact001417"
      unitRef="Shares">7371</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_custom_CommonStockOptionsMember"
      decimals="INF"
      id="Fact001418"
      unitRef="Shares">7367</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-09-30_custom_CommonStockOptionsMember"
      decimals="INF"
      id="Fact001419"
      unitRef="Shares">7367</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001420"
      unitRef="Shares">272801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001421"
      unitRef="Shares">272801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001422"
      unitRef="Shares">1411780</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-012026-09-30_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001423"
      unitRef="Shares">1411780</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact001425"
      unitRef="Shares">280172</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact001427"
      unitRef="Shares">280172</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact001429"
      unitRef="Shares">1419147</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001431"
      unitRef="Shares">1419147</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001433">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zYSAX1hGOfxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_824_zdZMZgntU3Yb"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under ASC 740, Income Taxes. The income tax provision for interim periods is determined using an estimated
annual effective tax rate, adjusted for discrete items, if any, recognized in the period in which they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the nine months ended September 30, 2025 and 2026, the Company recorded an income tax provision of $&lt;span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20250101__20250930_zgcDOCAPdqHg" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1434"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--IncomeTaxExpenseBenefit_c20260101__20260930_zbVAkuvivBde"&gt;330,186&lt;/span&gt; on pre-tax losses
of $&lt;span id="xdx_902_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn4n6_di_c20250101__20250930_z8MyZiddEdh8"&gt;8.68&lt;/span&gt; million and $&lt;span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn4n6_di_c20260101__20260930_z9a8JQN7N5ce"&gt;4.64&lt;/span&gt; million for effective tax rates of &lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20250930_zrlgh0oMEJ6b"&gt;0&lt;/span&gt;% and (&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20260101__20260930_zMiudd54lz78"&gt;7.12&lt;/span&gt;)%, respectively. The effective tax rate differed from the
statutory rate primarily because the Company recorded foreign withholding tax expense on China licensing revenue while receiving no corresponding
U.S. tax benefit due to its full valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z0N9bNQ9Ami1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are income taxes paid by jurisdiction:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zsXVHcSKjDbg" style="display: none"&gt;Schedule of Income Tax Paid&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250930_zE9DsVuE78lh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260101__20260930_z8dfJmSnmd2j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_maITEBzkTL_zUGi06w04z73" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Income Tax Payments - U.S. Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1443"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1444"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_maITEBzkTL_z9CmzONJ20Be" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Income Tax Payments - U.S. States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1447"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ForeignIncomeTaxExpenseBenefitContinuingOperations_maITEBzkTL_zFuVYbPxa0mf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;China - Income tax payments, net of refunds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1449"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;330,186&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzkTL_z94CMXlqwZ6i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 10pt"&gt;Total income taxes paid&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1452"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;330,186&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_za0ae8ILerq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001435"
      unitRef="USD">330186</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-09-30"
      decimals="-4"
      id="Fact001436"
      unitRef="USD">-8680000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-01to2026-09-30"
      decimals="-4"
      id="Fact001437"
      unitRef="USD">-4640000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact001438"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001439"
      unitRef="Pure">0.0712</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001441">&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z0N9bNQ9Ami1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are income taxes paid by jurisdiction:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zsXVHcSKjDbg" style="display: none"&gt;Schedule of Income Tax Paid&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250930_zE9DsVuE78lh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260101__20260930_z8dfJmSnmd2j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_maITEBzkTL_zUGi06w04z73" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Income Tax Payments - U.S. Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1443"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1444"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_maITEBzkTL_z9CmzONJ20Be" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Income Tax Payments - U.S. States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1447"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ForeignIncomeTaxExpenseBenefitContinuingOperations_maITEBzkTL_zFuVYbPxa0mf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;China - Income tax payments, net of refunds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1449"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;330,186&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzkTL_z94CMXlqwZ6i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 10pt"&gt;Total income taxes paid&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1452"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;330,186&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001450"
      unitRef="USD">330186</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001453"
      unitRef="USD">330186</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001455">&lt;p id="xdx_807_eus-gaap--SegmentReportingDisclosureTextBlock_zfHmfQG9GbSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span id="xdx_828_zDu48LMK3aM9"&gt;Segment Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;HCW
Biologics Inc. has &lt;span id="xdx_903_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20260101__20260930_zWBwAfsxgnAd" title="Number of reportable segments"&gt;one&lt;/span&gt; reportable segment: life science. The life science segment consists of operations focused on discovering and developing
novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and diseases. The Company&#x2019;s
CODM is the chief executive officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. &lt;span id="xdx_908_eus-gaap--SegmentReportingExpenseInformationUsedByCodmDescription_c20260101__20260930_zwdxBzfGPam5" title="Segment reporting, expense information used by CODM, description"&gt;The
CODM assesses performance for the life science segment based on net segment income (loss). The measure of segment assets is reported
on the condensed balance sheet as total assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not generated any product revenue from commercial product sales of internally-developed immunotherapeutic products for the
treatment of diseases, as no products have been approved for commercial sale as of September 30, 2026. The Company expects to continue to
incur significant expenses and operating losses for the foreseeable future as it advances molecules through all stages of development
and clinical trials and, ultimately, seek approval for commercial sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
such, the CODM uses cash forecast models in deciding how to invest into the life science segment. Such cash forecast models are reviewed
to assess the entity-wide operating results and performance in conjunction with monitoring the results of R&amp;amp;D experiments for preclinical
compounds and clinical trial data for clinical-stage compounds. The assessment of results of preclinical and clinical studies is critical
to the allocation of resources by the CODM.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_hus-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zfLsfupWeSGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tables below summarize the significant expense categories regularly reviewed by the CODM for the three and nine months ended September
30, 2025 and 2026&lt;b&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B5_zfSm4SXG6rze" style="display: none"&gt;Summary of Significant Expense Categories&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zFob7WaGduv4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zKKqtJd6Sk23" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zfyq90ITgsG4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zanSzrS4iFb4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Revenues:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zuitHZ0Q2gPa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;15,606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;55,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;27,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,734,032&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CostOfRevenue_i01N_di_zsnAfvf421Di" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,345&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,777&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(267,871&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GrossProfit_i01T_zUjCyyXvNBPf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt"&gt;Gross profit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,121&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;28,118&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,445&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,466,161&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zULgu7m4Cze2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpenseAbstract_i01B_zBoPkXPjoHH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--SalariesBenefitsAndRelatedExpensesMember_zZnHLPyU4bBk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Salaries, benefits and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;801,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;765,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,281,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,305,557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--ManufacturingAndMaterialsMember_zohmzHkpieeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Manufacturing and materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--PreclinicalExpensesMember_zySE7ZoPjlf6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Preclinical expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,661&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;639,785&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;615,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--ClinicalTrialsMember_zO6oyuEMn25b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Clinical trials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--OverheadAllocationsMember_zZ0A8FPIO1G2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Overhead allocations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;156,401&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;138,097&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;462,792&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;437,326&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i02_zaDVsXL3K4K3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,404,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,242,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,109,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,703,877&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zDy8xKyu7D0a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--SalariesBenefitsAndRelatedExpensesMember_zquRb6p3xrNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Salaries, benefits and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;699,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;522,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,254,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,569,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--ProfessionalServicesMember_zcnnZdP8Rvbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    services&lt;sup id="xdx_F49_zd29fzr3ZYy9"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;552,371&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;386,736&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,503,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,376,711&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--FacilitiesAndOfficeExpensesMember_zonVNcgNB1t3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Facilities and office expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125,521&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;331,588&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;326,434&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--DepreciationExpensesMember_zr8MmZr1rIFh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Depreciation expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,849&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152,076&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--RentAndOccupancyExpensesMember_zg5AEwZCMEE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Rent and occupancy expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--InsuranceMember_zNqIz3zH1GJ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt"&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;254,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;815,484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--TaxesMember_zzzgmSFc2gub" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt"&gt;Taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;285,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--OtherExpensesMember_zBuwE1wd0ioc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;99,303&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,909&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;427,484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;806,872&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i02_zUIS6BqIrm03" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,869,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,356,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,796,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,031,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_i02_z6sSgKTm88Sa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net segment loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,270,618&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,571,236&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,900,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,269,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SegmentReportingOtherItemAmount_i02_z9suhqGnVYri" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items&lt;sup id="xdx_F47_z1c1UkZVKatk"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,283,718&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;651,593&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,221,883&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,370,076&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_i02_zlAmOJObT8G5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss before income taxes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,554,336&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(3,222,829&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(8,678,941&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,639,395&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F06_zZTDpas3zyQk"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zxvqDcdaEHEi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    services consist primarily of audit and accounting advisory services, tax advisory services, corporate legal services and other services
    related to SEC compliance, and legal fees related to patent filings.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F03_z9QSNpMVgk55"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_zdq0xOE8tGN7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items include the following unusual or nonrecurring item that comprise other segment items for the three and nine months
    ended September 30, 2025 and 2026:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z1tigHajNIp9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zVcJU4kz97ti" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcrt3hsZB1Rj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zCeFVQE9K969" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LegalExpensesRecoveriesNet_z9n5jsngCfo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Arbitration legal fees (recoveries), net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,058&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(1,590,945&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;14,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccretionExpense_zAJPpz3i6fxl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accretion of fixed bonus upon maturity of Secured Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,609&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;390,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InterestExpense_zWBA5RZBBmCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,070&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,797&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;632,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;351,612&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--IndirectTaxExpense_zE5iJf11j5Qb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Indirect tax expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1600"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1601"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1602"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GainLossOnInvestments_iN_di_zz1NgCEPT0be" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of investment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,022,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1606"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,474,935&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1608"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of contingent liability, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,055,825&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;692,531&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zuuBvTRqIezj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1612"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,775,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_zuk6Uc38gwP7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gain on extinguishment of liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1615"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1617"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(483,383&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--GainLossOnDispositionOfAssets_zFFn54JNsHP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss on return of equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1620"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1622"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LossOnSaleOfInvestments_zewNm4CVmdRf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on sale of put shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1628"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherOperatingIncomeExpenseNet_zErWfz6uVRWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(13,290&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,554&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(54,412&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(19,992&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SegmentReportingOtherItemAmount_zryLyyRDL9ne" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Other segment items&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,283,718&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;651,593&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(1,221,883&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,370,076&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zh4CCakPtq9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001457"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription contextRef="From2026-01-01to2026-09-30" id="Fact001459">The
CODM assesses performance for the life science segment based on net segment income (loss). The measure of segment assets is reported
on the condensed balance sheet as total assets.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2026-01-012026-09-30_custom_SingleReportableSegmentMember"
      id="Fact001461">&lt;p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_hus-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zfLsfupWeSGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tables below summarize the significant expense categories regularly reviewed by the CODM for the three and nine months ended September
30, 2025 and 2026&lt;b&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B5_zfSm4SXG6rze" style="display: none"&gt;Summary of Significant Expense Categories&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zFob7WaGduv4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zKKqtJd6Sk23" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zfyq90ITgsG4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zanSzrS4iFb4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Revenues:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zuitHZ0Q2gPa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;15,606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;55,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;27,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,734,032&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CostOfRevenue_i01N_di_zsnAfvf421Di" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,345&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,777&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(267,871&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GrossProfit_i01T_zUjCyyXvNBPf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt"&gt;Gross profit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,121&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;28,118&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,445&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,466,161&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zULgu7m4Cze2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpenseAbstract_i01B_zBoPkXPjoHH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--SalariesBenefitsAndRelatedExpensesMember_zZnHLPyU4bBk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Salaries, benefits and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;801,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;765,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,281,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,305,557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--ManufacturingAndMaterialsMember_zohmzHkpieeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Manufacturing and materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--PreclinicalExpensesMember_zySE7ZoPjlf6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Preclinical expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,661&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;639,785&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;615,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--ClinicalTrialsMember_zO6oyuEMn25b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Clinical trials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i02_hsrt--ProductOrServiceAxis__custom--OverheadAllocationsMember_zZ0A8FPIO1G2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Overhead allocations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;156,401&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;138,097&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;462,792&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;437,326&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i02_zaDVsXL3K4K3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,404,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,242,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,109,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,703,877&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zDy8xKyu7D0a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--SalariesBenefitsAndRelatedExpensesMember_zquRb6p3xrNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Salaries, benefits and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;699,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;522,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,254,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,569,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--ProfessionalServicesMember_zcnnZdP8Rvbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    services&lt;sup id="xdx_F49_zd29fzr3ZYy9"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;552,371&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;386,736&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,503,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,376,711&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--FacilitiesAndOfficeExpensesMember_zonVNcgNB1t3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Facilities and office expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125,521&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;331,588&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;326,434&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--DepreciationExpensesMember_zr8MmZr1rIFh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Depreciation expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,849&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152,076&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--RentAndOccupancyExpensesMember_zg5AEwZCMEE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Rent and occupancy expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--InsuranceMember_zNqIz3zH1GJ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt"&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;254,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;815,484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--TaxesMember_zzzgmSFc2gub" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt"&gt;Taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;285,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i02_hsrt--ProductOrServiceAxis__custom--OtherExpensesMember_zBuwE1wd0ioc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;99,303&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,909&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;427,484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;806,872&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i02_zUIS6BqIrm03" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,869,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,356,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,796,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,031,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_i02_z6sSgKTm88Sa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net segment loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,270,618&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,571,236&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,900,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,269,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SegmentReportingOtherItemAmount_i02_z9suhqGnVYri" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items&lt;sup id="xdx_F47_z1c1UkZVKatk"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,283,718&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;651,593&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,221,883&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,370,076&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_i02_zlAmOJObT8G5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss before income taxes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,554,336&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(3,222,829&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(8,678,941&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(4,639,395&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F06_zZTDpas3zyQk"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zxvqDcdaEHEi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    services consist primarily of audit and accounting advisory services, tax advisory services, corporate legal services and other services
    related to SEC compliance, and legal fees related to patent filings.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F03_z9QSNpMVgk55"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_zdq0xOE8tGN7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items include the following unusual or nonrecurring item that comprise other segment items for the three and nine months
    ended September 30, 2025 and 2026:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z1tigHajNIp9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zVcJU4kz97ti" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcrt3hsZB1Rj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zCeFVQE9K969" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LegalExpensesRecoveriesNet_z9n5jsngCfo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Arbitration legal fees (recoveries), net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,058&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(1,590,945&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;14,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccretionExpense_zAJPpz3i6fxl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accretion of fixed bonus upon maturity of Secured Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,609&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;390,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InterestExpense_zWBA5RZBBmCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,070&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,797&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;632,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;351,612&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--IndirectTaxExpense_zE5iJf11j5Qb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Indirect tax expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1600"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1601"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1602"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GainLossOnInvestments_iN_di_zz1NgCEPT0be" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of investment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,022,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1606"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,474,935&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1608"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of contingent liability, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,055,825&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;692,531&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_zuuBvTRqIezj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1612"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,775,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_zuk6Uc38gwP7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gain on extinguishment of liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1615"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1617"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(483,383&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--GainLossOnDispositionOfAssets_zFFn54JNsHP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss on return of equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1620"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1622"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LossOnSaleOfInvestments_zewNm4CVmdRf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on sale of put shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1628"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherOperatingIncomeExpenseNet_zErWfz6uVRWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(13,290&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,554&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(54,412&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(19,992&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SegmentReportingOtherItemAmount_zryLyyRDL9ne" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Other segment items&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,283,718&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;651,593&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(1,221,883&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,370,076&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001463"
      unitRef="USD">15606</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001464"
      unitRef="USD">55463</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001465"
      unitRef="USD">27222</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001466"
      unitRef="USD">6734032</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001468"
      unitRef="USD">12485</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001469"
      unitRef="USD">27345</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001470"
      unitRef="USD">21777</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001471"
      unitRef="USD">267871</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001473"
      unitRef="USD">3121</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001474"
      unitRef="USD">28118</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001475"
      unitRef="USD">5445</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001476"
      unitRef="USD">6466161</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember"
      decimals="0"
      id="Fact001488"
      unitRef="USD">801504</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember"
      decimals="0"
      id="Fact001489"
      unitRef="USD">765859</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember"
      decimals="0"
      id="Fact001490"
      unitRef="USD">2281050</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember"
      decimals="0"
      id="Fact001491"
      unitRef="USD">2305557</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ManufacturingAndMaterialsMember"
      decimals="0"
      id="Fact001493"
      unitRef="USD">50259</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ManufacturingAndMaterialsMember"
      decimals="0"
      id="Fact001494"
      unitRef="USD">28590</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ManufacturingAndMaterialsMember"
      decimals="0"
      id="Fact001495"
      unitRef="USD">347042</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ManufacturingAndMaterialsMember"
      decimals="0"
      id="Fact001496"
      unitRef="USD">45704</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_PreclinicalExpensesMember"
      decimals="0"
      id="Fact001498"
      unitRef="USD">315725</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_PreclinicalExpensesMember"
      decimals="0"
      id="Fact001499"
      unitRef="USD">238661</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_PreclinicalExpensesMember"
      decimals="0"
      id="Fact001500"
      unitRef="USD">639785</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_PreclinicalExpensesMember"
      decimals="0"
      id="Fact001501"
      unitRef="USD">615144</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ClinicalTrialsMember"
      decimals="0"
      id="Fact001503"
      unitRef="USD">80358</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ClinicalTrialsMember"
      decimals="0"
      id="Fact001504"
      unitRef="USD">71370</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ClinicalTrialsMember"
      decimals="0"
      id="Fact001505"
      unitRef="USD">379113</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ClinicalTrialsMember"
      decimals="0"
      id="Fact001506"
      unitRef="USD">300146</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_OverheadAllocationsMember"
      decimals="0"
      id="Fact001508"
      unitRef="USD">156401</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_OverheadAllocationsMember"
      decimals="0"
      id="Fact001509"
      unitRef="USD">138097</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_OverheadAllocationsMember"
      decimals="0"
      id="Fact001510"
      unitRef="USD">462792</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_OverheadAllocationsMember"
      decimals="0"
      id="Fact001511"
      unitRef="USD">437326</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001513"
      unitRef="USD">1404247</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001514"
      unitRef="USD">1242577</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001515"
      unitRef="USD">4109782</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001516"
      unitRef="USD">3703877</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember"
      decimals="0"
      id="Fact001523"
      unitRef="USD">699989</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember"
      decimals="0"
      id="Fact001524"
      unitRef="USD">522879</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember"
      decimals="0"
      id="Fact001525"
      unitRef="USD">2254015</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SalariesBenefitsAndRelatedExpensesMember"
      decimals="0"
      id="Fact001526"
      unitRef="USD">1569696</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProfessionalServicesMember"
      decimals="0"
      id="Fact001528"
      unitRef="USD">552371</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProfessionalServicesMember"
      decimals="0"
      id="Fact001529"
      unitRef="USD">386736</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProfessionalServicesMember"
      decimals="0"
      id="Fact001530"
      unitRef="USD">1503381</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProfessionalServicesMember"
      decimals="0"
      id="Fact001531"
      unitRef="USD">1376711</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_FacilitiesAndOfficeExpensesMember"
      decimals="0"
      id="Fact001533"
      unitRef="USD">125521</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_FacilitiesAndOfficeExpensesMember"
      decimals="0"
      id="Fact001534"
      unitRef="USD">109641</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_FacilitiesAndOfficeExpensesMember"
      decimals="0"
      id="Fact001535"
      unitRef="USD">331588</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_FacilitiesAndOfficeExpensesMember"
      decimals="0"
      id="Fact001536"
      unitRef="USD">326434</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_DepreciationExpensesMember"
      decimals="0"
      id="Fact001538"
      unitRef="USD">58451</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_DepreciationExpensesMember"
      decimals="0"
      id="Fact001539"
      unitRef="USD">48206</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_DepreciationExpensesMember"
      decimals="0"
      id="Fact001540"
      unitRef="USD">178849</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_DepreciationExpensesMember"
      decimals="0"
      id="Fact001541"
      unitRef="USD">152076</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_RentAndOccupancyExpensesMember"
      decimals="0"
      id="Fact001543"
      unitRef="USD">39633</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_RentAndOccupancyExpensesMember"
      decimals="0"
      id="Fact001544"
      unitRef="USD">41276</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_RentAndOccupancyExpensesMember"
      decimals="0"
      id="Fact001545"
      unitRef="USD">151911</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_RentAndOccupancyExpensesMember"
      decimals="0"
      id="Fact001546"
      unitRef="USD">128325</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_InsuranceMember"
      decimals="0"
      id="Fact001548"
      unitRef="USD">254617</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_InsuranceMember"
      decimals="0"
      id="Fact001549"
      unitRef="USD">162102</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_InsuranceMember"
      decimals="0"
      id="Fact001550"
      unitRef="USD">815484</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_InsuranceMember"
      decimals="0"
      id="Fact001551"
      unitRef="USD">385523</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_TaxesMember"
      decimals="0"
      id="Fact001553"
      unitRef="USD">39607</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_TaxesMember"
      decimals="0"
      id="Fact001554"
      unitRef="USD">72028</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_TaxesMember"
      decimals="0"
      id="Fact001555"
      unitRef="USD">133775</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_TaxesMember"
      decimals="0"
      id="Fact001556"
      unitRef="USD">285966</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_OtherExpensesMember"
      decimals="0"
      id="Fact001558"
      unitRef="USD">99303</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_OtherExpensesMember"
      decimals="0"
      id="Fact001559"
      unitRef="USD">13909</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_OtherExpensesMember"
      decimals="0"
      id="Fact001560"
      unitRef="USD">427484</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_OtherExpensesMember"
      decimals="0"
      id="Fact001561"
      unitRef="USD">806872</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001563"
      unitRef="USD">1869492</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001564"
      unitRef="USD">1356777</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001565"
      unitRef="USD">5796487</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001566"
      unitRef="USD">5031603</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001568"
      unitRef="USD">-3270618</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001569"
      unitRef="USD">-2571236</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001570"
      unitRef="USD">-9900824</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001571"
      unitRef="USD">-2269319</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001573"
      unitRef="USD">1283718</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001574"
      unitRef="USD">651593</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001575"
      unitRef="USD">-1221883</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001576"
      unitRef="USD">2370076</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001578"
      unitRef="USD">-4554336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001579"
      unitRef="USD">-3222829</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001580"
      unitRef="USD">-8678941</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001581"
      unitRef="USD">-4639395</us-gaap:NetIncomeLoss>
    <HCWB:LegalExpensesRecoveriesNet
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001585"
      unitRef="USD">6006</HCWB:LegalExpensesRecoveriesNet>
    <HCWB:LegalExpensesRecoveriesNet
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001586"
      unitRef="USD">9058</HCWB:LegalExpensesRecoveriesNet>
    <HCWB:LegalExpensesRecoveriesNet
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001587"
      unitRef="USD">-1590945</HCWB:LegalExpensesRecoveriesNet>
    <HCWB:LegalExpensesRecoveriesNet
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001588"
      unitRef="USD">14583</HCWB:LegalExpensesRecoveriesNet>
    <us-gaap:AccretionExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001590"
      unitRef="USD">15502</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001591"
      unitRef="USD">9609</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001592"
      unitRef="USD">390809</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001593"
      unitRef="USD">38435</us-gaap:AccretionExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001595"
      unitRef="USD">127070</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001596"
      unitRef="USD">141797</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001597"
      unitRef="USD">632923</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001598"
      unitRef="USD">351612</us-gaap:InterestExpense>
    <HCWB:IndirectTaxExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001603"
      unitRef="USD">198146</HCWB:IndirectTaxExpense>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001605"
      unitRef="USD">-2022109</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001607"
      unitRef="USD">1474935</us-gaap:GainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001613"
      unitRef="USD">-1775992</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001618"
      unitRef="USD">483383</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001621"
      unitRef="USD">494683</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001623"
      unitRef="USD">494683</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001625"
      unitRef="USD">182146</us-gaap:LossOnSaleOfInvestments>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001627"
      unitRef="USD">182146</us-gaap:LossOnSaleOfInvestments>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001630"
      unitRef="USD">-13290</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001631"
      unitRef="USD">-3554</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001632"
      unitRef="USD">-54412</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001633"
      unitRef="USD">-19992</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001635"
      unitRef="USD">1283718</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001636"
      unitRef="USD">651593</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001637"
      unitRef="USD">-1221883</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001638"
      unitRef="USD">2370076</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001640">&lt;p id="xdx_808_eus-gaap--CommitmentsDisclosureTextBlock_zgB05SwU8zHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
&lt;span id="xdx_82D_zBNgJFWdyzTb"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Operating
Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has operating leases for approximately &lt;span id="xdx_90B_eus-gaap--AreaOfLand_iI_uArea_c20260930_zXwOkAmYcFGd"&gt;12,250&lt;/span&gt;
square feet of space located in Miramar, Florida. On January 27, 2025, the Company entered into a &lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20250301_zcReyw4ms3S4" style="display: none" title="Lease term"&gt;1&lt;/span&gt; one-year lease for the same
location which commenced on March 1, 2025 and terminated on &lt;span id="xdx_908_eus-gaap--LeaseExpirationDate1_dd_c20250301__20250301_z6gBwlBH3ouj" title="Lease termination date"&gt;February 28, 2026&lt;/span&gt;. On &lt;span id="xdx_901_eus-gaap--LeaseExpirationDate1_dd_c20260301__20260301_zcJIDtdXiiod" title="Lease termination date"&gt;February 2, 2026&lt;/span&gt;, the Company entered into a
one-year lease for the same location which commenced on March 1, 2026 and terminates on February 28, 2027. FASB ASC 842, Leases,
provides for an exception for short-term leases in ASC 842-20-25-2, whereby a lessee may elect to recognize lease payments in profit
or loss on a straight-line basis over the lease term and forego the requirement to recognize a ROU asset and lease liability. The
Company elected to account for its short-term operating leases on a straight-line basis over the lease term and did not recognize a
ROU asset or lease liability, as allowed for under the exception in ASC 842-20-25-2. The Company has no obligations under financing
leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended September 30, 2025 and 2026, rent expense recognized by the Company was $&lt;span id="xdx_90C_ecustom--RecognizedRentExpense_c20250701__20250930_z3tWWd4Wm4Qa" title="Recognized rent expense"&gt;52,619&lt;/span&gt; and $&lt;span id="xdx_90B_ecustom--RecognizedRentExpense_c20260701__20260930_zmFmJTtXyQo4" title="Recognized rent expense"&gt;55,715&lt;/span&gt;, respectively, of
which $&lt;span id="xdx_90E_ecustom--RecognizedRentExpense_c20250701__20250930__srt--ProductOrServiceAxis__custom--ResearchAndDevelopmentExpensesMember_zKTNIBd7wMTe" title="Recognized rent expense"&gt;27,557&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--RecognizedRentExpense_c20260701__20260930__srt--ProductOrServiceAxis__custom--ResearchAndDevelopmentExpensesMember_zy1HSRODoVf1" title="Recognized rent expense"&gt;29,178&lt;/span&gt;, respectively, are included in research and development in the accompanying condensed statements of operations.
For the nine months ended September 30, 2025 and 2026, rent expense recognized by the Company was $&lt;span id="xdx_90E_ecustom--RecognizedRentExpense_c20250101__20250930_zmVh7IcWQzZc" title="Recognized rent expense"&gt;155,794&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--RecognizedRentExpense_c20260101__20260930_zsC1OkdsXnhd" title="Recognized rent expense"&gt;165,080&lt;/span&gt;, respectively,
of which $&lt;span id="xdx_902_ecustom--RecognizedRentExpense_c20250101__20250930__srt--ProductOrServiceAxis__custom--ResearchAndDevelopmentExpensesMember_zLmRthqrORih" title="Recognized rent expense"&gt;81,590&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--RecognizedRentExpense_c20260101__20260930__srt--ProductOrServiceAxis__custom--ResearchAndDevelopmentExpensesMember_zBaqdkvof8B6" title="Recognized rent expense"&gt;86,453&lt;/span&gt;, respectively, are included in research and development in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual
Commitments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has commitments with R&amp;amp;D outsourcing and development companies to supply us with clinical grade materials or other development
services. As of September 30, 2026, it is under contract for future obligations of $&lt;span id="xdx_903_eus-gaap--ContractualObligation_iI_c20260930_zkfV9IlZlrRg" title="Future payment obligations"&gt;33,080&lt;/span&gt; it expects to pay during the year ending December
31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Legal
Matters&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Legal
Proceedings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company is a party to or otherwise involved in legal proceedings, including suits, assessments, regulatory actions
and investigations generally arising out of the normal course of business. In addition, the Company enters into agreements that may include
indemnification provisions, pursuant to which the Company agrees to indemnify, hold harmless and defend the indemnified parties for losses
suffered or incurred by the indemnified party. When the Company believes that the outcome of such a matter will result in a liability
that is probable to be incurred and result in a potential loss, or range of loss, that can be reasonably estimated, the Company will
accrue a liability and make the appropriate disclosure in the footnotes to the condensed financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Arbitration,
Settlement and General Release&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of July 13, 2024, the Company and Dr. Hing C. Wong, the Company&#x2019;s Founder and Chief Executive Officer, entered into a confidential
Settlement Agreement with Altor BioScience, LLC (&#x201c;Altor&#x201d;), NantCell, Inc. (&#x201c;NantCell&#x201d;), and ImmunityBio, Inc.
(the parent of Altor and NantCell, together with Altor and NantCell, &#x201c;ImmunityBio&#x201d;), to resolve the previously disclosed
Arbitration. The Arbitration and related Complaint were dismissed with prejudice as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company received a $&lt;span id="xdx_905_ecustom--InsuranceReimbursementForLegalDefenseCost_pn5n6_c20250101__20250131_zmv5ux2pZCg8" title="Insurance reimbursement"&gt;2.0&lt;/span&gt; million insurance reimbursement which was paid directly to Cooley LLP (&#x201c;Cooley&#x201d;),
the law firm that represented Dr. Wong in his defense in the Arbitration. On December 30, 2025, the Company entered a settlement agreement
with Cooley LLP (&#x201c;Cooley&#x201d;) related to the remaining balance of $&lt;span id="xdx_900_ecustom--LossContingencyObligationRemainingAmount_pn5n6_c20251230__20251230__us-gaap--TypeOfArrangementAxis__custom--CooleyLLPSettlementAgreementMember_zLfE6WDv1B1l" title="Loss contingency obligation remaining amount"&gt;7.5&lt;/span&gt; million still outstanding for the payment of legal fees
incurred in connection the defense of Dr. Hing C. Wong, the Company&#x2019;s Founder and Chief Executive Officer. As a result of that
agreement, the Company, Dr. Wong and Cooley agreed to settle a $&lt;span id="xdx_909_ecustom--LossContingencyObligationAmount_pn5n6_c20251230__20251230__us-gaap--TypeOfArrangementAxis__custom--CooleyLLPSettlementAgreementMember_zci2JbrIZS5a" title="Loss contingency obligation amount"&gt;7.5&lt;/span&gt; million obligation for $&lt;span id="xdx_909_eus-gaap--PaymentsForLegalSettlements_pn5n6_c20251230__20251230__us-gaap--TypeOfArrangementAxis__custom--CooleyLLPSettlementAgreementMember_z1Dl1STCH4li" title="Cash paid"&gt;2.0&lt;/span&gt; million in cash and contingent payments
up to $&lt;span id="xdx_90B_eus-gaap--LossContingencyAccrualPayments_pn5n6_c20251230__20251230__us-gaap--TypeOfArrangementAxis__custom--CooleyLLPSettlementAgreementMember_z6hxKc5Mvrbd" title="Cash and contingent payments"&gt;5.5&lt;/span&gt; million upon achievement of certain triggering events, all of which were deemed to be remote as of December 31, 2025 and September
30, 2026. During the nine months ended September 30, 2026, the Company paid Cooley $&lt;span id="xdx_909_eus-gaap--LossContingencyDamagesPaidValue_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--CooleyLLPSettlementAgreementMember_zNBBCleFMdZj" title="Loss contingency, damages paid, value"&gt;760,000&lt;/span&gt;. On October 27, 2026, the parties amended
the terms of their agreement. See Note 13. Subsequent events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026, the Company reported a liability of $&lt;span id="xdx_906_ecustom--LossContingencyLiabilityAmount_iI_pn5n6_c20260930__us-gaap--TypeOfArrangementAxis__custom--CooleyLLPSettlementAgreementMember_zQ0UDw9JP7r8" title="Loss contingency liability amount"&gt;5.4&lt;/span&gt; million for remaining amounts owed for legal fees related to the Arbitration
within Accounts payable on the accompanying condensed balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Legal
Matters related to Real Estate&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2025, certain subcontractors had filed mechanics liens related to unpaid invoices issued in connection with
the construction and renovation of a property owned by the Company. On April 17, 2025, the Company received a summons and a copy of a
complaint filed by BE&amp;amp;K in the Circuit Court of the 17th Judicial Circuit in and for Broward County, Florida (the &#x201c;BE&amp;amp;K
Complaint&#x201d;). Other Defendants named in the BE&amp;amp;K Complaint who are subcontractors elected to file counterclaims and cross-claims
as part of their responses to the BE&amp;amp;K Complaint. As of September 30, 2026, the Company reported a payable of $&lt;span id="xdx_905_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20260930__us-gaap--TypeOfArrangementAxis__custom--BEAndKComplaintMember_zAcm87tqrhH1" title="Accounts payable"&gt;2.2&lt;/span&gt; million within
Accounts payable on the accompanying condensed balance sheet. See Note 13. Subsequent Events. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 26, 2026, as part of a settlement with B&amp;amp;I Contractors, Inc. (&#x201c;B&amp;amp;I&#x201d;), we received notice that B&amp;amp;I had filed
a voluntary dismissal with prejudice of its crossclaims against us in the matter &lt;i&gt;BE&amp;amp;K Building Group, LLC v. HCW Biologics Inc.,
et al.&lt;/i&gt; pending in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. The matter arose from
a mechanics&#x2019; lien filed by B&amp;amp;I in connection with allegedly unpaid invoices relating to renovation work at our facility located
at 3300 Corporate Way, Miramar, Florida, which is being renovated for future office and laboratory use. In connection with the settlement,
B&amp;amp;I filed a final satisfaction of lien releasing a lien in the amount of approximately $&lt;span id="xdx_90E_eus-gaap--PaymentsForLegalSettlements_pn5n6_c20260626__20260626__us-gaap--TypeOfArrangementAxis__custom--BAndIContractorsIncMember_zieCz4HvZ7p9" title="Cash payment for legal settlement"&gt;1.1&lt;/span&gt; million. The dismissal and satisfaction
of lien completed the parties&#x2019; settlement and fully resolved all amounts claimed to be owed by us to B&amp;amp;I. There was &lt;span id="xdx_90F_eus-gaap--GainLossRelatedToLitigationSettlement_do_c20260626__20260626__us-gaap--TypeOfArrangementAxis__custom--BAndIContractorsIncMember_zApLOGxql2k6" title="Gain or loss on settlement"&gt;no&lt;/span&gt; gain
or loss on the settlement with B&amp;amp;I.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 24, 2025, the Company was notified by Cogent Bank that it exercised its discretion to make a demand that the Company cure the
Defaults no later than thirty (30) days after receipt of this letter in strict compliance with Section 7.2(3) of the Loan Agreement by:
(i) paying and discharging all of the Claims of Lien and causing satisfactions to be recorded in the Public Records of Broward County,
Florida for all of the Claims of Lien, and (ii) resolving all litigation against the Borrower and the mortgaged property described in
the Mortgage and causing such claims in the Foreclosure Actions to be dismissed and all related notices of lis pendens to be released.
The Company and Cogent Bank are negotiating terms for a forbearance agreement to provide additional time for the Company to comply with
the demands Cogent Bank made in their demand letter. As of September 30, 2026, the Company reported a current liability of $&lt;span id="xdx_90F_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn5n6_c20260930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zktL54WLnt2i" title="Balance due amount"&gt;6.1&lt;/span&gt; million
within Short-term debt, net on the accompanying condensed balance sheet. See Note 13. Subsequent Events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 8, 2026, the Company entered a Settlement and Release Agreement with Sartorius Stedim North America Inc. (&#x201c;Sartorius&#x201d;)
after Sartorius accepted the return of scientific equipment purchased by the Company for $&lt;span id="xdx_90A_ecustom--PurchaseOfScientificEquipment_iI_pn5n6_c20260708__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_ziMVVVbmdlYg" title="Purchase of scientific equipment"&gt;1.7&lt;/span&gt; million. As a result, all of the Company&#x2019;s
obligations to Sartorius were satisfied in full including the related unpaid invoices. According to the terms of the agreement, Sartorius
retained the Company&#x2019;s deposit of $&lt;span id="xdx_90A_eus-gaap--DepositAssets_iI_pn5n6_c20260708__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zs61FP3UO8g1" title="Deposits"&gt;494,683&lt;/span&gt;. In the three and nine months ended September 30, 2026, the Company recognized a Loss
on return of equipment of $&lt;span id="xdx_90B_eus-gaap--GainLossRelatedToLitigationSettlement_c20260701__20260930__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_znCeEYWiDtrh" title="Gain or loss on settlement"&gt;&lt;span id="xdx_906_eus-gaap--GainLossRelatedToLitigationSettlement_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_ziQaC13d39xg" title="Gain or loss on settlement"&gt;494,683&lt;/span&gt;&lt;/span&gt; in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Arbitration
Demand&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 13, 2026, the Company received a demand for arbitration from a placement agent alleging breach of contract and related claims
and seeking damages for unpaid &#x201c;tail fees&#x201d;. The Company believes the claims are without merit and intends to defend itself
in this matter vigorously. See Note 13. Subsequent Events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Matters&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 26, 2026, the Company paid all amounts due under a settlement agreement with EirGenix, Inc. (&#x201c;EirGenix&#x201d;), our contract
development and manufacturing organization, relating to manufacturing costs. Pursuant to the settlement agreement entered into on December
9, 2025, EirGenix agreed to accept $&lt;span id="xdx_90B_eus-gaap--LossContingencyLossInPeriod_pn5n6_c20260526__20260526__us-gaap--TypeOfArrangementAxis__custom--EirGenixIncMember_zTPt0AF0mHi" title="Loss contingency, amount"&gt;1.2&lt;/span&gt; million in full satisfaction of approximately $&lt;span id="xdx_90C_eus-gaap--ManufacturingCosts_pn5n6_c20251209__20251209__us-gaap--TypeOfArrangementAxis__custom--EirGenixIncMember_zZFOfeIlRGe9" title="Manufacturing costs"&gt;1.7&lt;/span&gt; million of outstanding amounts, provided payment
was made by an agreed deadline. As a result, all obligations under the settlement agreement were satisfied and the related unpaid invoices
and disputed credits were fully resolved. As a result, the Company recognized $&lt;span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260930_zlpMTbaCFOJb" title="Gain on extinguishment of a liability"&gt;483,383&lt;/span&gt; as a Gain on extinguishment of a liability for
the nine months ended September 30, 2026 in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 26, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) that the Company is in compliance
with Listing Rule 5550(b)(1) (the &#x201c;Equity Rule&#x201d;). On October 2, 2026, the Company received formal notice from Nasdaq that
the Company maintained compliance with Listing Rule 5550(a)(2) (the &#x201c;Bid Price Rule,&#x201d; along with all of the applicable continued
listing requirements until September 22, 2026, as required by the Panel decision dated May 29, 2026, as amended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 29, 2026, the SEC temporarily stayed the effectiveness of its July 22, 2026 order approving the Nasdaq&#x2019;s proposed rule change
to adopt a new $&lt;span id="xdx_907_ecustom--MarketValueOfListedSecurities_pn6n6_c20260729__20260729_ziQdxtgRkI69" title="Market value of listed securities"&gt;5.0&lt;/span&gt; million Market Value of Listed Securities continued listing requirement. In accordance with Rule 431(e), the July
22, 2026, order is stayed until the Commission orders otherwise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Inflationary
Cost Environment, Banking Crisis, Supply Chain Disruption and the Macroeconomic Environment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operations have been affected by many headwinds, including inflationary pressures, tariffs, rising interest rates, ongoing
global supply chain disruptions resulting from increased geopolitical tensions such as the war in the Middle East, the conflict between
Russia and Ukraine, China-Taiwan relations, financial market volatility and currency movements. The Company has been impacted by inflation,
and may continue to be so, when securing materials needed for our operations, the costs for recruiting and retaining employees and other
employee-related costs. Management employs a number of strategies to effectively navigate these issues, including product redesign, alternate
sourcing, and establishing contingencies in budgeting and timelines. Future developments in these and other areas present material uncertainty
and risk with respect to the Company&#x2019;s clinical trials, IND-enabling activities, as well as the Company&#x2019;s financial condition
and results of operations. The extent and duration of such events and conditions, and resulting disruptions to our operations, are highly
unpredictable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact001641"
      unitRef="Area">12250</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2025-03-01" id="Fact001643">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseExpirationDate1 contextRef="From2025-03-012025-03-01" id="Fact001645">2026-02-28</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1 contextRef="From2026-03-012026-03-01" id="Fact001647">2026-02-02</us-gaap:LeaseExpirationDate1>
    <HCWB:RecognizedRentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001649"
      unitRef="USD">52619</HCWB:RecognizedRentExpense>
    <HCWB:RecognizedRentExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact001651"
      unitRef="USD">55715</HCWB:RecognizedRentExpense>
    <HCWB:RecognizedRentExpense
      contextRef="From2025-07-012025-09-30_custom_ResearchAndDevelopmentExpensesMember"
      decimals="0"
      id="Fact001653"
      unitRef="USD">27557</HCWB:RecognizedRentExpense>
    <HCWB:RecognizedRentExpense
      contextRef="From2026-07-012026-09-30_custom_ResearchAndDevelopmentExpensesMember"
      decimals="0"
      id="Fact001655"
      unitRef="USD">29178</HCWB:RecognizedRentExpense>
    <HCWB:RecognizedRentExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact001657"
      unitRef="USD">155794</HCWB:RecognizedRentExpense>
    <HCWB:RecognizedRentExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001659"
      unitRef="USD">165080</HCWB:RecognizedRentExpense>
    <HCWB:RecognizedRentExpense
      contextRef="From2025-01-012025-09-30_custom_ResearchAndDevelopmentExpensesMember"
      decimals="0"
      id="Fact001661"
      unitRef="USD">81590</HCWB:RecognizedRentExpense>
    <HCWB:RecognizedRentExpense
      contextRef="From2026-01-012026-09-30_custom_ResearchAndDevelopmentExpensesMember"
      decimals="0"
      id="Fact001663"
      unitRef="USD">86453</HCWB:RecognizedRentExpense>
    <us-gaap:ContractualObligation
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001665"
      unitRef="USD">33080</us-gaap:ContractualObligation>
    <HCWB:InsuranceReimbursementForLegalDefenseCost
      contextRef="From2025-01-012025-01-31"
      decimals="-5"
      id="Fact001667"
      unitRef="USD">2000000.0</HCWB:InsuranceReimbursementForLegalDefenseCost>
    <HCWB:LossContingencyObligationRemainingAmount
      contextRef="From2025-12-302025-12-30_custom_CooleyLLPSettlementAgreementMember"
      decimals="-5"
      id="Fact001669"
      unitRef="USD">7500000</HCWB:LossContingencyObligationRemainingAmount>
    <HCWB:LossContingencyObligationAmount
      contextRef="From2025-12-302025-12-30_custom_CooleyLLPSettlementAgreementMember"
      decimals="-5"
      id="Fact001671"
      unitRef="USD">7500000</HCWB:LossContingencyObligationAmount>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2025-12-302025-12-30_custom_CooleyLLPSettlementAgreementMember"
      decimals="-5"
      id="Fact001673"
      unitRef="USD">2000000.0</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="From2025-12-302025-12-30_custom_CooleyLLPSettlementAgreementMember"
      decimals="-5"
      id="Fact001675"
      unitRef="USD">5500000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2026-01-012026-09-30_custom_CooleyLLPSettlementAgreementMember"
      decimals="0"
      id="Fact001677"
      unitRef="USD">760000</us-gaap:LossContingencyDamagesPaidValue>
    <HCWB:LossContingencyLiabilityAmount
      contextRef="AsOf2026-09-30_custom_CooleyLLPSettlementAgreementMember"
      decimals="-5"
      id="Fact001679"
      unitRef="USD">5400000</HCWB:LossContingencyLiabilityAmount>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2026-09-30_custom_BEAndKComplaintMember"
      decimals="-5"
      id="Fact001681"
      unitRef="USD">2200000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2026-06-262026-06-26_custom_BAndIContractorsIncMember"
      decimals="-5"
      id="Fact001683"
      unitRef="USD">1100000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2026-06-262026-06-26_custom_BAndIContractorsIncMember"
      decimals="0"
      id="Fact001685"
      unitRef="USD">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="AsOf2026-09-30_custom_LoanAgreementMember"
      decimals="-5"
      id="Fact001687"
      unitRef="USD">6100000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <HCWB:PurchaseOfScientificEquipment
      contextRef="AsOf2026-07-08_custom_SettlementAndReleaseAgreementMember"
      decimals="-5"
      id="Fact001689"
      unitRef="USD">1700000</HCWB:PurchaseOfScientificEquipment>
    <us-gaap:DepositAssets
      contextRef="AsOf2026-07-08_custom_SettlementAndReleaseAgreementMember"
      decimals="-5"
      id="Fact001691"
      unitRef="USD">494683000000</us-gaap:DepositAssets>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2026-07-012026-09-30_custom_SettlementAndReleaseAgreementMember"
      decimals="0"
      id="Fact001693"
      unitRef="USD">494683</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2026-01-012026-09-30_custom_SettlementAndReleaseAgreementMember"
      decimals="0"
      id="Fact001695"
      unitRef="USD">494683</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="From2026-05-262026-05-26_custom_EirGenixIncMember"
      decimals="-5"
      id="Fact001697"
      unitRef="USD">1200000</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:ManufacturingCosts
      contextRef="From2025-12-092025-12-09_custom_EirGenixIncMember"
      decimals="-5"
      id="Fact001699"
      unitRef="USD">1700000</us-gaap:ManufacturingCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001701"
      unitRef="USD">483383</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <HCWB:MarketValueOfListedSecurities
      contextRef="From2026-07-292026-07-29"
      decimals="-6"
      id="Fact001703"
      unitRef="USD">5000000.0</HCWB:MarketValueOfListedSecurities>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001705">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zVJ8RMc38eMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
&lt;span id="xdx_822_zWsf0dems8Jd"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
events have been evaluated through the date the financial statements were filed. In addition to the required recognition or disclosure
disclosed in the footnotes herein, there were also the following subsequent events after the reporting date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026, the Company reported $&lt;span id="xdx_903_eus-gaap--OtherShortTermBorrowings_iI_c20260930_zHQRT4WovB45" title="Short term borrowings"&gt;442,873&lt;/span&gt; within Short-term debt, net, for the amounts owed to the noteholders. As of October
1, 2026, the Secured Notes were settled by allocating a portion of the proceeds upon the sale or liquidation of AlloTera Therapeutics
shares according to the provision of Second Amendment to the Amended and Restated Note Purchase Agreement. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 2, 2026, the Company received formal notice from Nasdaq that the Company maintained compliance with Listing Rule 5550(a)(2) (the
&#x201c;Bid Price Rule,&#x201d; along with all of the applicable continued listing requirements until September 22, 2026, as required by
the Panel decision dated May 29, 2026, as amended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On October 22, 2026, the
Company entered a listing agreement with an internationally recognized real estate company to market and sell the Property. The
listing agreement contemplated completion of forbearance agreements with lienholders and Cogent Bank, which also contemplate the
sale of the Property. On November 4, 2026, the Company listed the Property for sale at an asking price of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20261104__20261104_zbB5Rg9jSpU2" title="Price of property for sale"&gt;15.0&lt;/span&gt;
million. As of the date of issuance of the Form 10-Q for the third quarter ended September 30, 2026, the forbearance agreements had
not been finalized, and the Board of Directors had not authorized the sale of the Property. Based on its evaluation of the facts and
circumstances, the Company concluded that the criteria for classification as held-for-sale were not met as of September 30, 2026.
Accordingly, the Property continued to be classified as held-and-used. Management also evaluated the relevant facts and
circumstances, including subsequent developments, and concluded that no indication of impairment adjustment was required as of
September 30, 2026.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 27, 2026, the Company and Cooley LLP (&#x201c;Cooley&#x201d;) entered an amended settlement and waiver agreement and an
amended contingent note agreement. Under the amended terms, the Company paid Cooley $&lt;span id="xdx_906_eus-gaap--RepaymentsOfRelatedPartyDebt_c20261027__20261027__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CooleyLLPMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAJlwK0eC2k3" title="Payment to related party"&gt;10,000&lt;/span&gt; upon signing the agreements and agreed
to pay Cooley $&lt;span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20270129__20270129__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CooleyLLPMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zTb547L1LZy2" title="Payment to related party"&gt;740,000&lt;/span&gt; by January 29, 2027, including interest on the unpaid amount at &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20261027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CooleyLLPMember_zX728nc9NBl5" title="Interest rate"&gt;8&lt;/span&gt;% per annum, and with monthly partial
payments of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_c20261027__20261027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CooleyLLPMember_z7ihhY7EzRd7" title="Monthly partial payments"&gt;10,000&lt;/span&gt; per month until paid. The amended terms for the contingent payments of up to $&lt;span id="xdx_905_eus-gaap--LossContingencyAccrualPayments_pn5n6_c20261027__20261027__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CooleyLLPMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjcjQVqhymp6"&gt;5.5&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
under the contingent note did not change the triggering events, all of which were deemed to be remote as of September 30,
2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 3, 2026, the Company entered into definitive agreements for a debt financing with gross proceeds of up to an aggregate of
$&lt;span id="xdx_906_eus-gaap--DeferredFinanceCostsNet_iI_pn5n6_c20261103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAfk8saUG2A5" title="Debt financing cost"&gt;10.0&lt;/span&gt;
million. In this transaction, the Company issued two secured promissory notes in the principal amounts of $&lt;span id="xdx_909_eus-gaap--UnsecuredDebt_iI_pn5n6_c20261103__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesOneMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zj2bM0iQ55w2" title="Unsecured debt"&gt;3.2&lt;/span&gt;
million and $&lt;span id="xdx_907_eus-gaap--UnsecuredDebt_iI_pn5n6_c20261103__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesTwoMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4EP9MSnxGCk" title="Unsecured debt"&gt;7.0&lt;/span&gt;
million, of which approximately $&lt;span id="xdx_907_eus-gaap--ConvertibleDebt_iI_pn5n6_c20261103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1dyRng6ERb2" title="Convertible debt"&gt;3.0&lt;/span&gt;
million (before deduction of fees, costs and expenses incurred in the transaction) was funded to the Company at closing and $&lt;span id="xdx_901_ecustom--DeferredFinanceClosingCostsNet_iI_pn5n6_c20261103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpI1fflCAdOk" title="Closing debt financing cost"&gt;7.0&lt;/span&gt;
million was deposited in a bank account held by HCWB Holdings, LLC, a wholly-owned subsidiary of the Company (the
&#x201c;Subsidiary&#x201d;), is pledged as security for both notes and is held pursuant to a deposit account control agreement among
the bank, the investor and the Subsidiary. The promissory notes accumulate interest at rates of &lt;span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentRate_dp_uPure_c20261103__20261103__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z77oIHssexSk" title="Interest rate"&gt;8&lt;/span&gt;%
and &lt;span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentRate_dp_uPure_c20261103__20261103__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z06HTL3IiQGi" title="Interest rate"&gt;5&lt;/span&gt;%,
respectively, per annum and mature 24 months after the issuance date. Interest will be partially offset with interest earned on the $&lt;span id="xdx_90D_eus-gaap--CommonStockHeldBySubsidiary_iI_pn5n6_c20261103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGGNamlFEzk3" title="Held in the subsidiary"&gt;7.0&lt;/span&gt; million held in the Subsidiary&#x2019;s bank account. The Company will be required to begin paying down outstanding amounts due beginning after
the six-month anniversary of the closing date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 13, 2026, the Company received a demand for arbitration from a placement agent alleging breach of contract and related claims
and seeking damages for unpaid &#x201c;tail fees&#x201d;. The Company believes the claims are without merit and intends to defend itself
in this matter vigorously. The legal expenses incurred in the Company&#x2019;s defense will be expensed as incurred. However, the Company
does not believe that outcome of this action will be material to the Company&#x2019;s financial position, results of operations or cash
flow. Because the matter is in its preliminary stages, the Company cannot predict the likely outcome or estimate the potential loss at
this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:OtherShortTermBorrowings
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001707"
      unitRef="USD">442873</us-gaap:OtherShortTermBorrowings>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2026-11-042026-11-04"
      decimals="-5"
      id="Fact001709"
      unitRef="USD">15000000.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2026-10-272026-10-27_custom_CooleyLLPMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001711"
      unitRef="USD">10000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2027-01-292027-01-29_custom_CooleyLLPMember_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001713"
      unitRef="USD">740000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-10-27_us-gaap_SubsequentEventMember_custom_CooleyLLPMember"
      decimals="INF"
      id="Fact001715"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2026-10-272026-10-27_custom_CooleyLLPMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001717"
      unitRef="USD">10000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="From2026-10-272026-10-27_custom_CooleyLLPMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001718"
      unitRef="USD">5500000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2026-11-03_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001720"
      unitRef="USD">10000000.0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:UnsecuredDebt
      contextRef="AsOf2026-11-03_custom_ConvertiblePromissoryNotesOneMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001722"
      unitRef="USD">3200000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt
      contextRef="AsOf2026-11-03_custom_ConvertiblePromissoryNotesTwoMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001724"
      unitRef="USD">7000000.0</us-gaap:UnsecuredDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2026-11-03_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001726"
      unitRef="USD">3000000.0</us-gaap:ConvertibleDebt>
    <HCWB:DeferredFinanceClosingCostsNet
      contextRef="AsOf2026-11-03_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001728"
      unitRef="USD">7000000.0</HCWB:DeferredFinanceClosingCostsNet>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2026-11-032026-11-03_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001730"
      unitRef="Pure">0.08</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2026-11-032026-11-03_srt_MinimumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001732"
      unitRef="Pure">0.05</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:CommonStockHeldBySubsidiary
      contextRef="AsOf2026-11-03_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001734"
      unitRef="USD">7000000.0</us-gaap:CommonStockHeldBySubsidiary>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2026-07-012026-09-30" id="Fact001735">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2026-07-012026-09-30" id="Fact001736">false</ecd:NonRule10b51ArrAdoptedFlag>
    <HCWB:Rule10B51ArrModifiedFlag contextRef="From2026-07-012026-09-30" id="Fact001738">false</HCWB:Rule10B51ArrModifiedFlag>
    <HCWB:NonRule10B51ArrModifiedFlag contextRef="From2026-07-012026-09-30" id="Fact001740">false</HCWB:NonRule10B51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2026-07-012026-09-30" id="Fact001742">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2026-07-012026-09-30" id="Fact001744">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000466"
          xlink:label="Fact000466"
          xlink:type="locator"/>
        <link:footnote id="Footnote000679" xlink:label="Footnote000679" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During
    the three months ended March 31, 2026, <xhtml:span
  id="xdx_902_ecustom--StockIssuedDuringPeriodSharesIssuedInConnectionWithAbeyance_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zryXSAv9NPmb"
  title="Common Stock issued in connection with abeyance shares, shares">162,834</xhtml:span> shares previously issued on November 20, 2025, and held in abeyance, were issued.
    As of September 30, 2026, there were no shares held in abeyance.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000466"
          xlink:to="Footnote000679"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000467"
          xlink:label="Fact000467"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000467"
          xlink:to="Footnote000679"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0468"
          xlink:label="xdx2ixbrl0468"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0468"
          xlink:to="Footnote000679"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0469"
          xlink:label="xdx2ixbrl0469"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0469"
          xlink:to="Footnote000679"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000471"
          xlink:label="Fact000471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000471"
          xlink:to="Footnote000679"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001528"
          xlink:label="Fact001528"
          xlink:type="locator"/>
        <link:footnote id="Footnote001582" xlink:label="Footnote001582" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Professional
    services consist primarily of audit and accounting advisory services, tax advisory services, corporate legal services and other services
    related to SEC compliance, and legal fees related to patent filings.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001528"
          xlink:to="Footnote001582"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001529"
          xlink:label="Fact001529"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001529"
          xlink:to="Footnote001582"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001530"
          xlink:label="Fact001530"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001530"
          xlink:to="Footnote001582"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001531"
          xlink:label="Fact001531"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001531"
          xlink:to="Footnote001582"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001573"
          xlink:label="Fact001573"
          xlink:type="locator"/>
        <link:footnote id="Footnote001583" xlink:label="Footnote001583" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other
    segment items include the following unusual or nonrecurring item that comprise other segment items for the three and nine months
    ended September 30, 2025 and 2026:</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001573"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001574"
          xlink:label="Fact001574"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001574"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001575"
          xlink:label="Fact001575"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001575"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001576"
          xlink:label="Fact001576"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001576"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
